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Abstract 
 
Persistent antigen presentation by tumor cells and during chronic infections functionally 
impairs T cells over time, limiting progress of adoptive T cell therapies for such diseases. To 
address how different kinetics and dosage of antigen presentation affect CD4+ T cells in the 
absence of confounding pathologies of chronic infections, we followed TCR transgenic T cells 
transferred into antigen-transgenic recipients. There they received either transient or chronic 
TCR signals of varying strengths. We show that CD4+ T cells exposed to different levels of 
persisting antigen presentation display phenotypes with varying kinetics and consequences. 
Chronically antigen-exposed CD4+ T cells show impaired cytokine production upon re-
stimulation, dose-dependent upregulation of exhaustion-, anergy-, and Tfh-associated 
markers and transcription factors. Continuous antigen presentation was sensed by the T cells, 
as indicated by Nur77-driven GFP-reporter expression and NFATc1 nuclear translocation, 
even at the highest dose where the TCR and LAT are chronically downregulated. When 
challenged, signaling pathways respond to strong TCR signals with Ca2+ fluxes being the most 
robust one while the MAPK and Akt pathways were more easily tuned by persisting antigen. 
The cells' transcriptional profiles reflected the qualitative and quantitative changes in antigen 
presentation by dose-dependent upregulation of exhaustion, anergy- and Tfh-associated, as 
well as downregulation of memory-associated genes. Comparisons with naturally occurring 
anergic and LCMV clone13-exhausted CD4+ T cells highlighted a common transcriptomic 
signature describing antigen-induced T cell anergy and exhaustion. Despite upregulation of 
Tfh-associated markers, antigen-exhausted CD4+ T cells lost their ability to provide help to B 
cells over time. Our results demonstrate that dose and timing of antigen presentation beyond 
the expansion phase reveal the plasticity of CD4+ T cells and determine their range of 
dysfunctionalities within an otherwise sterile environment.  
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Zusammenfassung 
 
Persistierende Antigenpräsentation durch chronische Virusinfektionen oder Tumor-
erkrankungen beeinträchtigt oft die Funktion von T-Zellen und führt zur sogenannten T-Zell-
Erschöpfung und somit zur Minderung von adaptiven T-Zell-basierten Immuntherapien. 
Obwohl CD8+ T-Zell-Erschöpfung bereits umfangreich charakterisiert wurde, sind ähnlich 
Zustände bei CD4+ T-Zellen unter chronischen Konditionen unzureichend erforscht. In dieser 
Arbeit wurde untersucht, wie CD4+ T-Zellen durch persistierendes Antigen beeinflusst werden. 
Mittels eines transgenen Mausmodells konnten wir TCR-transgene CD4+ T-Zellen nach 
adaptivem T-Zell-Transfer in Antigen-transgene Rezipienten in vivo analysieren und dabei 
zusätzlich verkomplizierenden Pathologien, wie sie chronische Infektionsmodelle mit sich 
bringen, ausschließen. Transferierte T-Zellen wurden entweder transient oder persistent drei 
unterschiedlich starken Antigendosen (gering, mittel und stark) ausgesetzt und zu 
unterschiedlichen Zeitpunkten untersucht. Wir konnten zeigen, dass chronisch stimulierte 
CD4+ T-Zellen unterschiedliche Antigendosen detektieren können und spezifisch darauf 
reagieren. So wiesen chronisch stimulierte T-Zellen dosisabhängige Phänotypen mit 
unterschiedlicher Kinetik und Konsequenzen auf. Neben einer deutlich verminderten Zytokin-
Produktion wurden dosisabhängige Expressionsmuster der erschöpfungsassoziierten 
Checkpoint-Molekülen, Anergie-assoziierten und Tfh-assoziierten Markern, sowie 
Transkriptionsfaktoren induziert. T-Zellen, die mit der höchsten Dosis stimuliert wurden, 
zeigten eine dauerhafte Abnahme des Oberflächen-TCRs und der LAT Expression und 
konnten interessanterweise dennoch kontinuierlich Antigen detektieren. Identifizierte 
Transkriptionsprofile reflektieren die quantitativen und qualitativen Veränderungen der 
Antigenpräsentation. So fanden wir eine dosisabhängige Induktion von erschöpfungs-, 
anergie- und Tfh-assoziierten und eine Reduktion von gedächtnis-assoziierten Genen. Die 
aufschlussreichen Vergleiche unserer drei unterschiedlichen, antigenerschöpfter CD4+ T-
Zellen mit natürlich vorkommenden anergen und mit LCMV Klon13-erschöpften CD4+ T-Zellen, 
verdeutlichten eine gemeinsame Signatur, die sowohl antigeninduzierte T-Zell-Erschöpfung als 
auch Anergie beschreibt. Zusätzlich verloren antigenerschöpfte CD4+ T-Zellen ihre Fähigkeit, 
trotz deutlich erhöhter Expression von Tfh-assoziierten Markern, B-Zell-Hilfe zu leisten. 
Zusammenfassend verdeutlichen unsere Ergebnisse, dass die Antigendosis und die 
Präsentationsdauer nach der Expansionsphase für die Plastizität und den Grad der 
Dysfunktionalität von CD4+ T-Zellen innerhalb eines (sonst) sterilen Milieus entscheidend sind.   
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1. Introduction 
 
 
During our entire life, we encounter a variety of pathogens that put our health at risk and may 
lead to life-threatening conditions. To fight them, the immune system has evolved that employs 
innate immune and adaptive defense mechanisms. Effector T cells are the most important 
players of the adaptive immunity, the loss of which is associated with disease progression and 
compromised fitness and survival of the affected individual. Besides genetic or acquired 
immunodeficiencies and pathogenic mechanisms of immune evasion, it has been observed that 
immune responses to self and chronically persisting antigens are physiologically impaired. 
Understanding the mechanisms of such impaired immune responses potentially provides 
information to improve therapeutic strategies to treat chronic infections, autoimmune disorders, 
and cancer. Here, the current understanding of T cell dysfunctions is introduced, and the biology 
of T cells exhausted by antigen in terms of their phenotype, functionality, and transcriptional 
profile is investigated. 
1.1 T cell activation and differentiation 
During acute infections or upon vaccinations naïve T cells are activated and primed by mature 
antigen-presenting dendritic cells (DCs). Effective T cell activation requires three different 
signals. Signal one is transmitted by interactions of the T cell receptor (TCR) with peptide/major 
histocompatibility complex (pMHC) molecules, signal two via co-stimulatory receptors like CD28 
binding to its ligands CD80 (B7-1) or CD86 (B7-2), and signal three by cytokines. Following 
antigen-specific activation, T cells undergo proliferation to expand and differentiate into short-
lived effector cells (Teff). They directly control infections and kill target cells by producing 
effector cytokines and cytotoxic molecules (granzyme B and perforin) (Cui and Kaech, 2010; 
Zinkernagel, 1996). Upon successful antigen clearance the majority of Teff die via apoptosis 
and only a small subset of long-lived cells survive as memory cells with a down-modulated 
effector program (Cui and Kaech, 2010; O'Shea and Paul, 2010; Swain et al., 2012). Stem-like 
memory T cells acquire the ability of self-renewal (IL-7 and IL-15 driven slow homeostatic 
proliferation) and the potential to survive in an antigen-independent fashion (Cui and Kaech, 
2010; O'Shea and Paul, 2010; Swain et al., 2012), and yet promote an effective immune 
response upon recall infections (Figure 1A).  
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In contrast, during chronic infections and cancer when pathogen or antigen persist over time, 
efficient protection by functional effector and memory T cells fails and so-called exhausted T 
cells (Tex) develop instead (Figure 1B). Tex cells represent a unique subset of T cells as they 
are phenotypically and functionally distinct from effector and memory T cells found during acute 
infections and vaccinations.  
 
A                 B                   
 
 
                                  C 
 
 
 
 
 
 
 
 
 
 
 
 
                                       
Figure 1: Model of T cell differentiation in response to acute or chronic infection/vaccination. A, B, and C was 
modified from McLane L. M. et al., 2019. Red lines represent antigen load over time, purple lines represent the T cell 
response over time, circled arrows indicate a stem-like, self-renewable capacity. Teff = effector T cells, Tmen = 
memory T cells, Trm = residential memory T cells, Tex = exhausted T cells. (A) Schematic outline representing an 
acute immune response. (B) Schematic outline representing a chronic immune response. (C) Schematic outline of 
Th cell differentiation and plasticity. 
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1.2 Lineage commitment and plasticity of helper CD4+ T cells 
Upon antigen encounter naïve CD4+ T cells undergo extensive cell proliferation and 
differentiate, dependent on their stimulating milieu, into specific T helper (Th) cell subsets, such 
as T helper type 1 (Th1) cells, Th2, Th9, Th17, Th22, T follicular helper (Tfh), and T regulatory 
(Treg) cells, with unique phenotypes and functions (Bluestone et al., 2009; Caza and Landas, 
2015; O'Shea and Paul, 2010) (Figure 1C). Th cell-linage commitment is influenced and 
determined by TCR stimulation (signal #1), co-receptor stimulation (signal #2), and cytokine 
milieu (signal #3) during the initial priming phase of a naïve CD4+ T cell. Activated professional 
antigen presenting cells (APCs) present pathogen-derived peptides on MHC II molecules, 
upregulate co-stimulatory molecules, such as CD80 and CD86, and secrete pro-inflammatory 
cytokines, such as type I interferons (IFN-I), tumor necrosis factors (TNF), interleukin 1 (IL-1), 
IL-4, IL-6, and IL-12, and thus influence Th cell differentiation. Th1 cells polarize during the 
response to viral infections by high levels of IL-12, IFN-I and IFN-γ within the priming milieu and 
produce large amounts of the Th1 effector-cytokines TNF-α, IFN-γ, and IL-2. In response to 
helminths, where high levels of IL-4 are found within the priming milieu, Th cells preferentially 
differentiate towards Th2 type cells, which produce large amounts of IL-4 and IL-13 (Figure 1C). 
However, T cell polarization has been shown to be plastic as polarized Th2 cells transferred 
into LCMV infected recipients acquired a Th1-like phenotype, producing high levels of IFN-γ 
and low amounts of IL-4 (Hegazy et al., 2010). The polarization of Tfh cells is driven by IL-21 
and IL-6 within the priming microenvironment. They produce IL-21, provide help to B cells 
thereby driving germinal center (GC) development, promote antibody affinity maturation, and 
support long-lived plasma cell differentiation (Crawford et al., 2014; Crotty, 2015; Hale et al., 
2013). However, whether Tfh cells represent a unique T helper cell subset or rather a state of 
the other Th cells is still unclear (Fazilleau et al., 2009; King et al., 2008; Zhou et al., 2009) 
(Figure 1C). Moreover, priming signals received chronically beyond the priming phase further 
influence CD4+ T cell differentiation and function (Vella et al., 2017).  
1.3 Occurrence of exhausted T cells 
T cell exhaustion was first described during chronic LCMV infection in mice (Ahmed et al., 1984; 
Gallimore et al., 1998; Moskophidis et al., 1993; Moskophidis and Zinkernagel, 1995; Zajac et 
al., 1998). Today, we know that Tex cells are also generated during chronic viral infections in 
man, such as hepatitis B virus (HBV) (Ye et al., 2015), hepatitis C virus (HCV) (Gruener et al., 
2001; Lechner et al., 2000), and human immunodeficiency virus (HIV) (Day et al., 2006; 
Goepfert et al., 2000) infections. Tumor-specific CD8+ Tex cells are found in several human 
cancers including ovarian cancer (Matsuzaki et al., 2010), chronic lymphocytic leukemia 
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(Fraietta et al., 2018; Riches et al., 2013), chronic myeloid leukemia (Mumprecht et al., 2009), 
Hodgkin lymphoma (Gandhi et al., 2006), melanoma (Ahmadzadeh et al., 2009; Baitsch et al., 
2011; Fourcade et al., 2010; Huang et al., 2017; Lee et al., 1999), non-small cell carcinoma 
(Bengsch et al., 2018; Zhang et al., 2010). Tumor-infiltrating lymphocytes (TILs) also show 
features of Tex cells (Ahmadzadeh et al., 2009; Baitsch et al., 2011; Bengsch et al., 2018; 
Bengsch et al., 2010; Fourcade et al., 2010; Lee et al., 1999; Matsuzaki et al., 2010; Radoja et 
al., 2001; Riches et al., 2013). Exhaustion has been widely studied focusing on CD8+ T cells, 
yet it was also described for their CD4+ T cell counterparts (Crawford et al., 2014) and other 
immune cell populations including B cells (Moir and Fauci, 2014) and NK cells (Bi and Tian, 
2017). Thus, understanding the mechanisms underlying T cell exhaustion will help to improve 
immunotherapies targeting these cells in order to reinvigorate effector functions and thereby 
promote immunity to chronic infections and cancer. 
1.4 Features of CD8+ Tex cells 
Tex cells are a unique population of immune cells that are characterized by impaired effector 
functions, sustained high surface expression of multiple inhibitory receptors (IRs), altered 
transcriptional and epigenetic profiles, as well as changes in cell metabolism. Additionally, 
heterogeneity was described within the Tex pool with stem-like progenitor Tex cells that give 
rise to more terminally exhausted T cells (for more details see section 1.4).  
1.4.1 Loss of effector function 
During chronic infections, CD8+ Tex cells lose the ability to efficiently produce the cytokines  
IFN-γ (Gallimore et al., 1998; Zajac et al., 1998), IL-2, and TNF-α (Fuller and Zajac, 2003; 
Wherry et al., 2003a) as well as the cytotoxic molecules granzyme B and perforin. This loss was 
described to be a hierarchical and progressive process with IL-2 production being lost first, 
followed by TNF-α (Fuller and Zajac, 2003; Wherry et al., 2003a) and in more severe stages, 
correlating with more terminally differentiated Tex cells, defects in IFN-γ production occur 
(Agnellini et al., 2007; Fuller et al., 2004; Mackerness et al., 2010; Shin et al., 2009; Wherry et 
al., 2003a). Furthermore, it was reported that under certain conditions CD8+ Tex cells gained 
the ability to skew cytokine production profile towards IL-10 production (Abel et al., 2006; 
Crawford et al., 2014; Ejrnaes et al., 2006; Zanussi et al., 1996) and in some situations with 
very high antigen stimulation physiological depletion of Tex cells was reported (Wherry et al., 
2003b; Zajac et al., 1998). Thus, T cell exhaustion may consist of a variety of functional defects. 
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1.4.2 Surface expression of multiple IRs 
A characteristic of exhausted T cells is the increased and sustained surface expression of 
multiple IRs. Up to now, numerous IRs have been identified that negatively influence the 
activation and function of the corresponding lymphocytes (Figure 3). Transient expression of 
IRs on Teff cells has an important role in restraining the immune response and attenuating T 
cell activation and function at the end of acute infections to prevent from autopathology 
destroying healthy cells and tissues. In contrast, sustained high expression level of multiple IRs, 
as found during chronic infections and cancer, results in a dysfunctional state of Tex cells 
(Bengsch et al., 2014; Bengsch et al., 2010; Blackburn et al., 2009; Day et al., 2006; Kaufmann 
et al., 2007; Petrovas et al., 2006; Radziewicz et al., 2007; Trautmann et al., 2006; Urbani et 
al., 2006; Wherry et al., 2007). Moreover, the abundance and the specific expression patterns 
of IRs directly correlate with the severity of T cell exhaustion (Blackburn et al., 2009). Thus, T 
cell exhaustion can occur with a variety of dysfunctional states that can be categorized by their 
phenotypic surface expression patterns. 
1.4.3 Transcriptional and epigenetic profile  
Not only IRs are differentially expressed and regulated by Tex cells. Another feature of Tex cells 
is their unique transcriptional and epigenetic profile. Transcriptional and epigenetic profiling of 
Tex cells has provided a better understanding of T cell exhaustion. Gene expression changes 
occur in genes encoding for IRs and co-stimulatory receptors (CRs), transcription factors, 
cytokines, TCR signaling molecules, and cell metabolism. Therefore, Tex cells have a distinct 
transcriptional profile in comparison to effector and memory T cells and thus make up a unique 
T cell subset (Alfei and Zehn, 2017; Crawford et al., 2014; Doering et al., 2012; Pauken et al., 
2016; Sen et al., 2016; Wherry et al., 2007) (For more details see section 1.6.). 
1.5 Development of T cell exhaustion 
The exact mechanisms and pathways driving T cell exhaustion are incompletely understood. 
However, it is clear that the development of CD8+ T cell exhaustion is a progressive and 
dynamic process caused by antigen persistence and/or prolonged inflammation (McLane et al., 
2019). The signals received by T cells can be put into three categories. Signal 1 is mediated by 
TCR stimulation, signal 2 by co-stimulation, and signal 3 by soluble cytokines and inflammation. 
This three-signal model has been, with modifications, applied to the development of T cell 
exhaustion (McLane et al., 2019) and will be followed here. However, additional mediators are 
involved in Tex development as both early loss of CD4+ T cell help during chronic viral infections 
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(Matloubian et al., 1994) and the presence of immunoregulatory cells, such as regulatory T cells 
(Treg) (Veiga-Parga et al., 2013) have been described to contribute to CD8+ T cell exhaustion.  
1.5.1 The three-signal model applied to T cell exhaustion 
Persisting signal 1 transmitted via chronic antigen presentation by tumors, virally infected cells, 
and/or professional antigen-presenting cells (APCs) causes a hyperactive state of T cells that 
is followed by and eventually even drives the upregulation of multiple IRs. Their specific ligands 
are additionally presented by signal-1-providing cells thus, also providing an altered signal 2. 
Signal 2 mediated via IRs provides inhibitory signals and therefore, prevent optimal T cell 
activation and diminishes effector responses (more on IRs in section 1.2.2 and following). 
Additionally, chronically antigen-presenting cells as well as Treg cells provide an altered signal 
3 by producing inhibitory cytokines such as IL-10 or TGF-β (Soyer et al., 2013). 
1.5.2 Signal 1: Persistent antigenic TCR stimulation 
What chronic infections and tumors have in common is the persistent antigen presentation to T 
cells (Blackburn et al., 2009; Bucks et al., 2009; Mueller and Ahmed, 2009; Shin et al., 2009; 
Streeck et al., 2008; Utzschneider et al., 2016a; Wherry et al., 2007). Both, high-dose antigen 
levels and prolonged exposure correlate with the severity of CD8+ T cell exhaustion during 
LCMV cl13 infections in mice or HBV, HCV, and HIV infections in man (Boni et al., 2007; El-Far 
et al., 2008; Goepfert et al., 2000; Reignat et al., 2002; Shankar et al., 2000; Wherry and 
Kurachi, 2015; Wherry et al., 2003b; Zajac et al., 1998). Development of T cell exhaustion 
appears to be progressive, since CD8+ T cells isolated during an early exhaustion phase (within 
the first two weeks post LCMV cl13 infection) are able to reverse the Tex phenotype and recover 
to Tmem cells when transferred back into acutely infected wild type mice (Angelosanto et al., 
2012; Brooks et al., 2006a). However, extended priming by chronic antigenic stimulation 
resulted in un-rescuable T cell dysfunction and exhausted phenotype (Angelosanto et al., 2012; 
Brooks et al., 2006a; Utzschneider et al., 2016b). Thus, the severity of CD8+ T cell exhaustion 
is dependent on antigen dose and the duration of antigen presentation.  
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1.5.2.1   TCR signal transduction pathways 
Antigen presentation plays an important role already during T cell development in the thymus. 
Only T cells that are able to recognize self-pMHC complexes in the thymic cortex receive signals 
to survive, a process called positive selection (Hogquist et al., 1994, 2012; Starr et al., 2003). 
In contrast, during negative selection in the thymic medulla, all T cells that recognize self-pMHC 
complexes with a strong reactivity are depleted to prevent autoimmunity (Klein et al., 2014; 
Nossal, 1994; Starr et al., 2003).  
 
 
                  
 
Figure 2: Model of TCR-mediated signaling pathways. Figure adapted from Morris and Allen, 2012. Upon 
TCR/pMHC interaction, the protein tyrosine kinase Lck bound to coreceptor (CD4 or CD8) is recruited and 
phosphorylates the immunoreceptor tyrosine-based activation motif (ITAM) domains of the CD3ζ subunit, generating 
the docking-site of zeta-chain-associated protein kinase 70 (ZAP-70), which in turn phosphorylates the 
transmembrane protein linker of activated T cells (LAT). Downstream of LAT several signaling pathways are involved. 
Mitogen-activated protein (MAP) kinase signaling results in activation protein 1 (AP-1) transcription factor generation 
(green cascade) and calcium signaling induces NFAT transcription factors (yellow cascade). 
 
 
TCR/pMHC engagement triggers the formation of the so-called immunological synapse at the 
interface between the T cell and the APC, also known as supramolecular activation cluster 
(SMAC) (Monks et al., 1998). SMACs control T cell activation and polarized secretion of 
cytotoxic granules and cytokines and are divided into the central c-SMAC and the peripheral p-
SMAC. Upon TCR/pMHC engagement and cluster formation, complex molecular mechanisms 
are induced. First, the corresponding co-receptors (CD4 or CD8) bind to agonistic pMHC (Li et 
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al., 2004; Turner et al., 1990) thus, recruiting the constitutively bound protein tyrosine kinase 
Lck (Barber et al., 1989; Turner et al., 1990) to the TCR/CD3 complex. In the proximity of CD3, 
Lck phosphorylates the immunoreceptor tyrosine-based activation motif (ITAM) domains of the 
CD3ζ subunit, probably following conformational changes in the cytoplasmic tail of the CD3ε 
and CD3ζ (Aivazian and Stern, 2000; Nika et al., 2010; Xu et al., 2008), and thus generates the 
docking-site of zeta-chain-associated protein kinase 70 (ZAP-70). Subsequently, ZAP-70 is 
recruited to its docking-site where it is now able to phosphorylate the transmembrane protein 
linker of activated T cells (LAT) (Paz et al., 2001). Phosphorylated LAT serves as an adaptor 
protein for several signaling molecules, such as the scaffold protein SLP-76 and PLCγ-1. These 
proteins then control Ca2+ influx and the production of second messengers diacylglycerol (DAG) 
and IP3, which leads to gene transcription driven by AP-1, NFAT, and NFkB. Thus, mediating 
TCR downstream signaling with the final outcome of productive T cell activation, proliferation, 
differentiation, and cytokine production (Figure 2). 
1.5.3 Signal 2: Inhibitory receptors 
Inhibitory signaling via IRs is mediated after IR engagement with its cognate ligand. Cognate 
ligands are expressed on professional APCs, virally infected cells during chronic infections, and 
tumor cells (Keir et al., 2008; Virgin et al., 2009). Several mechanisms have been described by 
which IRs modulate T cell functions (Odorizzi and Wherry, 2012; Schietinger and Greenberg, 
2014).  
In 2018 two scientists, James P. Allison, then at the University of California, now at the 
University of Texas MD Anderson Cancer Center and Tasuku Honjo at the Kyoto University 
have won the Nobel Prize for medicine for developing blocking monoclonal antibodies (mABs) 
targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 
(PD-1) respectively. These are probably the best-studied IRs. Using blocking mABs are 
promising treatment strategies referred to as immune checkpoint therapy to combat cancer in 
human with a fundamentally change in outcome for patients with advanced cancer (Sharma 
and Allison, 2015). Therefore, it is important to understand the underlying molecular 
mechanisms. 
1.5.3.1   PD-1 
PD-1 is a marker for early T cell activation as it is transiently expressed on functional Teff cells 
and is reduced to baseline expression levels after activation. However, during chronic situations 
sustained high PD-1 surface expression-levels are established on Tex cells (Barber et al., 2006; 
Boni et al., 2007; Day et al., 2006; Iwai et al., 2002; Urbani et al., 2006; Wherry et al., 2007). 
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There are two ligands described, PD-L1 (B7.H1) and PD-L2 (B7.DC) (Araki et al., 2013; Odorizzi 
and Wherry, 2012; Okazaki et al., 2013). PD-L1 is found on immune and non-immune cells, 
such as tumor cells, whereas PD-L2 is found on germinal center B cells, DCs, and macrophages 
(Keir et al., 2008; Liang et al., 2003).  
The cytoplasmic tail of PD-1 harbors an immunoreceptor tyrosine-based inhibitory motif (ITIM) 
and an immunoreceptor tyrosine-based switch motif (ITSM) (Riley, 2009) that recruit adapter 
proteins, such as tyrosine-protein phosphatases SHP1 (PTPN6) and SHP2 (PTPN11) 
(Chemnitz et al., 2004; Yokosuka et al., 2012) proteins and thus, inhibits positive signaling 
events mediated by both, T cell receptor (TCR) and co-stimulation via CD28 (Hui et al., 2017; 
Kamphorst et al., 2017; Yokosuka et al., 2012) (Figure 3a). Particularly, the phosphoinositide 
3-kinase (PI3K)/AKT pathway is impaired by PD-1 signaling (Riley, 2009), which links PD-1 also 
to cell cycle control (Patsoukis et al., 2012). Finally, downstream signaling of PD-1 induces the 
expression of inhibitory genes that in turn negatively regulate the expression of the transcription 
factor BATF (Quigley et al., 2010). BATF was shown to control T cell differentiation by binding 
to AP-1 binding sites after forming heterodimers with the AP-1 transcription factor family 
member JUN (Dorsey et al., 1995; Schraml et al., 2009). However, PD-1 expression is not 
necessarily required for T cell exhaustion as Tex cell can also develop in a PD-1-independent 
fashion shown by PD-1-/- CD8+ T cells (Odorizzi et al., 2015). These cells are more terminally 
exhausted meaning PD-1 protects some functions. Furthermore, PD-1 is also expressed by Tfh 
cells (Schmitt and Ueno, 2013). 
1.5.3.2   CTLA-4 
Another mechanism of inhibition is evolved by CTLA-4 that competes with the co-stimulatory 
receptor CD28 for ligand binding. During normal T cell activation CD28 binds to its ligand B7-1 
(CD80) and B7-2 (CD86) and in concert with TCR signal transduction activates PI3K/AKT 
pathways driving T cell proliferation and effector cytokine production. During chronic situations 
CTLA-4 expression is elevated, binds the same ligands as CD28 (Pentcheva-Hoang et al., 
2004), induces intercellular transfer of its ligands (Qureshi et al., 2011), and thus hinders proper 
T cell activation  (Figure 3b). Furthermore, CTLA-4-knockout mice develop a severe phenotype 
as their T cells are activated in the periphery, proliferate spontaneously, infiltrate organs, and 
cause tissue damage (Tivol et al., 1995). These mice suffer from pancreatitis and myocarditis 
(Tivol et al., 1995). 
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1.5.3.3   Lag-3 
The IR Lymphocyte-activation gene 3 (Lag-3) is expressed on activated T cells during acute 
infections (Huard et al., 1994a). Lag-3 binds its main ligand MHC class II with higher affinity 
than CD4 and thus, oust CD4/MHC class II interactions (Baixeras et al., 1992; Huard et al., 
1995). This way, Lag-3 interferes with the positive-signaling cascade and provides inhibitory 
signals (Figure 3c). Furthermore, the DC-SIGN family member LSECtin, which is highly 
expressed on many tumors, is suggested to be a further ligand for Lag-3 (Xu et al., 2014). As 
Lag-3 is highly expressed on Tex cells (Blackburn et al., 2009; Richter et al., 2010) and TILs 
(Matsuzaki et al., 2010) the interaction also with this ligand might contribute to diminished T cell 
proliferation, activation, and cytokine production within this tissues (Anderson et al., 2016; 
Blackburn et al., 2009; Hannier et al., 1998; Huard et al., 1994b). Lag-3-deficient T cells 
revealed per se no phenotype but Lag-3-knockout T cells exhibit reduced expansion and 
increased cell death thus, suggesting that Lag-3 regulates T cell expansion (Workman and 
Vignali, 2003). There are more IRs that work in a similar way, such as Tim-3. 
1.5.3.4   Tim-3 
T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) is an IR that interacts with 
multiple components of the TCR complex (Lee et al., 2011; van de Weyer et al., 2006). 
Engagement of Tim-3 with its ligand galectin-9 (Wada and Kanwar, 1997) induces Ca2+ flux and 
drives apoptosis (Zhu et al., 2005) thus, providing inhibitory signals and negatively regulate T 
cell functions (Tomkowicz et al., 2015) (Figure 3c). Tim-3 is highly expressed on CD8+ Tex cells 
during chronic viral infections (Jin et al., 2010) and cancer (Fourcade et al., 2010; Gao et al., 
2012; Lu et al., 2017; Shayan et al., 2017; Yang et al., 2012) and is described to drive T cell 
exhaustion in concert with Lag-3 and PD-1 (Blackburn et al., 2009). Moreover, during 
experimental autoimmune encephalomyelitis (EAE) in mice, Tim-3 expression is induced on 
CD4+ Th1 cells and correlates with the severity of the disease (Monney et al., 2002). Therefore, 
Tim-3 inhibition is also a promising candidate for immunotherapy. 
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Figure 3: Collection of selected inhibitory receptors (IRs). Figure modified from McLane L. M. et al., 2019. (a – 
d) Schematic illustration of different mechanisms of IRs mediating inhibitory signals to impair T cell activation and 
effector function. IRs such as PD-1 signal via intracellular ITIM/ITSM domains interfere with co-stimulatory signals 
(a), other IRs, such as CTLA-4 directly compete with co-stimulatory receptors (b). Another group of IRs, including 
Lag-3 and Tim-3, induce unconventional signaling (c) or use a combination of both, such as TIGIT (d). 
 
1.5.3.5   TIGIT 
T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an IR that mechanistically combines 
the inhibition pathways of other IRs, such as receptor competition (e.g. CTLA-4) and 
unconventional signaling (e.g. Lag-3, Tim-3). It competes with CD226 for ligand (CD155) 
binding (Yu et al., 2009b) and additionally contains an ITIM domain via which unconventional 
signaling inhibits PI3K and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) pathways and thus, T cell activation (Ho et al., 1998). TIGIT expression is elevated and 
sustained on CD8+ T cells during chronic viral infections, as HIV infections (Chew et al., 2016) 
as well on CD8+ T cells and CD8+ TILs in cancer patients (Chauvin et al., 2015). Blocking TIGIT-
mediated signaling using mABs was shown to rejuvenate the effector function of HIV-specific 
CD8+ T cells regarding cell proliferation and cytokine production (Chew et al., 2016) and 
enhanced tumor rejection in mice (Chauvin et al., 2015).  
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1.5.4 Signal 3: Inhibitory cytokines 
Signal 3 provides positive signals during acute viral infections via soluble mediators, such as 
interleukin 2 (IL-2). Positive signal 3 is required for T cell activation and survival (Vella et al., 
1998). In contrast, during chronic infections the inflammatory milieu has changed. Anti-
inflammatory cytokines, such as IL-10 (Wilson and Brooks, 2011; Yi et al., 2010) and TGF-β 
(Derynck and Zhang, 2003; Li et al., 2006; Tinoco et al., 2009), promote the development of T 
cell exhaustion. Today, a number of proinflammatory cytokines are known to influence the 
development of Tex cells even though, signal 3 alone is not sufficient to induce Tex phenotype 
in absence signal 1 and/or signal 2 (Stelekati et al., 2014). Indeed, IL-10 production is increased 
in many chronic viral infections in mice and man, such as LCMV cl13, HBV, HCV, and HIV (Yi 
et al., 2010), where Tex cells are found. Blocking IL-10-mediated negative signal 3 using 
neutralizing IL-10 mABs in combination with other checkpoint blockades, such as anti-PD-1, 
reduced the Tex development and reverted Tex cells into functional Teff and Tmem cells during 
chronic LCMV infections (Brooks et al., 2008; Brooks et al., 2006b; Ejrnaes et al., 2006). Similar 
approaches are currently being tested for cancer treatment (Ni et al., 2015; Zarour, 2016) (more 
on immunotherapies in section 1.9). 
1.6 Heterogeneity within the Tex pool 
Tex cells represent a unique cell lineage that is distinct from Teff and Tmem cells regarding 
their phenotype and functionality (McLane et al., 2019). Within the CD8+ Tex pool heterogeneity 
exists. Tex cells arise from MPEC precursor cells (Figure 1) that give also rise to Teff and Tmem 
cells (Angelosanto et al., 2012). Progenitor Tex cells are stem-like as they have the potential of 
self-renewal and give rise to the more terminal differentiated exhausted T cells (Paley et al., 
2012). Terminal Tex cells represent the majority of all Tex cells; these cells lost their ability to 
proliferate and finally enter cell death if high-dose antigen stimulation continues to persist (Paley 
et al., 2012) (Figure 4). Progenitor CD8+ Tex cells isolated during an early phase of LCMV cl13-
induced exhaustion (up to two weeks post infection) and transferred into antigen-free hosts 
where able to establish effector functions nevertheless, terminal Tex cells failed to do so. 
Recently, Bengsch et al. identified approximately nine different subsets of Tex cells based on 
their surface marker expression characteristics using high-dimensional cytometry (Bengsch et 
al., 2018). Progenitor Tex cells are characterized by T-bethi, PD-1int, and CD44hi expression and 
are responsive to checkpoint blockades. In contrast, the more terminal Tex cells are rather 
unresponsive and are defined by an EOMEShi, PD-1hi, and CD44int surface expression profile 
(Figure 4). 
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Figure 4: Model of progressive Tex development. Graphic illustration of the progression of T cell exhaustion over 
time and dependent on antigen load. Progenitor Tex cells have a self-renewable capacity and are rescuable by 
checkpoint blockades and differentiate into terminal Tex cells that finally enter cell death when antigen continuous to 
persist. 
 
1.7 Transcriptional control and epigenetic landscape of Tex cells 
As mentioned above (section 1.3.3) one of the features of Tex cells are significant changes in 
gene-expression. Transcription factor expression and their transcriptional connectivity play a 
major role in T cell exhaustion (Doering et al., 2012; Paley et al., 2012). Network analysis 
revealed that Tex cells are able to reuse transcription factors expressed by Teff or Tmem cells 
in a new, context-specific way within another network connectivity (Doering et al., 2012). 
Context-specific activity of transcription factors may be on the basis of binding-partners, co-
factors, differently regulated localization within the cellular compartments, and dose-dependent 
binding potential. Additionally, chromatin accessibility of Tex cells has a major function in 
controlling gene-expression patterns (Pauken et al., 2016; Philip et al., 2017; Scott-Browne et 
al., 2016). Therefore both, context-specific activity of transcription factors and chromatin 
accessibility modulate T cell activation, differentiation, and fate commitment. Here, the function 
and role of some exhaustion-associated transcription factors are highlighted. 
1.7.1  NFAT 
The nuclear factor of activated T-cells (NFAT) family member transcription factors play an 
important role during T cell activation (Crabtree and Olson, 2002; Rao et al., 1997) and is also 
involved in T cell exhaustion (Martinez et al., 2015; Schietinger and Greenberg, 2014; Wherry, 
2011) and anergy (Macian et al., 2002) (more on T cell anergy in section 1.9). Upon acute TCR 
stimulation Ca2+ flux is induced, which in turn results in nuclear NFAT translocation. Once 
progenitor Tex cells terminal Tex cells
cell death
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located in the nucleus, NFATs form heterodimers with AP-1 (a heterodimer built by Fos and 
Jun) and together, drive T cell activation and effector function (Macian et al., 2000; McHenry et 
al., 1998). By contrast, during chronic viral infections nuclear NFAT abundance is increased in 
absence of AP-1 family members (Wherry, 2011; Wherry et al., 2007). A constitutive 
nuclear/active mutant of NFAT1, which is unable to form heterodimers together with AP-1, so-
called “partnerless” NFAT, provides negative signals attenuating activation and effector 
signaling (Martinez et al., 2015), probably by binding to different exhaustion-associated genes, 
such as genes encoding for the IRs PD-1, Lag-3, and Tim-3 (Martinez et al., 2015; Oestreich et 
al., 2008; Quigley et al., 2010). 
1.7.2  Tcf-1 
T-cell factor 1 (Tcf-1) is a transcription factor that is required during thymic and peripheral T cell 
development, associated with memory formation (Verbeek et al., 1995; Yu et al., 2009a), and 
functions as a “gatekeeper” of T-cell fate during early T cell activation (Germar et al., 2011). Tcf-
1 is expressed by functional Tmem cells as well as by a subpopulation of Tex cells. In both T 
cell populations Tcf-1 maintains the stemness and promotes the progenitor capacity (Man et 
al., 2017; Utzschneider et al., 2016b; Wu et al., 2016). 
1.7.3  c-Maf 
Musculoaponeurotic fibrosarcoma oncogene homolog (Maf) expression is significantly induced 
in CD8+ TILs in melanoma patients as well as in virus-induced Tex cells and is reported to 
mechanistically drive CD8+ T cell exhaustion (Verdeil, 2016) but, in CD4+ T cells, is associated 
with Th2 and Tfh differentiation (Ho et al., 1998; Kroenke et al., 2012; Xu et al., 2009). 
1.7.4  TOX 
The transcription factor nuclear HMG-box protein TOX is transiently expressed during positive 
selection and thus, is associated with thymic T cell development and linage commitment (Huang 
et al., 2014; Wilkinson et al., 2002). Moreover, it is also found significantly upregulated on CD8+ 
T cells during many cancers including breast, lung, and gastric cancer, leukemia, and lymphoma 
(Yu and Li, 2015). Nowadays, TOX expression is used as a biomarker for cancer progression 
and prognosis (Huang et al., 2014).  
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1.8 CD4+ T cells during acute vs. chronic viral infections  
In acute viral infections, antigen-specific CD4+ T cells preferentially differentiate into functional 
Th1 cells producing IFN-γ (Hale et al., 2013; Sallusto, 2016) or into Tfh cells providing help to 
B cell-mediated immunity by driving germinal center (GC) development, promoting antibody 
affinity maturation, and supporting long-lived plasma cell differentiation (Crawford et al., 2014; 
Crotty, 2015; Hale et al., 2013). In contrast, during chronic viral infections the differentiation 
profile and functions of antigen-specific CD4+ T cells can differ from that generated during acute 
infections (Crawford et al., 2014) as they show a compromised ability to produce regular Th1-
specific cytokines. This defect is probably driven by persistently high levels of antigen beyond 
the priming phase (Han et al., 2010). However, since chronically LCMV-cl13-infected mice only 
established a lifelong unresolving viremia upon CD4+ T cell depletion during infection 
(Matloubian et al., 1994), CD4+ T cells are not entirely dysfunctional during chronic viral 
infections, but display another phenotype (Aubert et al., 2011). Indeed, the cytokine production 
profile of chronic CD4+ T cells is changed, as the production of IFN-γ, TNF-α, and IL-2 is 
significantly reduced (Crawford et al., 2014; Han et al., 2010) whereas the expression of IL-21 
is elevated (Crawford et al., 2014; Elsaesser et al., 2009; Fahey et al., 2011; Fröhlich et al., 
2009; Vella et al., 2017). It was also reported that chronic CD4+ T cells skew towards a Tfh 
phenotype as they express the key Tfh-driving transcription factor B cell lymphoma 6 (BCL-6) 
as well as Tfh-specific surface markers as ICOS, CXCR5, and PD-1(Fahey et al., 2011). 
Moreover, significant amounts of virus-specific T-cell-dependent antibodies are found during 
chronic LCMV cl13 infections in mice as well as HCV infections in man (Bartosch et al., 2003) 
indicating that at least some features of T cell help to B cells are still intact. In agreement with 
these findings is the fact that broadly-neutralizing antibodies rarely occur in HIV patients 
(Caskey et al., 2019). Together, these findings support the hypothesis that at least some 
antigen-specific CD4+ T cells differentiate towards Tfh cells during chronic infections. However, 
it was also shown that chronic CD4+ T cells up-regulate the surface expression of multiple IRs 
such as PD-1, CTLA-4, TIM-3, and Lag-3 like their CD8+ counterparts and genome-wide 
transcriptional profiling of chronic CD4+ T cells revealed no obvious skewing towards one of the 
T helper subsets mentioned above, including the Tfh phenotype (Vella et al., 2017). Additionally, 
similar to CD8+ Tex cells, chronic CD4+ cells have their unique gene-expression profile and 
both, CD8+ Tex and chronic CD4+ T cells, share a certain gene-expression signature of 
exhaustion but still being different cell types (Vella et al., 2017). Thus, whether chronic CD4+ T 
cells differentiate into Tfh or other cells or whether they become exhausted as their CD8+ 
counterparts still remain unclear. To improve CD4+ T cell effector functions it is important to gain 
further insights into the mechanisms and pathways involved in CD4+ T cell dysfunction. 
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1.9 T cell anergy 
T cell anergy is an acquired dysfunctional state of cells. The term anergy has been introduced 
by Pirquet who reported that children infected with measles are transiently unresponsive to 
tuberculin prick tests and called it the anergic phase (Pirquet, 1908). About 80 years later, such 
a hyporesponsive state was described for antigen-specific CD4+ Th1 cells that had been first 
stimulated in vitro by fixed APCs exclusively providing signal 1 and subsequently by live APCs 
providing full activating conditions (signal 1, 2, and 3). As these T cells failed to proliferate and 
to produce IL-2, this unresponsive state was termed clonal anergy (Jenkins and Schwartz, 1987; 
Schwartz et al., 1989). T cell anergy has also been shown in a number of mouse models. It was 
observed in mice treated with the protein staphylococcal enterotoxin B (SEB), a superantigen. 
In this model, in vivo stimulated T cells exhibited a proliferative defect and failed to produce IL-
2 in response to in vitro re-stimulation with SEB or exogenous IL-2, respectively (Rellahan et 
al., 1990). However, in vivo induced clonal anergy was reversible upon antigen removal (Rocha 
et al., 1993). And it was shown that in vitro T cell stimulation using anti-CD3/TCR antibodies 
alone (signal 1) induced an anergic phenotype, while using anti-CD3/TCR together with anti-
CD28 (signal 2) was sufficient to fully activate the T cells (Jenkins and Johnson, 1993). In 1994, 
the induction of T cell anergy was reported to be dependent on the levels of presented pMHC 
complexes in vivo (Ferber et al., 1994). High levels of pMHC caused TCR downregulation and 
rapidly induced an hyporesponsive state (Taams et al., 1999). Later, TCR tg mouse models 
have allowed further in vivo studies, which revealed that in vivo induced anergy is different from 
in vitro induced clonal anergy. Thus, in vivo also other effector cytokines, such as IL-4 and IFN-
γ were downregulated. Furthermore, the anergic phenotype depended on antigen persistence, 
and in vivo anergized T cells failed to proliferate in response to exogenous IL-2 (Chiodetti et al., 
2006). Therefore, it was suggested to name the in vivo-anergic state adaptive tolerance 
(Schwartz, 2003).  
Anergy is thought to play a role for peripheral tolerance induction and to protect the hosts from 
autoimmune disorders (Kalekar et al., 2016; Schwartz, 1990; Wells, 2009) and 
immunopathology (Knoechel et al., 2005; Martinez et al., 2012). Anergic T cells are also found 
in cancer patients where positive signal 2/co-stimulation is missing or is overwritten by a 
negative signal 2 mediated by IRs (Blank et al., 2004; Curiel et al., 2003; Zou and Chen, 2008). 
In mice, in vivo anergized T cells are characterized by high CD73 and FR4 surface expression 
(Martinez et al., 2012) and are associated with low IL-2 production, cell cycle arrest, improper 
mTOR and MAPK signaling (Zheng et al., 2012), and surface expression of IRs such as PD-1, 
CTLA-4, and Lag-3. Early growth response gene 2 (Egr2) and NFAT as homodimers are central 
transcription factors regulating the anergy-inducing gene-transcription profile 
(Anandasabapathy et al., 2003; Soto-Nieves et al., 2009; Zheng et al., 2012). Furthermore, 
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anergic CD4+ T cells are described to be precursors for peripheral FoxP3-expressing Treg cells 
(Kalekar and Mueller, 2017; Kalekar et al., 2016). Notably, the anergic state is reversible as loss 
of FoxP3 expression leads to the conversion of anergic CD4+ T cells towards functional Teff 
and Tmem cells (Zhou et al., 2009). However, the exact molecular and cellular mechanisms 
driving T cell anergy are still poorly understood. 
1.10 Immunotherapy: Reinvigoration of effector functions in Tex cells 
As mentioned above, immunotherapies have become very promising and revolutionizing 
strategies to combat cancer (Pardoll, 2012), chronic viral infections (Blackburn et al., 2009), as 
well as autoimmune diseases (Feldmann and Steinman, 2005). Currently, there are more than 
864 antibody-based clinical stage (phase I/II/III) candidates for immunotherapies, including 
antibody-based molecules, such as antibodies targeting checkpoint molecules (discussed 
above, section 1.4.3 and following), T-cell-attracting bispecific antibodies, BiTes, and chimeric 
antigen receptor (CAR) T cell-based approaches (Strohl, 2018). Up to date, 74 antibody-based 
molecules have already been approved by the US Food and Drug Administration (FDA) and are 
being in clinical use. Probably, the most promising immunotherapeutic approach are antibody-
based checkpoint blockades; mAbs inhibiting IR-mediated pathways, such as pembrolizumab 
and nivolumab targeting PD-1, atezolizumab, avelumab, and durvalumab targeting PD-L1, and 
ipilimumab targeting CTLA-4. These checkpoint-blocking mAbs are approved to treat 
melanoma, non-Hodgkin lymphoma, lung carcinoma, and several other types of cancer and are 
either being used as monotherapy or in combination (Balachandran et al., 2017; Ribas and 
Wolchok, 2018; Topalian et al., 2012, 2015; Wolchok et al., 2013) to reinvigorate effector 
functions of Tex cells, representing the key responding cells to checkpoint blockades (Huang et 
al., 2017; Kamphorst et al., 2017; Twyman-Saint Victor et al., 2015). Additionally, targeting CRs 
or cytokine receptors in combination with checkpoint blockades are also currently in clinical 
trials to improve Tex rejuvenation. Recently, the first two CAR-T-cell-based immunotherapies 
to treat B cell lymphoma patients targeting CD19-expressing B cells have been approved by the 
FDA. Since CAR T cells are supposed to act within the exhaustion-promoting microenvironment 
of solid tumors, checkpoint inhibitor treatment might have to be administered in combination to 
prevent exhaustion of CAR T cells upon administration. 
What do all these immunotherapeutic strategies have in common? They collectively rely on the 
understanding of the biology of T cell exhaustion. Therefore, it is necessary to deepen our 
understanding of the molecular mechanisms and pathways involved in the development and 
control of exhaustion. 
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1.11 The iMCC and cMCC antigen-presenting mouse models 
T cell exhaustion has been mainly studied using the LCMV cl13 infectious model. Since a LCMV 
cl13 infection typifies a chronic viral infection with continuously high productive replication 
(Virgin et al., 2009) complex immune responses are initiated, including innate and adaptive 
immunity. Besides the complexity of the induced immune response, the LCMV cl13 infection 
model brings with it confounding factors that affect the animal´s immune system more generally. 
It causes permanent splenocytic lymphopenia (Ejrnaes et al., 2006) and immunosuppression 
(Borrow et al., 1995), as infected hosts fail to establish an efficient immune response against 
unrelated Vaccinia virus for at least one month (Althage et al., 1992). It has also been shown 
that unspecific (bystander) T cells become unresponsive during a LCMV cl13 infection 
(Barnstorf et al., 2019; Mothe et al., 2007). Additionally, LCMV cl13 infected mice are actually 
able to clear the pathogen within 40 to 80 days (Matloubian et al., 1994). However, the 
contributions of the LCMV cl13 model are very important for our understanding of T cell 
mediated immunity. 
To avoid complex immune responses that are hard to dissect, a minimalistic system without the 
induction of responses where innate and adaptive immunity can be triggered independently 
would be an ideal tool to investigate T cell exhaustion. Here we have used a dtg mouse model 
for the manipulation of specific antigen presentation by DC which has been used already to 
investigate DC activation and maturation (Obst et al., 2007), CD4+ T cell priming (Obst et al., 
2005; Rabenstein et al., 2014), and to address questions regarding antigen persistence in vivo 
(Han et al., 2010).  
This minimalistic antigen-presenting mouse model is based on Bujard´s tetracycline system 
(Figure 5) and consists of two genetically modified antigen-presenting recipient mouse lines of 
the B10.BR background (iMCC and cMCC) as well as an MCC-specific TCR-transgenic CD4+ 
T cell donor mouse line (AND). In the inducible iMCC model, antigen presentation of moth 
cytochrome C (MCC) by H-2Ek can be induced in DCs by doxycycline-induced expression of 
the reverse tetracycline transactivator transgene (rTA-S2) driven by invariant chain (Ii, CD74) 
promoter and MHC class II enhancer elements. Ii-rTA tg expression then drives the expression 
of the second tg (TIM) encoding for a modified Ii cDNA where the CLIP region is replaced by 
MCC93-103 (Figure 5). In the constitutive cMCC model, a fusion protein of the invariant chain (Ii) 
of MHC class II and the MCC88-103 peptide is constitutively expressed under the control of H-
2Eα promoter elements (Figure 5) thus presenting high dose antigen. Adoptively transferred 
AND TCR transgenic CD4+ T cells specifically recognize MCC93-103 and MCC88-108 in the context 
of H-2Ek (Han et al., 2010; Kaye et al., 1989) (Figure 6) (more on the mouse models see section 
4.2.3). 
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Fig. 5: Transgenic systems for manipulated antigen MCC expression in vivo. Genetically modified antigen-
presenting recipient mice of the B10.BR genetic background present moth cytochrome C (MCC) by H-2Ek (MHC 
class II) either in an inducible (left: iMCC) or constitutive (right: cMCC) manner. In the iMCC model (on the left), MCC 
expression can be induced in DCs by doxycycline-induced expression of the reverse tetracycline transactivator 
transgene (rTA-S2) driven by invariant chain (Ii, CD74) promoter. In presence of doxycycline (dox) Ii-rTA transgene 
expression drives the expression of the second transgene (TIM) encoding for a modified invariant chain (Ii) cDNA 
where the class II-associated invariant chain peptide (CLIP) region is replaced by MCC93-103. In the constitutive cMCC 
model (on the right), a fusion protein of the invariant chain of MHC class II and the MCC88-103 peptide is constitutively 
expressed under the control of H-2Eα promoter elements. In both mouse models, MCC on H-2Ek can be specifically 
recognize by MCC-specific TCR-transgenic CD4+ T cells (AND).  
 
 
Thus, this minimalistic mouse model offers the opportunity to investigate T cell plasticity for 
several reasons. First, antigen presentation in the iMCC strain can be rapidly induced and 
terminated at any given time point e.g. after T cell priming on day three to generate memory T 
cells, or after 10 or even 30 days post transfer to generate early and late antigen-exhausted T 
cells, respectively (Han et al., 2010). Second, antigen dose is tunable depending on the amount 
of dox, which is fed with the drinking water (section 4.2.6). This allows us to analyze different T 
cell behaviors in response to varying amounts of presented antigen. In this regard, low or 
intermediate levels of antigen using the iMCC model and high-level antigen using the cMCC 
model. Third, antigen presentation is reversible, meaning we can study secondary responses 
as we reapply dox at a given time point. Most importantly, chronic antigen presentation can be 
investigated in the absence of potentially distracting innate, CD8+ T cell, or B cell responses, 
without complicating inflammation, permanent splenocytic lymphopenia, and 
immunosuppression (Han et al., 2010). Thus, whether and how CD4+ T cells become exhausted 
or dysfunctional by persistent antigen presentation can be studied within an otherwise sterile 
environment.  
 
 
 
Ii-rTA TIM
dox
AND TCR tg
Ek/ MCC93-103
AND TCR tg
H-2Ea Ii-MCC
Ek/ MCC88-103
cMCCiMCC
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2. Motivation and Aim of the Thesis 
 
During our entire life, we encounter a large variety of pathogens. On average, we are chronically 
infected with eight to 12 different viruses (Virgin et al., 2009). Some of them are so common 
that we consider them as part of our normal microbial flora, our metagenome (Virgin et al., 
2009). However, chronic infections are considered as one of the biggest global health threats 
(Frebel et al., 2010). This raises the questions how our immune system deals with chronic 
pathogens and how it copes with persistent non-self-antigen presentation. During chronic viral 
infections e.g. with HBV, HCV, or HIV, as well as during cancer, T cells enter a progressively 
dysfunctional state and become “exhausted”. The same phenomenon was reported for about 
40% of cancer patients treated with CAR-T-cell-based immunotherapy targeting CD19+ B cell 
acute lymphoblastic leukemia (B-ALL) (McLane et al., 2019; Wang et al., 2017). Furthermore, 
it has been reported that for a maximal antitumor CAR-T-cell-based response, the ratio of used 
naïve CD4+ to central memory CD8+ T cells plays a crucial role, thus implying the importance 
of functional CD4+ T cells. In the context of T cell exhaustion, CD8+ T cell responses have been 
extensively studied in mice primarily using chronic LCMV cl13 infections. Even though the 
importance of CD4+ T cells during such chronic viral infections has been demonstrated some 
time ago (Matloubian et al., 1994), the role and function of CD4+ T cells during chronic viral 
infections and cancer is still unclear.  
Therefore, the aim of this study was to investigate the role of persisting antigen presentation 
beyond the priming phase of CD4+ T cells and to analyze their differentiation profile and 
functionality in response to increasing antigen-dose and -timing. Understanding the underlying 
molecular mechanisms involved in CD4+ T cell exhaustion may allow to improve immunological 
approaches, such as immunotherapies, to rejuvenate functional effector T cell responses in 
endogenous CD4+ and CAR T cells. 
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3.  Materials and Methods 
3.1 Materials 
3.1.1 Chemicals and solutions 
Product Supplier 
2-Mercaptoethanol  Carl Roth, Arlesheim, Switzerland 
Agarose Peqlab, Erlangen, Germany 
Antibiotic/antimycotic  GE Healthcare, Chalfont St Giles, UK 
BD Cytofix Buffer BD, Franklin Lakes, NJ, USA 
BD PermBuffer III BD, Franklin Lakes, NJ, USA 
Bovine serum albumin (BSA), Fraction V Fisher Scientific, Schwerte, Germany 
Brefeldin A  Sigma-Aldrich, Steinheim, Germany 
Casy ton Roche, Basel, Switzerland 
CellTraceTM Violet  Invitrogen, Carlsbad, CA, USA 
CFDA-SE Cell Tracer Kit  Invitrogen, Carlsbad, CA, USA 
Chloroform  Carl Roth, Arlesheim, Switzerland 
DAPI (4´,6-diamidino-2-phenylindole) Invitrogen, Carlsbad, CA, USA 
Dimethyl sulfoxide (DMSO) Fischer Scientific, Schwerte, Germany 
DMEM (powder)  AppliChem, Darmstadt, Germany 
dNTPs  Peqlab, Erlangen, Germany 
Doxycycline  AppliChem, Darmstadt, Germany 
EDTA (Gibco)  Life Technologies, Carlsbad, CA, USA 
Ethanol  Diagonal, Münster, Germany 
Ethidium bromide (1% solution)  AppliChem, Darmstadt, Germany 
FCS (Gibco)  Life Technologies, Carlsbad, CA, USA 
Foxp3/ Transcription Factor staining buffer set eBioscience, San Diego, CA, USA 
     Fixation/Permeabilization Concentrate  
     Fixation/Permeabilization Diluent  
     Permeabilization buffer (10x)  
FVD (eFlour450 and eFlour660)  eBioscience, San Diego, CA, USA 
Gelatin  Sigma-Aldrich, St. Louis, MO, USA 
Gene ruler (Fermentas)  Thermo Fisher Scientific, Waltham, MA, USA 
GenEluteTM-LPA Sigma-Aldrich, St. Louis, MO, USA 
Glycerin AppliChem, Darmstadt, Germany 
H2O AppliChem, Darmstadt, Germany 
Hen egg lysozyme (HEL) Sigma-Aldrich, St. Louis, MO, USA 
HEPES (PAA)  GE Healthcare, Chalfont St Giles, UK 
IC Fixation Buffer eBioscience, San Diego, CA, USA 
Imject® Alum Thermo Fisher Scientific, Waltham, MA, USA 
Ionomycin (IM) Diagonal, Münster, Germany 
Isopropanol  Diagonal, Münster, Germany 
L-Glutamine (PAA)  GE Healthcare, Chalfont St Giles, UK 
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Linear Polyacrylamide (LPA) Sigma-Aldrich, St. Louis, MO, USA 
MACS anti-biotin MicroBeads Miltenyi Biotec, Bergisch Gladbach,Germany 
MEM non-essential amino acids (PAA)  GE Healthcare, Chalfont St Giles, UK 
Moth cytochrome C (MCC) peptide CGG-88-103 Peptides & Elephants, Potsdam, Germany 
Orange G  Sigma-Aldrich, St. Louis, MO, USA 
Pancoll human PAN Biotech GmbH, Aidenbach, Germany 
Paraformaldehyde Diagonal, Münster, Germany 
PCR Buffer  Peqlab, Erlangen, Germany 
PCR Enhancer  Peqlab, Erlangen, Germany 
PCR Water  AppliChem, Darmstadt, Germany 
Phorbol myristate acetate (PMA) Sigma-Aldrich, Steinheim, Germany 
Pigeon cytochrome C (PCC) peptide 93-103 Sigma-Aldrich, Steinheim, Germany 
Polymycin B  AppliChem, Darmstadt, Germany 
Proteinase K  Diagonal, Münster, Germany 
RCB Lysis Buffer  Biolegend, San Diego, CA, USA 
RPMI 1640 + GlutaMAX Supplement Life Technologies, Carlsbad, CA, USA 
Streptavidin (PE, PeCy7, BV450)  Biolegend, San Diego, CA, USA 
Taq all inclusive Peqlab, Erlangen, Germany 
     (peqGOLD Taq DNA polymerase, reaction  
     buffer, enhancer solution P, dNTP-mix)  
TRIS AppliChem, Darmstadt, Germany 
Triton X-100 (Fluka)  Sigma-Aldrich, St. Louis, MO, USA 
Trizol LS reagent Life Technologies, Carlsbad, CA, USA 
Trypan Blue  Carl Roth, Arlesheim, Switzerland 
Volvic, Water Danone Waters, Frankfurt, Germany 
 
3.1.2 Buffers and media 
Buffers or Media Ingredients 
Agarose gel (1%) 1.5 g Agarose 
 150 mL TAE (1 x) 
  
Cell transfer buffer DMEM 
 10 mM HEPES 
  
CFSE/CTV medium  PBS (1 x) 
 0.1% BSA (w/v) 
  
Culture medium RPMI + GlutamaxTM  
 10% BSA 
 5 mM HEPES 
 5 mM nonessential amino acids 
 2 µL β-Mercaptoethanol 
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DMEM (pH 7.0) DMEM (w/v) 
 3.7 g NaHCO3 
 10 mL HEPES 
 50 mL BSA 
 add up to 1 L H2O 
  
DNA isolation buffer (10 x)  H2O 
 670 mM TRIS, pH8.8 
 166 M (NH4)2SO4 
 65 mM MgCl2 
 0.1% Gelatin 
  
Doxycycline (20 mg/mL) 1 g Doxycycline 
 add up to 50 mL H2O (Volvic) 
  
Ethidiumbromid 7.44 mL H2O 
 650 µL Ethidium bromide (1%) 
  
FACS medium DMEM  
 HyCloneTM HEPES solution  
 1% bovine serum albumin (BSA) 
  
FACS medium ø BSA DMEM w/ HEPES 
  
Gene ruler  100 µL Marker 
 700 µL TAE 
 200 µL Loading buffer 
  
Loading buffer (6 x) 250 mg Orange G 
 30 mL Glycerol 30% 
 70 mL H2O 
  
MACS buffer degassed PBS (1 x) 
 0.5% BSA (w/v) 
 1 mM EDTA 
  
Paraformaldehyde buffer (2%) pH 7.4 PBS 
 2% Paraformaldehyde 
  
PCR mastermix H2O 
 1 x PCR buffer 
 0.5x PCR enhancer 
 0.5 µM Oligonucleotide 1 
 0.5 µM Oligonucleotide 2 
 0.2 mM dNTPs 
 0.026 U/µL Taq polymerase 
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Phosphate buffered saline (PBS) (10 x) 90 g NaCl 
 14.33 g Na2HPO4x2H2O 
 2.17 g KH2PO4 
 add up to 1 L H2O  
Phosphate buffered saline (PBS) (1 x) 100 mL PBS (10 x) 
 add up to 1L H2O 
  
Proteinase K buffer DNA isolation buffer (1 x) 
 0.3 mg/mL Proteinase K 
 0.5% Triton X-100 
 1% β-Mercaptoethanol 
  
T cell medium  RMPI 1680 
 10 % FCS (v/v) 
 2 mM Glutamine 
 MEM non-essential amino acids 
 5 μM β-Mercaptoethanol 
  
TAE (50 x) 242 g TRIS 
 57.1 mL acetic acid 99% 
 100 mL EDTA 0.5 M, pH8 
 add up to 1 L with H2O 
  
TAE (1 x) 20 mL TAE (50 x) 
 add up to 1L H2O 
  
TE  H2O 
 1 M TRIS, pH 7.6 
 0.5 M EDTA 
  
Tissue digestion buffer PCR H2O 
 DNA isolation buffer (1 x) 
 0.3 mg/mL Proteinase K 
 0.5% Triton X-100 
  
Tris-EDTA 10 mM Tris, pH 7.6 
 1 mM EDTA 
  
Trypan Blue solution (10 x)  PBS 
 0.05% Trypan Blue (w/v) 
  
3.1.3 Kits 
Product Supplier 
Agilent RNA 6000 Pico Agilent, Böblingen, Germany 
CTV Cell Tracer Kit Invitrogen, Carlsbad, CA, USA 
NucleoSpin® RNA Clean-up XS Macherey-Nagel, Düren, Germany 
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3.1.4 Oligonucleotides 
Target gene/construct Primer name  Sequence (5’-3’) 
CD45.1 RO489 CATGGGGTTTAGATGCAGGA 
 RO490 GCAAGGCAGGATGCTAGAAA 
   
CD45.2 RO484 GAGCCTGTATCTAAACCTGAGT 
 RO487 GGCAACATGCCCCTTAACT 
   
li-rTA RO281  GTCTCAGAAGTGGGGGCATA 
 RO282  GGACAGGCATCATACCCACT 
   
NR4 RO445 CGGGTCAGAAAGAATGGTGT 
 RO446 CAGTTTCAGTCCCCATCCTC 
   
SWHEL HC RO373 GTCTCTGCAGGTGAGTCCTAACTTCT 
 RO374 CAACTATCCCTCCTCCAGCCATAGGAT 
   
SWHEL LC RO375 CAGGGCCAGCCAAAGTATTG 
 RO376 TCCAACCTCTTGTGGGACAGTT 
   
TIM RO235  CTCATCTCAAACAAGAGCCA 
 RO236 CACTGCTTACTTCCTGTACC 
   
EAMCC RO295 CAGGCCACCACTGCTTACTT 
 RO296 ATCTTCCAGTTCACGCCATC 
 
3.1.5 Enzymes 
Enzyme Supplier 
rDNAse Macherey-Nagel, Düren, Germany 
Proteinase K Diagonal, Münster, Germany 
Peg Gold Tag DNA Polymerase Peqlab, Erlangen, Germany 
 
3.1.6 Antibodies 
3.1.6.1   Antibodies for flow cytometry and cell sorting 
Specificity  Conjugate(s)  Clone Reactivity Company 
CD4  PerCP-Cy5.5, 
Al647 
RM4-5  rat anti-mouse Biolegend, San Diego, CA, USA 
CD4  PE, PE/Cy7 Gk1.5  rat anti-mouse eBioscience, San Diego, CA, USA 
CD5  bio, PE 53-7.3  rat anti-mouse Biolegend, San Diego, CA, USA 
CD8α  bio 53-6.7  rat anti-mouse Biolegend, San Diego, CA, USA 
CD11b  bio M1/70  rat anti-mouse Biolegend, San Diego, CA, USA 
CD11c  bio N418  armenian hamster α-mouse Biolegend, San Diego, CA, USA 
CD19 Al647 6D5 rat anti-mouse Biolegend, San Diego, CA, USA 
CD44 FITC, PE/Cy7  IM7  rat anti-mouse/human Biolegend, San Diego, CA, USA 
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CD45.1  Al488, Al647, 
PerCP, 
BV510 
A20  mouse anti-mouse Biolegend, San Diego, CA, USA 
CD45.2  PE, Al647  104 mouse anti-mouse Biolegend, San Diego, CA, USA 
CD45R 
PeCy7, 
BV510 RA3-6B2 
rat anti-mouse 
Biolegend, San Diego, CA, USA 
CD49b bio DX5  rat anti-mouse Biolegend, San Diego, CA, USA 
CD62L  PE MEL-14  rat anti-mouse Biolegend, San Diego, CA, USA 
CD69  PE H1.2F3  armenian hamster α-mouse Biolegend, San Diego, CA, USA 
CD73 PE TY/11.8 rat anti-mouse Biolegend, San Diego, CA, USA 
CD90.1 Fitc HIS51 mouse anti-mouse eBioscience, San Diego, CA, USA 
CD90.1 PE KW322 mouse anti-mouse/rat Biolegend, San Diego, CA, USA 
CD90.1  Al647, PerCP OX7 rat anti-mouse Biolegend, San Diego, CA, USA 
CD127 PE A7R34 rat anti-mouse eBioscience, San Diego, CA, USA 
CD134 
(Ox40) 
PE Ox-86 rat anti-mouse Biolegend, San Diego, CA, USA 
CD137L PE TKS-1 rat anti-mouse Biolegend, San Diego, CA, USA 
CD154 
(CD40L) 
PE MR1 armenian hamster α-mouse Biolegend, San Diego, CA, USA 
CD200 
(Ox2) 
PE OX-90 rat anti-mouse Biolegend, San Diego, CA, USA 
CD218a    
(IL-18Ra) 
PE P3TUNYA rat anti-mouse eBioscience, San Diego, CA, USA 
CD223 
(LAG-3) 
bio C9B7W rat anti-mouse Biolegend, San Diego, CA, USA 
CD244.2 
(2B4) 
FITC m2B4 
(B6)458.1 
mouse anti-mouse Biolegend, San Diego, CA, USA 
CD278 
(ICOS) 
FITC C398.4A armenian hamster α-mouse Biolegend, San Diego, CA, USA 
CD279    
(PD-1) 
PE/Cy7 RMP1-30 rat anti-mouse Biolegend, San Diego, CA, USA 
CD366 
(Tim-3) 
PE RMT3-23 rat anti-mouse Biolegend, San Diego, CA, USA 
cMaf PE symOF1 mouse anti-mouse/human Invitrogen, USA 
FC-
receptor  
unconjugated  2.4G2  rat anti-mouse BioXcell, West Lebanon, NH, USA 
Foxp3 eFluor® 660 FJK-16s rat anti-mouse eBioscience, San Diego, CA, USA 
FR4 PE/Cy7 eBio12A5  rat anti-mouse eBioscience, San Diego, CA, USA 
IFN-γ  APC XMG1.2  rat anti-mouse Biolegend, San Diego, CA, USA 
IL-2 PE/Cy7 JES6-5A4 rat anti-mouse eBioscience, San Diego, CA, USA 
IRF4 PE IRF4.3E4 mouse anti-mouse/human Biolegend, San Diego, CA, USA 
LAT unconjugated   rabbit anti-mouse Cell Signaling, Cambridge, UK 
Ly-6C FITC HK1.4 rat anti-mouse Biolegend, San Diego, CA, USA 
NFATc1 Al488 7A6 mouse anti-mouse/human Biolegend, San Diego, CA, USA 
TCR β FITC, AL647 H57-597  armenian hamster α-mouse Biolegend, San Diego, CA, USA 
Ter119  bio TER-119 rat anti-mouse Biolegend, San Diego, CA, USA 
TIGIT PE 1G9 mouse anti-mouse Biolegend, San Diego, CA, USA 
TNF-α  FITC MP6-
XT22 
rat anti-mouse Biolegend, San Diego, CA, USA 
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TOX PE TXRX10 rat anti-mouse Invitrogen, USA 
Vα11 APC RR8-1 rat anti-mouse eBioscience, San Diego, CA, USA 
Vβ3  FITC  Kj25  
 
Kindly provided by N. Asinovski, 
C. Benoist and D. Mathis (Harvard 
Medical School, Boston, MA, USA) 
3.1.6.2   Secondary antibodies  
Specificity  Conjugate(s)  Clone Reactivity Company 
Anti-Rabbit IgG FITC Poly4055 Goat BD, Franklin Lakes, NJ, USA 
 
3.1.6.3   Isotype control antibodies 
Specificity   Conjugate(s)  Clone Reactivity Company 
IgG unconjugated  DA1E Rabbit Cell Signaling, Cambridge, UK 
IgG1, κ Al488, PE MOPC-21 Mouse Biolegend, San Diego, CA, USA 
IgG1, κ FITC, APC RTK2071 Mouse Biolegend, San Diego, CA, USA 
IgG2a, κ Al488, PE, PE/Cy7 RTK2758 Mouse Biolegend, San Diego, CA, USA 
 
3.1.6.4   Antibodies used in vivo or in vitro 
Specificity Clone Company 
CD40 FGK45.5 BioXcell, West Lebanon, NH, USA 
CD3 145-2C11 BioXcell, West Lebanon, NH, USA 
CD28 37.51 BioXcell, West Lebanon, NH, USA 
 
3.1.7 Consumables 
Product Supplier 
Cannulas 23G blue Carl Roth, Arlesheim, Switzerland 
Casy cups Roche, Basel, Switzerland 
Cell culture plate, 6-well  Sarstedt, Nümbrecht, Germany 
Cell culture plate, 96-well round bottom  Sarstedt, Nümbrecht, Germany 
Cell strainer (100 µm, sterile)  BD, Franklin Lakes, NJ, USA 
Cover slides (glass)  Diagonal, Münster, Germany 
Dissecting scissors WPI-europe, Hertfordshire, UK 
Ear punch, 10 cm, 2 mm diameter WPI-europe, Hertfordshire, UK 
FACS tubes  Sarstedt, Nümbrecht, Germany 
Filter tips OneTip, 1-10 µL Starlab, Hamburg, Germany 
Filter tips OneTip, 2-20 µL Starlab, Hamburg, Germany 
Filter tips, 1000 µL Diagonal, Münster, Germany 
Glaspipette 5 mL Diagonal, Münster, Germany 
Gloves small Diagonal, Münster, Germany 
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Insulin syringes 0.5 mL 0.30 x 8 mm Diagonal, Münster, Germany 
Insulin syringes 1 mL 0.33(29G) x 12.7 mm Diagonal, Münster, Germany 
MACS LS columns Miltenyi, Bergisch-Gladbach, Germany 
Microfine Syringes for i.p and i.v. injections  BD, Franklin Lakes, NJ, USA 
Non-Stick Rnase-Free 1.5 mL Microfuge Tubes Thermo Fisher Scientific, Waltham, MA, USA 
Omnifix 1 mL syringes Diagonal, Münster, Germany 
Omnifix 20 mL syringes Diagonal, Münster, Germany 
Operating scissors WPI-europe, Hertfordshire, UK 
PCR reaction tubes stripes Diagonal, Münster, Germany 
PCR-plates, 96-well  Diagonal, Münster, Germany 
Petri dish 60 mm x 15 mm Diagonal, Münster, Germany 
Pipette tips 20-200 µL, yellow Brand, Wertheim, Germany 
Pipette tips 50-1000 µL, blue Brand, Wertheim, Germany 
Polyamide-mesh, pore size 150 µm  RCT, Heidelberg, Germany 
Polyamide-mesh, pore size 80 µm  RCT, Heidelberg, Germany 
Reaction tube rack Carl Roth, Arlesheim, Switzerland 
Reaction tubes 50 mL Greiner, Kremsmünster, Austria 
Reaction tubes round-bottom 4 mL and 14 mL BD, Franklin Lakes, NJ, USA 
Reaction tubes Safeseal 1.5 mL Sarstedt, Nümbrecht, Germany 
Rotilabo-Abdeckfolien für PCR-Platten Carl Roth, Arlesheim, Switzerland 
Serological pipettes 5 mL, 10 mL, 25 mL Sarstedt, Nümbrecht, Germany 
Steril filter Milex-GP 0.22 µm Diagonal, Münster, Germany 
TPP Bottle-Top-Filter 500 mL, 0.22 µm Sigma-Aldrich, ST. Louis, MO, USA 
 
 
3.1.8 Laboratory equipment 
Device Manufacturer 
Affymetrix Mouse Gene ST 2.0 arrays  Thermo Scientific, Rockford, IL, USA 
BD FACSCalibur Flow Cytometer BD Bioscience, Franklin Lakes, NJ, USA 
BD FACSCanto II Flow Cytometer BD Bioscience, Franklin Lakes, NJ, USA 
Bioanalyzer Agilent, Böblingen, Germany 
CASY Cell Counter & Analyzer Omni Life Science, Bremen, Germany 
Centrifuge 5417R  Eppendorf, Hamburg, Germany 
Centrifuge 5424  Eppendorf, Hamburg, Germany 
Centrifuge Rotanta 460 R  Hettich, Tuttlingen, Germany 
Electrophoresis Power supply (EPS200)  Pharmacia Biotech, Upsalla, Sweden 
Encore® Biotin Module NuGEN Technologies, San Carlos, CA, USA 
Fridge, Freezer Liebherr, Bulle, Switzerland 
Gamma-cell 40  AECL, Chalk River Laboratories, Canada 
Gel-documentation system  Intas, Göttingen, Germany 
GeneChip Scanner 3000 7G Thermo Scientific, Rockford, IL, USA 
Heatblock Thermomixer 5436 Eppendorf, Hamburg, Germany 
HeraeusTM MultifugeTM X3R Thermo Scientific, Rockford, IL, USA 
Ice machine Scotsman, Radevormwald, Germany 
ImageStream®X Imaging Flow Cytometer EMD Millipore Seattle, WA, USA 
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Incubator 5 % CO2  Heraeus, Hanau, Germany 
Incubator 5% CO2, 3% O2  Heraeus, Hanau, Germany 
Laminar airflow cabinet HeraSafe  Heraeus, Hanau, Germany 
Microscope Labovert FS  Leitz, Wetzlar, Germany 
Microscope Leica Leica Microsystems GmbH, Wetzlar, Germany 
Microwave DAEWOO, Seoul, South Korea 
MoFlo XDP Sorter Beckman Coulter, Indianapolis, IN, USA 
Multichannel pipette  Brandt, Wertheim, Germany 
Multifuge X3R Heraeus, Hanau, Germany 
Ovation Pico WTA System V2  NuGEN Technologies, San Carlos, CA, USA 
Pipette 12-channel, 20-200 µL Eppendorf, Hamburg, Germany 
Pipette 8-channel, 0.1-10 µL Eppendorf, Hamburg, Germany 
Pipettes Brandt, Wertheim, Germany 
Thermocycler TADVANCED Biometra, Göttingen, Germany 
Thermocyler T1  Biometra, Göttingen, Germany 
Vortex Genie 2 Bender & Hobein, Zürich, Switzerland 
Water bath  Lauda, Lauda-Köningshofen, Germany 
 
 
3.1.9 Software 
Software Company 
BD cell quest  BD, Franklin Lakes, NJ, USA 
FACSDiva 6.1.2  BD, Franklin Lakes, NJ, USA 
Flowjo 10.4.2 for Mac  Treestar Ashland, OR, USA 
Gel Documentation System  Intas, Göttingen, Germany 
GenePattern 3.7.0  Broad Institute, Cambridge, MA, USA 
Graph Pad Prism 7.0c for Mac  GraphPad, La Jolla, CA, USA 
IDEAS Application Version 6.2 Merck KGaA, Darmstadt, Germany 
Microsoft Office for Mac 2011 Microsoft, Redmond, WA, USA 
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3.2  Mice and treatment of mice 
3.2.1 Wild type (wt) mice  
Mice with the B10.BR-H2k2H2-T18a/SgSnJ background were used as wild type mice and were 
originally received from the Jackson Laboratory (stock number 004804). 
3.2.2 Congenic markers 
For identification of adoptively transferred cells the congenic markers CD45.1 (Ly5.1) and 
CD90.1 (Thy-1.1) were used. Both markers were originally derived from B6.SJL-Ptprca 
Pepcb/BoyJ and B6.PL-Thy1a/CyJ mice, respectively and provided by Diane Mathis and 
Christophe Benoist at Harvard Medical School in Boston, MA, USA. 
3.2.3 Genetically modified mice 
3.2.3.1   T cell receptor transgenic mice 
AND T cell receptor (TCR) transgenic (tg) mice (B10.BR-Tg(TcrAND)53Hed) harbor T cells with 
predominant expression of a MHC II-restricted TCR consisting of productively rearranged 
Vα11.1-Jα84 and Vβ3-Jβ1.2 chains that recognize a core epitope derived from moth 
cytochrome c (MCC93-103) or pigeon cytochrome c (PCC94-104) in the context of H-2Ek (Kaye et 
al., 1989). AND-tg mice were kindly provided by Diane Mathis and Christophe Benoist at 
Harvard Medical School in Boston, MA, USA. The Vα11 and Vβ3 transgenic constructs were 
obtained from the CD4+ T cell clones AN6.2 and 5C.C7, respectively and contain endogenous 
promotor and enhancer elements. To generate AND-tg mice both constructs were co-injected 
into male pronuclei of (B6xSJL) F2 zygotes (Kaye et al., 1989). For some experiments, RAG1 
deficient AND TCR-tg mice were used. They produce > 90% TCR-tg CD4+ T cells in the lymph 
nodes. Such ANDxRAGo/o mice lack endogenous B and T cell pool and exclusively harbor T 
cells that express the AND TCR. For TCR signal transduction experiments, double transgenic 
(dtg) AND+Nur77-EGFP-reporter mice were used. To generate such reporter mice AND TCR-
tg animals were crossed to Nur77-EGFP-reporter mice (Tg(Nr4a1-EGFP/cre)820Khog) which 
were generated by inserting an enhanced green fluorescent protein (eGFP) reporter gene at 
the ATG start site of a Nr4a1 BAC transgene (Moran et al., 2011). Nur77-EGFP-reporter mice 
were purchased from Jackson Laboratory. All mice were maintained on the B10.BR background 
with one of the congenic markers mentioned above. 
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3.2.3.2   Tet-inducible antigen-expressing double transgenic (dtg) mice 
Dtg iMCC mice expressing the cognate antigen of AND TCR-tg CD4+ T cells, MCC93-103 in the 
context of H-2Ek on MHC II positive cells in a doxycycline-dependent manner (Obst et al., 2005) 
were generated by crossing Ii-rTA tg mice (Tg(Cd74-rtA)#Doi) (Obst et al., 2005) to mice 
carrying the tetracycline (tet)-inducible invariant chain (Ii) with MCC93-103 (TIM) transgene 
Tg(tetO-Cd74/MCC)#Doi (van Santen et al., 2000; van Santen et al., 2004). Since MCC93-103 
replaces the CLIP region of the invariant chain, it is efficiently delivered to the H-2Ek binding 
groove. Dtg iMCC mice were received from Diane Mathis and Christophe Benoist from Harvard 
Medical School in Boston, MA, USA. All mice were maintained on the B10.BR background. 
 
 
3.2.3.3   Constitutive antigen-expressing transgenic mice 
The cMCC mice (Tg(H2-Ea-Cd74/MCC)37Gnnak) constitutively express a fusion protein that 
consists of the invariant chain of MHC II and the MCC88-103 peptide under the control of H-2Eα 
promotor and enhancer elements. Thus, cMCC mice present the cognate antigen MCC88-103 on 
H-2Ek constitutively at a high abundance to AND TCR-tg CD4+ T cells. The cMCC mice were 
kindly provided by Naoko Nakano, Science University of Tokio, Japan and Diane Mathis and 
Christophe Benoist at Harvard Medical School, Boston, MA, USA. All mice were maintained on 
the B10.BR background. 
  
 
3.2.3.4   B cell receptor (BCR) transgenic cMCCxSWHEL mice 
Most B cells of the SWHEL mice (Tg(H2-Ea-Cd74/MCC)37GNnak-Ightm1Rbr Tg(IgkHyHEL10) 
1Rbr-Ptprca) express an anti-hen egg lysozyme (HEL) light chain transgene. SWHEL mice were 
generated by a knock-in of a rearranged VHDJH gene at its physiological position at the 5’ end 
of the IgH locus (Phan et al., 2003) and are able to undergo class switch recombination to all 
Immunoglobulin (Ig) classes. SWHEL mice were kindly received from Martin Turner, Babraham 
Institute of Cambridge, UK. SWHEL mice were crossed to cMCC mice to generate HEL-specific 
Eα enhancer/ Ii promotor rtTAs-S2 CMV-Pcore Ii tetO 
+ do
x 
Ii-rTa TIM 
CLIP  MCC93-103 
Eα enhancer Ii 
MCC88-103 
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B cells presenting MCC88-103 on H-2Ek constitutively. These mice were maintained on the 
B10.BR background with the congenic marker CD45.1. 
3.2.4 Breeding and housing of mice 
All animals were bred and maintained at the animal facility of the Institute for Immunology, 
Ludwig-Maximilians-University of Munich, Munich, Germany. All experiments were approved by 
the Government of Upper Bavaria and conducted in compliance with German federal guidelines. 
3.2.5  Genotyping of mice  
AND TCR-tg mice were typed by surface staining of peripheral blood lymphocytes for the AND 
specific β-chain Vβ3, CD4, and the congenic marker CD45.1 or CD90.1. To do so, 2-3 drops of 
blood from the tail vail were collected and processed and flow cytometric analysis was 
performed as described in section 3.3.3.3. 
All other mice were genotyped by polymerase chain reaction (PCR). For primers and protocols 
see section 3.1.4 and 3.3.1.2.  
3.2.6 Doxycycline treatment 
To induce antigen presentation in iMCC mice, animals were treated with doxycycline (dox) 
diluted in drinking water low in divalent cations (Volvic, Danone Waters, Frankfurt, Germany) to 
prevent formation of precipitates that form in the presence of Mg2+ and Ca2+ and might reduce 
bioactivity of dox. Mice were fed with either low dose (10 µg/ml) or high dose (100 µg/ml) of dox 
in the drinking water, resulting in a “low” and “intermediate” expression on antigen, respectively. 
Dox treatment started usually one day before adoptive T cell transfer and was continued 
according to the experimental set up as indicated within the experimental schemes. 
3.2.7 Intra-peritoneal application of monoclonal antibodies 
DCs were activated in vivo for optimal T cell priming and memory differentiation with a 
stimulatory mAB against CD40 (Hawiger et al., 2001; Obst et al., 2007). Sterile dilution of 
monoclonal antibody α-mouse CD40 (clone FGK45.5) were prepared using 1 x PBS. 20 µg α-
mouse CD40 were injected intraperitoneal (i.p.) per mouse in a volume of 100 µl. 
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3.3 Methods 
3.3.1 Molecular biology 
3.3.1.1   Tissue digest 
Tail biopsies (approximately 2 mm) were removed from mice to be typed and subsequently 
digested in 100 µl proteinase K buffer at 56 °C for at least 6 hours. After digestion proteins were 
denatured by incubation at 90 °C for 10 minutes. 
3.3.1.2   Polymerase chain reaction (PCR) 
For genotyping of transgenic mice, the digested tissue samples were diluted 1:10 in H2O. One 
µL of each dilution was mixed on ice with 24 µL of PCR master mix solution, prepared as 
described in Tab.1. The final PCR reaction mixture was covered with a drop of mineral oil and 
run in the thermo cycler using a standard PCR program, described in Tab. 2. 
 
PCR master mix   
PCR H2O 
 
PCR buffer 1 x 
PCR enhancer 0.5 x 
Oligonucleotide 1 0.5 µM 
Oligonucleotide 2 0.5 µM 
dNTPs 0.2 mM 
Taq polymerase 0.026 U/µL 
 
Table 1: PCR master mix components. 
 
 
 
 
 
 
 
 
Table 2: Standard PCR program. 
 
 
Step Cycle # Repeats Time Heat 
Initial denaturation 1 1 5 min 95 °C 
Denaturation 2 - 36 35 30 sec 95 °C 
Primer annealing 2 - 36 35 30 sec 55 °C 
DNA elongation 2 - 36 35 45 sec 72 °C 
Final elongation 37 1 5 min 72 °C 
Cooling period 38 1 10 sec 20 °C 
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3.3.1.3   Agarose gel electrophoresis 
PCR-amplified DNA fragments were analyzed by agarose gel electrophoresis. DNA samples 
were mixed with sample buffer and loaded side by side with a 100 bp marker ladder on a 1,5% 
agarose gel and run at 120 V for 25 min in 1 x TAE running buffer. To visualize the results, the 
gels were exposed to UV light within a gel documentation system and pictures were taken. 
3.3.1.4   RNA isolation and clean-up 
To isolate total RNA from samples that were FACS sorted in Trizol LS and stored at -80 °C 
(protocol described in section 3.3.3.5) samples were thawed on ice. 300 µL chloroform was 
added and subsequently handshaked 15 times. Samples were incubated for 3 min at RT and 
centrifuged for 15 min (12,000 x g, 4 °C). The upper aqueous phase containing the RNA was 
transferred into new tubes and 1 volume of isopropanol + 1 µL linear polyacrylamide (LPA) was 
added. RNA samples were incubated o/n at -20 °C to increase the precipitation yield. Samples 
were centrifuged for 10 min (12,000 x g, 4 °C), supernatants were removed, and RNA pellets 
were washed with 1 mL of 70% EtOH. Final RNA pellets were dissolved in 100 µL RNAse-free 
water. The NucleoSpin® RNA Clean-up XS kit (Macherey-Nagel) was used to purify RNA 
according to manufacturer´s instructions. Finally, RNAs were eluted in 12 µL supplied RNAse-
free H2O and stored at -80 °C. 
3.3.1.5   RNA quality check 
To assess RNA quality the Agilent RNA 6000 Pico kit was used according to manufacturer´s 
instructions. RNA integrity number (RIN) was measured for each sample using a 2100 
Bioanalyzer and all samples with high quality RNA (RIN > 8) were used for microarray analysis. 
3.3.1.6   Gene expression analysis 
RNA amplification, labeling, and hybridization was done by Martin Irmler and Johannes 
Beckers, Institute of Experimental Genetics, Helmholtz Zentrum München, Neuherberg. For 
RNA amplification the Ovation Pico WTA System V2 together with the Encore Biotin Module 
(Nugen) were used. Amplified cDNA was hybridized on Affymetrix Mouse Gene ST 2.0 arrays 
containing 35,000 probe sets. According to the Affymetrix expression protocol, including minor 
modifications as suggested in the Encore Biotin protocol, staining and scanning were performed 
using a GeneChip Scanner 3000 7G. 
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3.3.2 Cellular methods 
3.3.2.1   Organ removal and generation of single cell suspensions 
Mice were sacrificed by carbon dioxide (CO2) asphyxiation and fixed in a supine position on a 
dissection trey and disinfected with 70% ethanol. The skin was opened medially and laterally. 
Axillary, brachial, and inguinal lymph nodes (LN) were dissected and pooled in 5 mL FACS 
buffer (Van den Broeck et al., 2006). The abdominal wall was opened, the spleen was removed 
and stored in 5 mL FACS buffer kept on ice. Single cell suspensions from lymph nodes and 
spleens were generated by two methods. Organs were ground using the rough side of two 
microscope glass slides and filtered through a mesh with 150 µm pores when cells were 
intended for flow cytometric analysis. For adoptive transfers sterile cell strainers were used. 
Lymph node cell suspensions were centrifuged for 5 min (1,500 x rpm, 4 °C) and the pellets 
were resuspended in 1 mL FACS buffer. Spleen cell suspensions were underlaied with 3 mL 
Pancoll and centrifuged 10 min (2,000 x rpm, 4 °C, deceleration ramp 5 of 9) for separation. 
The lymphocyte layer between Pancoll and FACS buffer was carefully removed, transferred into 
new tubes, and washed with FACS buffer. Pellets were resuspended in 3 mL FACS buffer.  
3.3.2.2   Magnetic-activated cell sorting (MACS) of CD4+ T cells 
Enrichment of polyclonal CD4+ T cells was achieved by negative selection by magnetic-
activated cell sorting (MACS). This technique allows for separation of a certain cell population 
based on characteristic surface marker expression. Cells to be depleted were stained with 
biotinylated antibodies specific for such characteristic surface molecules and subsequently 
incubated with paramagnetic anti-biotin-beads. Thus, allowing separation of labeled and 
unlabeled cells within MACS columns placed in a strong magnet. Magnetically labeled, 
unwanted cells stick to the MACS columns while unlabeled cells can be collected in the flow 
through. CD4+ T cells to be sorted for microarray analysis were thus selected before FACS-
sorting (described in section 3.3.3.5), LN and spleen single cell suspensions were generated 
as described in 3.3.2.1 and pooled from the same mouse. Cell suspensions were centrifuged 
for 5 min (1,500 x rpm, 4 °C), incubated in 200 µL FACS buffer containing biotinylated mAbs as 
listed in tab.3 for 15 min on ice. Cells were washed three times with 3 mL FACS buffer and two 
small aliquots from each sample were taken, one for a pre-MACS purity check using flow 
cytometry analysis and the other (10 µL) to count cell numbers before MACS purification. After 
the last washing step pellets were resuspended in 90 µL FACS buffer and 10 µL anti-biotin-
beads were added per mouse. Samples were incubated for 20 min at 4 °C and swirled gently 
for 10 min. Samples were washed twice with MACS buffer and resuspended in 2 mL MACS 
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buffer. For negative selection cell suspensions were loaded onto equilibrated MACS columns. 
Columns were washed twice with 3 mL MACS buffer. Eluted cells were collected, centrifuged 
for 5 min (1,300 x rpm, 4 °C) and resuspended in 1 mL FACS buffer. Two aliquots were taken, 
one for post-MACS purity check and the other one (10 µL) to count cells post MACS enrichment. 
 
Volume / mouse mAb specificity Target cells 
5 µL CD8 T cells, DCs 
5 µL CD45R B cells 
3 µL CD11b DCs, Macrophages 
3 µL CD11c DCs 
3 µL CD49 NK cells 
3 µL Gr-1 Granulocytes 
3 µL TER119 Erythrocytes 
 
Table 3: Biotinylated mAbs for MACS purification of CD4+ T cells. 
3.3.2.3   Counting live cells in single cell suspension  
Live cells were either counted manually using a Neubauer counting chamber (depth 0.1 mm, 
0.0025 mm2) or automatically, using a CASY Cell Counter & Analyzer. 
For manual cell counting, 10 µL single cell suspension was diluted twice 1:10 in Tryptan blue 
buffer. Under the light microscope live and dead cells could be distinguished by the fact that 
only dead cells take up Tryptan blue. Round unstained cells of two quarters of the counting 
chamber were counted, averaged, and multiplied by 1 x 106 to obtain the cell number per mL. 
For automatic cell counting, 10 µL of a single cell suspension were diluted 1:1000 in CASY 
buffer (10 mL) and measured using CASY Cell Counter & Analyzer. The read with this dilution 
factor equaled to the cell number per 1 mL. 
3.3.2.4   Cell trace violet (CTV) labeling 
Cell trace violet (CTV) is a proliferation indicator dye that binds proteins in the cell and thus gets 
diluted by half per cell division. Therefore, this dye is used for flow cytometric visualization of 
cell proliferation indicated by the reduction of CTV intensity. Using this dye, 1 to 8 cell divisions 
can be detected (Quah and Parish, 2012). To calculate the average number of divisions (N) 
even if peaks were indistinguishable, the MFI values of whole populations were used 
(Rabenstein et al., 2014):   
 
N = log2(CTV MFIctr/CTV MFIsample) 
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To label cells of interest, single cell suspensions were adjusted to 20 x 106 cells per mL of pre-
warmed (37 °C) PBS supplemented with 0.1% BSA. 2 µL 5 mM CTV stock were added per 20 
x 106 cells while gently vortexing. Samples were incubated for 10 min at 37 °C in the dark and 
swirled after 5 min of incubation. After incubation 1 mL pre-warmed PBS + 0.1% BSA was added 
and 1 mL pre-warmed heat-inactivated FCS was underlaid. Samples were centrifuged for 5 min 
(1,500 x rpm, 4 °C) and washed twice with transfer buffer. Cells were counted as described in 
3.3.2.3 and adjusted to 1 x 106 cells/100 µL transfer buffer. 
3.3.2.5   Adoptive T cell transfer 
For adoptive T cell transfer lymph node single cell suspensions from donor LNs were generated 
according to the protocol in section 3.3.2.3. For phenotypic characterization of lymphocytes from 
donor mice, small aliquots of cells were taken and stained for surface markers as listed in Tab. 
4, depending on the congenic markers of these mice. Flow cytometric analysis was used for 
marker visualization (protocol in 3.3.3.1/3.3.3.3). Transgenic TCR expression was confirmed by 
positive Vβ3 staining on CD4+ T cells, congenic marker expression was confirmed by CD45.1 
or CD90.1 surface expression, and lacking CD45R expression verified the ANDxRAGo/o 
phenotype. CD62L and CD44 surface expression determined the activation status of donor 
lymphocytes as naïve CD4+ T cells are CD44lo/intCD62Lhi. Only samples with more than 90% 
naïve cells were used for transfers. Also, the percentage of transgenic CD4+ T cells was 
analyzed. Data were acquired on a Canto II flow cytometer. 
 
Staining FITC PE PerCP PeCy7 Al647 PB BV510 
A Vβ3  CD62L CD4 CD44 CD45.1 Dapi 
 
B Vβ3  CD62L CD4 CD44 CD90.1 Dapi 
 
C Vβ3  CD62L CD4 CD44 CD45.1 Dapi CD45R 
 
Table 4: Antibody-staining strategies for phenotypic characterization of AND T cells 
 
Upon successfully characterizing donor CD4+ T cells, cell numbers were measured (see 3.3.2.3) 
and absolute transgenic CD4+ T cell numbers were calculated.  
Lymphocytes were washed with 1 mL transfer buffer and adjusted to 1 x 106 transgenic CD4+ T 
cells/100 µL transfer buffer. Cells were always kept on ice. The tails of recipient animals were 
heated briefly and disinfected with 70% ethanol, and 100 µL buffer containing 1 x 106 cells were 
injected intravenously (i.v.). 
  Materials and Methods 
 
	 38	
3.3.2.6   Secondary adoptive T cell transfer 
For secondary adoptive T cell transfers recipient mice were sacrificed, organs were removed, 
and single cell suspensions were generated as described in 3.3.2.1. CD4+ T cells were MACS 
purified according to 3.3.2.2 and prepared and adoptively transferred as described in 3.3.2.5.  
3.3.2.7   Adoptive B cell transfer 
For adoptive B cell transfers single cell suspensions from donor spleens were generated as 
described in 3.3.2.1. Upon Pancoll based separation of splenocytes the percentage of B cells 
was determined by FACS analysis. Antibody staining strategy was used as indicated below. 
Cells were counted and labeled with CTV following the protocol in section 3.3.2.4. The amount 
of CTV labeled B cells was set to 5 x 106 B cells in 100 µL transfer buffer and injected i.v. 
 
Staining FITC PE PerCP PeCy7 Al647 PB 
A HEL-Ig CD62L CD45.1 CD44 CD19 Dapi 
 
Table 5: Antibody staining strategy for phenotypic characterization of B cells 
3.3.2.8   T cell re-stimulation using phorbol myristate acetate and ionomycin 
To investigate CD4+ T cell functionality upon chronic antigen exposure in vivo, cytokine 
production was quantified using flow cytometry upon re-stimulation with PMA and ionomycin in 
vitro. Therefore, splenocyte single cell suspensions were generated as described in section 
3.3.2.3. 4 x 106 cells/well were transferred into a 96-well round-bottom plate and stimulated in 
200 mL RPMI Full media with 20 ng/mL PMA in conjunction with 1 µg/mL Ionomycin. PMA 
stimulates protein kinase C and the Calcium ionophore Ionomycin facilitates the flux of Ca2+ 
ions into cells, thus inducing a very strong TCR-independent stimulation of T cells (Truneh et 
al., 1985). Plates were cultured for 4 h at 37 °C and 5% CO2. 10 µg/mL Brefeldin A, inhibiting 
secretory vesicle formation and transport at the Golgi apparatus and thus preventing cytokine 
release, was included during the last 2 h of incubation (Rabenstein et al., 2014). 
3.3.3 Flow cytometry 
3.3.3.1   Fluorescence-activated cell sorting (FACS) 
The technique of modern high-throughput flow cytometry is used to simultaneously detect, 
measure, and distinguish multiple characteristics of several cell populations within a single cell 
suspension. Cell-specific surface and intracellular markers are usually stained with mAbs either 
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directly or secondarily labeled with a fluorochrome or are genetically modified to be linked to a 
certain fluorescent protein like the enhanced green fluorescent protein (eGFP). To accurately 
measure the fluorescently labeled markers and optical characteristics for identification, labeled 
cells pass uniformly, one cell at the time, through focused laser beams. Also, relative cell size 
and granularity can be estimated by detecting forward-scattered light (FSC) and side-scattered 
light (SSC), respectively. Nowadays, flow cytometers have multiple lasers and detectors 
allowing for multiple mAb labeling and thus enable a precisely identification of target cells and 
their phenotypic characteristics. Using the droplet technology certain cell populations can be 
sorted based on several parameters including cell size and morphology, as well as marker 
expression. Sorted cells and can be later used for other experimental purpose. 
For experimental data acquisition the BD FACSCanto II and for blood-genotyping data 
acquisition the BD FACSCalibur flow cytometers were used. Data analysis was performed using 
FlowJo 10.4 for Mac. 
3.3.3.2   Imaging Flow Cytometry (IFC) 
The technology of imaging flow cytometry combines the common high-throughput single-cell 
identification of conventional flow cytometry with single cell imaging properties of microscopy. 
The advantage of imaging flow cytometry is clearly the production of extraordinarily detailed 
fluorescent single cell images. 
For experimental data acquisition the Millipore ImageStream®X and for data analysis the IDEAS 
Application Version 6.2 were used. 
3.3.3.3   Surface staining of lymphocytes 
To stain surface markers of interest, single cell suspensions were transferred into 96-well plates 
with 3-5 x 106 cells per well, centrifuged for 5 min (1,500 x rpm, 4 °C), and resuspended in 50 
µL mAb solution where Dapi was added to discriminate live and dead cells. Samples were 
incubated for 30 min at 4 °C in the dark and washed twice before flow-cytometric analysis. 
Antibodies were usually diluted 1:400, streptavidin and Dapi were diluted 1:1000. All staining 
and washing steps were performed using FACS buffer. 
3.3.3.4    Intracellular staining of lymphocytes 
For intracellular staining of cytokines PMA/IM stimulated lymphocytes were surface stained as 
describes in 3.3.3.3 but either Dapi (1:1000 in FACS buffer) or fixable viability dye (FVD) 
eFlour450 or eFlour660 (1:1000 in PBS) were used. Cells were fixed in 100 µL IC fixation buffer 
for 20-30 min at RT in the dark, incubated for 5 min at RT in 100 µL BD Perm Buffer III to 
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permeabilize the cell membrane, and washed twice with PBS. Fcγ-receptors were blocked 
using 100 µL 2.4G2 mAb diluted 1:400 in PBS (10 min at RT in the dark) and cytokines were 
stained intracellularly in 100 µL mAb solutions under the conditions described in Tab. 6. 
For intracellular staining of molecules and transcription factors lymphocytes were transferred 
into 96-well plates with 4 x 106 cells/well, stained for 10 min at 4 °C in the dark within 100 µL 
FVD-eFlour450 or -eFlour660 (live/dead discrimination dye) diluted 1:1000 in PBS, washed, 
and subsequently surface stained as describes in 3.3.3.3. Cells were fixed and permeabilized 
using the FoxP3 staining kit following the manufacturer’s protocol. After permeabilization the 
Fcγ-receptors were blocked and intracellular staining was performed as described above but 
instead of PBS, 1 x Permeabilization Buffer was used. 
 
Specificity or dye Dilution Staining condition 
2.4G2  1:400 10 min, RT 
Anti-Rabbit Ig 1:400 30 min, 4°C 
cMaf 1:400 30 min, 4°C 
Draq5 1:1000 1 h, RT or o/n, 4 °C 
FoxP3 1:400 30 min, 4°C 
IFNγ  1:200 30 min, 4°C 
IL-2 1:400 30 min, 4°C 
IRF4 1:400 30 min, 4°C 
LAT  1:100 1 h, 4 °C 
NFATc1 1:100 1 h, RT or o/n, 4 °C 
TCF-1 1:400 30 min, 4°C 
TCR β 1:400 30 min, 4°C 
TNFα 1:100 30 min, 4°C 
Tox 50 µg/well 30 min, 4°C 
 
Table 6: Antibody and dye staining conditions 
3.3.3.5    Cell sorting by flow cytometry for microarray analysis 
Single cell suspensions from LNs and Spleen were pooled and subsequently, CD4+ T cells were 
MACS purified as described in section 3.3.2.2. After a test-surface staining with a small aliquot 
of cells to characterize the adoptively transferred CD4+ T cells via flow cytometry, enriched CD4+ 
T cells were surface stained with α-TCR-Fitc, α-CD90.2-PE, α-CD4-PerCP-Cy5.5, Streptavidin-
PeCy7, α-CD45.1-Al647, and Dapi to identify AND TCR-tg T cells. Surface stained, enriched 
CD4+ T cells were sorted using a Beckman Coulter MoFlo XDC Sorter operated by Lynette 
Henkel (AG Schieman, Institute for Medical Microbiology, Immunology and Hygiene, Technical 
University of Munich, Germany). To achieve high purity two doublet exclusion gates were 
included in the sorting strategy and all samples were sorted twice (see Figure 19). After the first 
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round all cells were sorted into tubes containing 250 µL FACS buffer with Dapi (1:1000) and a 
small fraction of cells were sorted into tubes containing 250 µL FACS buffer for purity check #1. 
During the second round a second small fraction of cells were sorted into tubes containing 250 
µL FACS buffer for purity check #2 and all remaining cells were sorted into tubes containing 
500 µL Trizol LS. Trizol samples were mixed and stored at -80 °C until further processing. 
Control samples were analyzed using flow cytometry (see Figure 20) and found > 99% pure. 
3.3.3.6   Statistical analysis 
Statistical analysis of FACS data was performed using GraphPad Prism® 7.0c and on 
Microarray data using the R 3.5.1 Software. If not indicated otherwise, geometric means, 
standard deviation and p values from unpaired two-tailed Student´s t-test are shown. P values 
< 0.05 were considered as statistically significant. Microarray analyses were done by Dr. Tobias 
Straub, LMU München. 
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4.  Results 
4.1 Identification of transgenic (tg) mice and prove of concept 
4.1.1 Identification of AND TCR transgenic (tg) mice 
To identify AND CD4+ TCR-tg mice, blood genotyping was performed using flow cytometry. 
Blood lymphocytes were tested for the expression of AND specific TCR beta chain Vβ3, lineage 
marker CD4, and congenic marker, either CD90.1 (Figure 6A) or CD45.1 (Figure 6B, upper row: 
RAGwt/wt mice, lower row: RAG0/0 mice). 
To test for TCR transgenes it was sufficient to test for either Vβ3 or Vα11 expression since both 
chains are integrated at the same gene locus. Thus, the positivity of one of both chains, in this 
case Vβ3, indicated the expression of the AND TCR-transgene. For flow cytometric analyses, 
doublets were excluded based on forward scatter area (FSC-A) vs. height (FSC-H), lymphocyte 
gates were set according to the cell´s characteristics on FSC-A vs. side scatter (SSC-A), and 
dead cells were omitted by gating on Dapi negative cells. AND TCR-tg CD4+ T cells were 
identified by CD4+CD45.1+ or CD4+CD90.1+ and Vβ3 surface expression, respectively. 
All AND donor mice were re-typed using flow cytometry before being used for adoptive T cell 
transfer in all experiments. To this purpose both, transgenic TCR expression and activation 
status based on CD44 and CD62L surface expression were tested (Figure 6C). Naïve CD4+ T 
cells express low levels of the activation marker CD44 (Curtsinger et al., 1999) and show a high 
expression of the homing receptor CD62L (Smalley and Ley, 2005). Upon T cell activation CD44 
gets up- and CD62L downregulated (Smalley and Ley, 2005). Only animals with less than eight 
percent activated AND TCR-tg CD4+ T cells were used for transfer experiments. 
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Figure 6: Blood genotyping and identification of AND TCR-tg mice. Flow cytometric identification of AND TCR-
tg mice. All animals were tested for the expression of the AND specific Vβ3 chain and co-expression of the congenic 
marker (A) CD90.1 or (B) CD45.1, according to tested mouse lines. Within the ANDxCD45.1 line we used either 
RAGwt/wt (upper row) or RAG0/0 (lower row) TCR-tg animals. (C) Before mice were used for adoptive T cell transfer 
lymphocytes were re-genotyped. Surface expression of CD4, specific congenic marker CD45.1 or CD90.1, Vβ3 
chain, and activation markers CD44 and CD62L was analyzed. Mice with less than 8% of activated 
CD4+CD44hiCD62Llo T cells were used for experiments. 
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4.1.2 PCR genotyping of antigen-presenting recipient mice 
Antigen-presenting recipient mice were typed by polymerase chain reaction (PCR) according to 
section 3.3.1.2. Here, dtg iMCC mice expressing MCC93-103 in the context of H-2Ek were PCR 
typed for the tetracycline (tet)-inducible invariant chain (Ii) (Figure 7, upper part) and the MCC93-
103 (TIM) transgene (Figure 7, lower part). To exclude genotyping mistakes each transgene was 
tested by two different sets of primer pairs. Double positive animals with matching PCR results 
were used for the following experiments. 
 
                             
 
 
Figure 7: PCR genotyping of genetically modified recipient mice. Representative PCR products from iMCC 
transgenic mice analyzed by agarose gel electrophoresis. Double transgenic mice were tested for the transactivator 
Ii-rTA (upper gel) and the Ii-MCC93-103 fusion protein (lower gel). Two sets of primer pairs were used for reliable 
identification of the two transgenes. From left to right: DNA marker (M) indicating DNA fragment size, water control 
(H2O), negative control (N), PCR-amplified DNA of individual samples (+ or -). 
 
 
4.1.3 Basic gating strategies to identify adoptively transferred cells 
Adoptively transferred AND TCR-tg CD4+ T cells are identified by surface expression of 
congenic markers (CD45.1 or CD90.1) since the recipients carry the .2 allelic variants of each. 
Using this advantage, we were able to follow and analyze adoptively transferred ANDs by flow 
cytometry. Depending on the experimental nature we either characterized the cell´s surface 
marker expression using the gating strategy described in Figure 8A or identified intracellular 
markers such as transcription factors or cytokines according to the gating strategy shown in 
Figure 8B. Doublets were excluded based on forward scatter area (FSC-A) versus height (FSC-
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H). Next, we gated on lymphocytes according to the cell´s characteristics on FSC-A versus side 
scatter (SSC-A) and omit dead cells by gating on either Dapi negative viable cells or FVD 
negative fixed cells. This gating strategy was used for all experiments. 
 
            
Figure 8: General flow cytometric gating strategies to identify cells of interest. Representative gating scheme 
to identify (A) viable or (B) fixed AND TCR-tg CD4+ T cells and (C) to identify viable HEL-specific BCR-tg B cells and 
AND T cells upon consecutively adoptive cell transfer. (A, B) Depicted are splenocytes 10 days post transfer (dpt) 
(C) and 15 dpt. 
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To follow and distinguish two different cell types consecutively transferred into the same 
recipients we took advantage of two congenic markers CD45.1 and CD90.1 to identify BCR tg 
B and TCR tg CD4+ T cells respectively, according to the gating strategy in Figure 8C. Thus, 
HEL-specific BCR tg B cells expressing CD45.1 and AND CD4+ T cells expressing CD90.1 were 
identified by their congenic and cell type specific markers CD45R (B220) and CD4, respectively. 
This gating strategy was also used to distinguish co-transferred AND T cells, which were either 
GFP reporter positive or negative. 
 
4.1.4 CD4+ T cells encounter three different doses of antigen in MCC recipients 
Having observed that AND CD4+ T cells recognize and respond to cognate antigen presented 
by dendritic cells (DCs) in iMCC and cMCC transgenic recipient mice (Han et al., 2010), we 
asked how AND cells respond to cognate antigen presentation in a dose-dependent fashion. 
We labeled AND T cells with Cell Trace Violet (CTV) and adoptively transferred them into 
different hosts. To induce antigen presentation recipient iMCC mice were treated with 
doxycycline (dox) in the drinking water starting the day before transfer (Obst et al., 2005) as 
described in Figure 9A. The dose of dox positively correlates with the amount of MCC93-103 in 
context of H2Ek on DCs in iMCC-recipient mice (Obst et al., 2005), indicated by a higher T cell 
proliferation rate (N ≥ 4) in mice treated with high amount (100 µg/mL) of dox compared to the 
one in mice treated with low amount (10 µg/mL) of dox (N ≥ 3) (Figure 9B and C). In cMCC-
recipient mice, constitutively expressing very high amounts of the agonistic peptide MCC88-103 
in context of H2-EK (Han et al., 2010), we found the highest proliferation rate (N ≥ 6). We found 
TCR downregulation in iMCC recipients, indicating high TCR stimulation as shown by reduced 
Vβ3 surface expression in Figure 9B and C. TCR downregulation is reported to be induced by 
T cell activation via TCR engagement with high affinity peptide MHC (pMHC) (Valitutti et al., 
1995a; Valitutti et al., 1996; Zanders et al., 1983) and is seen as a control mechanism to prevent 
from hyper-activation.  
Next, we used ANDxNur77-GFP reporter mice (Moran et al., 2011) to measure TCR signal 
strength by the three different priming conditions with increasing antigen dose 16 hours post 
transfer (hpt). ANDxNur77-GFP reporter cells were always co-transferred with reporter-negative 
AND T cells to assess specific GFP-reporter expression as opposed to mere changes of 
autofluorescence. TCR stimulation in iMCC treated with high amount (100 µg/mL) of dox and 
cMCC recipients induced high Nur77-GFP-reporter expression, indicating functional TCR 
stimulation and thus, T cell activation by intermediate and high-level of presented antigen.  
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Figure 9: Specific CD4+ T cells respond to three different doses of antigen and respond dose-dependently to 
increasing amount of cognate antigen presented in MCC-transgenic recipients. (A) Schematic outline of the 
experimental approach, adoptive T-cell transfer and treatment strategy of recipient mice. The dose of doxycycline 
(dox) positively correlates with the amount of MCC93-103 in the context of H-2Ek on dendritic cells in iMCC-recipient 
mice. cMCC-recipient mice constitutively express high amounts of the agonistic peptide MCC88-103 in context of H-
2EK. Thus, different AND T cell priming conditions with increasing antigen load could be generated. (B-E) CTV dilution 
and TCR expression of 1 x 106 adoptively transferred AND T cells isolated from recipient spleens using flow 
cytometry. All T cells shown were identified using the gating strategy described in Figure 8A. (B) T cell proliferation 
was used as readout for antigen presentation. Histograms show CellTrace Violet (CTV) dilution of AND T cells in 
response to increasing amounts of cognate antigen three days post transfer. Average numbers of AND T cell 
divisions were calculated with N = log2(gMFIctrl/gMFIsample). The data are representative of three independent 
experiments. (C) Compilation of CTV dilution (upper panel) and TCR (Vβ3) surface expression (lower panel) of AND 
T cells in different recipients three dpt.  Data from at least two independent experiments are shown. (D) Histograms 
show the expression profile of the early T cell activation markers Nur77-GFP and CD69 16 h post T cell transfer. 
Results are representative of two independent experiments. (E) CD69 surface expression in low-dose hosts, 
analyzed 16, 24, and 48 h post T cell transfer. The data are representative of two independent experiments. Antigen 
(Ag), doxycycline (dox). 
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However, low TCR stimulation (iMCC recipients treated with low amount of dox) was insufficient 
to induce Nur77-GFP and surface expression of the early activation marker CD69 (Figure 9D). 
Therefore, we followed AND T cells exposed to low-level antigen presentation over time (16, 
24, and 48 hpt) and found a time-dependent upregulation of CD69 surface expression (Figure 
9E). These data indicate that T cell activation by low-level antigen presentation require more 
time of interaction and accumulate over time to overcome the activation threshold to divide 
(Faroudi et al., 2003). Our results demonstrate that AND TCR-tg CD4+ T cells encounter antigen 
of three different doses in vivo in these recipients at a constant level. 
 
4.2 Characterization of AND T cells exposed to antigen for 10 days  
4.2.1 Experimental setup and survival of antigen exposed CD4+ T cells 
The transgenic mouse models described enabled us to address the role of persisting antigen 
presentation beyond the priming phase on CD4+ T cells in a dose- and time-dependent manner 
within an otherwise sterile environment (Han et al., 2010; Obst et al., 2005). We compared naïve 
and memory AND T cells with those that were exposed to low, intermediate (int), or high antigen 
levels beyond the priming phase. To do so, we generated the above-mentioned conditions 
according to the treatment scheme depicted in Figure 10A.  
iMCC and cMCC recipient mice were injected with 20 µg/mL α-CD40 mAb i.p. on day -1 to 
induce DC maturation as described before (Bonifaz et al., 2004; Hawiger et al., 2001; Kerksiek 
et al., 2005; Obst et al., 2007; Shakhar et al., 2005). Dox treatment of iMCC recipient mice was 
started on the same day. Mice were fed with high dose dox (100 µg/mL) in the drinking water to 
establish antigen presentation in recipient mice. 1 x 106 naïve AND T cells were adoptively 
transferred on the next day (day 0). High dose dox was administered until three dpt to ensure 
that all AND T cells were primed the same way. Memory AND TCR-tg CD4+ T cells were 
generated by switching off antigen presentation by dox removal three dpt (Obst et al., 2007). 
The same day dox was either changed to the low dose (10 µg/mL) or was maintained on the 
high dose (100 µg/mL) to present low and intermediate antigen levels beyond the priming 
phase, respectively. Dox water was changed every three to five days. In the cMCC model there 
is constitutive high presentation of antigen and thus no dox treatment required. For the “naïve” 
condition 1 x 106 naïve AND T cells were transferred into wild type (wt) mice three days before 
analysis. This was necessary as AND T cells disappear from recipients in the absence of 
antigen (Obst et al., 2007), a phenomenon described for other TCRs as well (Hataye et al., 
2006). Recipient spleens and lymph nodes (LNs) were harvested and analyzed 10 dpt. In the 
following work I refer to AND T cells generated in the above described way as “naïve”, “memory 
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(mem)”, “low”, “intermediate (int)”, and “high” AND T cells, actually describing the amount of 
antigen they were exposed to beyond the priming phase.  
Naïve, memory, low, intermediate, and high AND T cells were isolated and analyzed from the 
spleen (Figure 10B, C) and LNs (data not shown) of recipient mice, demonstrating the survival 
of AND CD4+ T cells chronically stimulated by cognate antigen of varying dose and time. In 
general LN cells showed similar marker expression compared to splenocytes. 
 
 
 
Figure 10: AND T cell survival in MCC-transgenic recipients with persistent antigen presentation of different 
quantity analyzed on day 10. (A) Schematic outline of the general treatment strategy to generate naïve, memory, 
low, intermediate (int), and high AND T cells. Recipient mice were injected with 20 µg α-CD40 antibody to induce DC 
maturation and were treated with dox in the drinking water as indicated to induce antigen presentation one day before 
adoptive cell transfer of 1 x 106 AND T cells. Dox treatment was continued as indicated and changed every three to 
five days. Spleens were harvested 10 dpt. (B, C) Quantification of adoptively transferred AND T cells using flow 
cytometry following the gating strategy described in Figure 8A. (B) Representative cytometric plots identifying AND 
T cells. (C) Graphs show percentage and absolute numbers of AND T cells. Data are shown of five independent 
experiments; each data point represents one mouse. Memory (mem), low, intermediate (int), and high represents 
the dose of antigen AND T cells have seen beyond the priming phase as schemed in Figure 10A. 
 
4.2.2 CD4+ Tmem phenotype is hampered early by persisting antigen 
We determined surface marker expression by flow cytometry to phenotype AND CD4+ T cells 
upon encountering low, intermediate, and high levels of cognate antigen chronically (Figure 11). 
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cells (Tokoyoda et al., 2009) was reduced in a dose-dependent manner (Figure 11A and B). 
These results show that CD4+ T cells are able to sense and respond differently to increasing 
amount of antigen after the priming phase.  
 
          
Figure 11: Persisting antigen induces phenotypic changes in specific CD4+ T cells that indicate a dose-
dependent loss of memory phenotype. (A, B) Quantification of 1 x 106 adaptively transferred AND T cells using 
flow cytometry. Spleens and LNs were harvested 10 days post transfer. AND T cells shown were identified using the 
gating strategy described in Figure 8A. (A) Representative histograms showing surface marker expression of AND 
T cells exposed to increasing amounts of antigen isolated from the spleen. (B) Statistical quantification of surface 
marker expression. Delta geometrical means were calculated by gMFISample - gMFIisotype control. Data were pooled from 
at least three independently performed experiments, each data point represents one mouse. *p < 0.05, **p < 0.001, 
***p < 0.0001, ns = not significant (parametric unpaired two-tailed t-test). Memory (mem), low, intermediate (int), and 
high represents the dose of antigen AND T cells have seen beyond the priming phase as depicted in Figure 10A. 
 
4.2.3 Persisting high-dose antigen stimulation causes TCR downregulation 
TCR downregulation is an aspect of in-vitro T cell activation (Salio et al., 1997; Valitutti et al., 
1995b; Viola and Lanzavecchia, 1996) and is induced by TCR/pMHC engagement (Valitutti et 
al., 1995a; Valitutti et al., 1996; Zanders et al., 1983), especially by high affinity peptides (Cai 
et al., 1997). Degradation of TCR-CD3 complex is seen as a control mechanism to down-
regulate TCR surface expression, though the biological relevance is still unclear (Alcover et al., 
2018; Valitutti, 2012).  
We have shown that TCR down-modulation is induced in vivo by very high antigenic stimulation 
only (Figure 9B, 11A). We then asked whether TCR downregulation in cMCC recipients (Figure 
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11A) is caused by TCR degradation or whether the TCR complexes are internalized and 
maintained intracellularly. We measured intracellular TCR abundance of memory, intermediate 
and high AND T cells by flow cytometry. To this end we fixed, permeabilized, and stained the 
cells for intra- and extracellular TCR β-chains and compared total (extracellular (EC) + 
intracellular (IC)) with surface (extracellular) TCR abundance. An eight-fold increase of TCR 
was found in the spleen and a 23-fold increase in the LNs of cMCC recipient mice (Figure 12A). 
Total TCR levels of high AND T cells were similar to that of memory and intermediate AND T 
cells, indicating that TCR complexes are not degraded but maintained in intracellular 
compartments. These findings have been reproduced by Shu-Hung Wang, a master student in 
our laboratory. He could also show that TCR surface expression was recovered after an 
overnight rest in the absence of antigen in vitro (data not shown). 
In cMCC animals, the MCC/Ek epitope is expressed not only in DCs but also in B cells (data not 
shown). To exclude that TCR downregulation is induced by antigen presenting B cells in these 
mice, we crossed them to the RAG0/0 background. These cMCC+RAG0/0 mice lack the 
recombination-activating gene (RAG) enzyme RAG-2 and, therefore, lack the endogenous B 
and T cell pools and thus exhibit lymphopenia. We performed adoptive AND T cell transfer into 
such cMCC+RAG0/0 recipients and harvested the spleens 10 dpt. The T cells downregulated the 
TCR surface expression to a similar extent under lymphopenic conditions (Figure 12B). To 
exclude that lymphopenia itself caused the downregulation we took advantage of cMCC+CD30/0 
animals that exclusively lack the endogenous T cell pool and do harbor antigen presenting B 
cells. Also, under such T lymphopenic conditions TCR/CD3 complexes are comparably 
downregulated (Figure 12B). These results indicate that TCR downregulation is B-cell- as well 
as lymphopenia-independent and is rather induced by chronic antigen presentation at a high 
level. We tried to trigger TCR complex downregulation in AND T cells persistently exposed to 
intermediate amount of antigen in iMCC recipient mice by increasing the likelihood of AND T 
cells to interact with mature antigen presenting DCs. To this end, iMCC recipients were crossed 
to RAG0/0 background. Within dox treated (100 µg/mL) and with anti-CD40 mAb injected (20 µg) 
iMCC+RAG0/0 lymphopenic recipients transferred (1x106) AND T cells encounter continuously 
mature DCs presenting cognate antigen in absence of any endogenous T cells competing for 
DC interactions. Such increased frequency of MCC-presenting cells failed to trigger the 
downregulation of surface TCRs on intermediate AND T cells (Figure 12 right part, bottom row). 
Memory and intermediate AND T cells served as positive and high AND T cells served as 
negative controls. These data demonstrate that lymphopenia itself does not affect TCR complex 
downregulation. Taken together, these findings reveal that AND CD4+ T cells down-regulate 
their TCR surface expression in response to a high antigen stimulation in a B cell-independent 
manner. 
  Results 
 
	 52 
             
 
Figure 12: High quantity TCR stimulation drives TCR downregulation on antigen specific CD4+ T cells. (A, B) 
Quantification of 1 x 106 adaptively transferred AND T cells using flow cytometry. Organs were harvested 10 days 
post transfer, AND T cells shown were identified following the gating strategy described in Figure 8A. (A) Histograms 
showing extracellular and total (extra- plus intracellular) TCR (Vβ3) expression of AND T cells exposed to increasing 
amounts of antigen in vivo. Numbers indicate the percentage of AND T cells positive for TCR expression, top left: 
extracellular TCR, top right: total (intra- plus extracellular) TCR. (B) Flow cytometric quantification of TCR (Vβ3) 
surface expression of AND T cells isolated from the transgenic recipients, indicated data are from one experiment. 
Memory (mem), low, intermediate (int), and high represents the dose of antigen AND T cells have been exposed to 
after the priming phase as depicted in Figure 10A, RAGo/o and CD3o/o describe the recipients additional background 
genotype. 
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Exhaustion is a state of T cell dysfunctionality caused by persistent viral infections and cancer 
(Doering et al., 2012; Schietinger and Greenberg, 2014; Wherry, 2011). As a hallmark of 
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cytokines were measured by flow cytometry. In contrast to naïve T cells, memory T cells 
expressed significant amounts of effector cytokines, such as IL-2, TNF-α, and IFN-γ (Figure 
13B, C). In response to persistent antigen-presentation AND T cells showed significantly 
impaired IL-2 production by all three different doses of antigen. TNF-α and IFN-γ production 
was significantly reduced by intermediate- and high-level antigen and showed a trend of 
reduction by low level TCR stimulation (Figure 13B, C). These results indicate that chronic 
antigen presentations impair effector functions in a dose-dependent fashion.  
 
                  
 
Figure 13: Effector function of antigen specific CD4+ T cell is hampered rapidly upon chronic TCR 
stimulation. (A) Schematic outline of the experimental set up. (B – D) Quantification of 1 x 106 adaptively transferred 
AND T cells using flow cytometry. Spleens were harvested 10 days post transfer, splenocytes were re-stimulated 
with PMA/IM for 4 h, Brefeldin A was added after 2 h of stimulation. AND T cells shown were identified using the 
gating strategy described in Figure 8B. (B) Representative histograms showing intracellular cytokine expression. (C) 
Statistical quantification of cytokine expression pattern. Delta geometrical means were calculated by gMFISample - 
gMFIisotype control. Data were pooled from at least three independently performed experiments, each data point 
represents one mouse. *p < 0.05, **p < 0.001, ***p < 0.0001, ns = not significant, parametric unpaired two-tailed t-
test. (D) Flow cytometric analysis for total CD154 (CD40L) expression. Data shown from one experiment. Memory 
(mem), low, intermediate (int), and high represents the dose of antigen AND T cells have seen beyond the priming 
phase as schemed in Figure 10A. 
Professional APCs communicate with T cells via the CD40/CD40L route (Foy et al., 1996; 
Schrader et al., 1997). CD40L expression is induced upon T cells activation, transmits co-
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stimulatory signals and thus contributes to proper T cell activation and induction of effector 
function (Grewal and Flavell, 1998; Kennedy et al., 1994; Ranheim and Kipps, 1993). Due to its 
rapid turnover induced by engagement with CD40 (Graf et al., 1995), we measured total (intra- 
and extracellular) CD40L (CD154) expression of AND T cells, persistently exposed to different 
amounts of antigen beyond the priming phase, using in vitro re-stimulation with PMA/IM and 
Brefeldin A (Kirchhoff et al., 2007). We found that the induction of CD40L expression was dose-
dependently reduced in low, intermediate, and high CD4+ T cells compared to naïve and 
memory CD4+ T cells in respond to PMA/IM stimulation in vitro (Figure 13D). This suggests that 
chronic hyper-stimulations reduced the co-stimulatory signals transduced via CD40/CD40L 
pathway of cell communication. Yet, this is a preliminary finding that is currently reproduced in 
our laboratory.  
As we have shown that in high AND T cells TCR surface expression rapidly recovers after 
overnight (o/n) rest in absence of antigen in vitro (described above) we asked if such rescued 
TCRs are responsive to TCR stimulation and are able to produce the effector cytokine IFN-γ 
triggered by TCR/pMHC interactions in vitro. To this end, Stefanie Pennavaria rested naïve, 
memory, and high AND T cells in vitro o/n and re-stimulated them with both, either PMA/IM 
bypassing the TCR as a control or B cells plus cognate antigen MCC88-103 for four h in the 
presence of Brefeldin A during the last two h of stimulation. She showed that rested high AND 
T cells that had regained their TCR surface levels still fail to produce IFN-γ, despite the fact that 
their PMA/IM stimulated counterparts did do so (data not shown). Her data indicate that the 
TCR signal transduction pathway after o/n rest in vitro is still impaired proximal to the TCR. 
 
4.3 TCR signal transduction following chronic TCR stimulation 
4.3.1 Chronic high-dose TCR stimulation impairs TCR signal transduction  
 Upon TCR stimulation the protein tyrosine kinase ZAP-70 is activated and phosphorylates the 
transmembrane protein linker for activation of T cells (LAT) (Au-Yeung et al., 2018; Paz et al., 
2001). LAT has a central role in TCR signal transduction as it recruits other adapter proteins 
and signaling molecules upon phosphorylation (Paz et al., 2001). Since we assume that 
chronically high dose antigen stimulations impaired TCR signaling proximal to the TCR we 
asked whether LAT expression was affected and compared intracellular LAT expression levels 
of memory, low, intermediate, and high AND T cells. We found LAT abundance being 
significantly reduced in high AND T cells only (Figure 13A). LAT reduction thus is correlated 
with TCR downregulation and might be involved in impaired TCR function. Data shown in Figure 
24 will show that LAT is downregulated transcriptionally. 
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Figure 14: Chronic TCR stimulation of high quantity impairs TCR signal transduction. (A, B) Quantification of 
1 x 106 adaptively transferred AND T cells using flow cytometry. Spleens were harvested 10 days post transfer. AND 
T cells shown were identified using the gating strategy described in Figure 8A. (A) Representative histograms 
showing intracellular LAT expression ex vivo on the left. Statistical quantification of LAT expression on the right. (B) 
Quantification of TCR signal transduction using Nur77-GFP reporter expression in ANDxNur77 T cells ex vivo. 
Representative histograms on the left and statistical analysis on the right. Delta geometrical means were calculated 
by (A) gMFIsample - gMFIisotype control and (B) gMFIGFP-reporter – gMFInon-reporter AND. Data were pooled from (A) five and (B) 
three independent experiments, each data point represents one mouse. *p < 0.05, **p < 0.001, parametric unpaired 
two-tailed t-test. Memory (mem), low, intermediate (int), and high represents the dose of antigen AND T cells have 
seen beyond the priming phase as schemed in Figure 10A. 
 
 
 
Next we asked whether all three conditions of chronic TCR stimulation are able to induce chronic 
TCR signals. Especially high dose TCR stimulation, which causes TCR downregulation and 
LAT reduction, is of interest, since it is unclear if internalized TCR complexes can still transmit 
TCR signals (Rothenberg, 1996; Saveanu et al., 2019). To measure TCR signal strength we 
used the Nur77-GFP reporter (Moran et al., 2011). Memory, low, intermediate, and high AND T 
cells were generated as described in Figure 10A, except that ANDxNur77 GFP-reporter T cells 
were co-transferred with non-reporter GFP-negative ANDx90.1 T cells. To exclude background 
signals measured GFP signals of reporter-negative AND T cells were subtracted from the 
values measured for GFP-reporter positive AND T cells. Spleens were harvested and analyzed 
by flow cytometry 10 dpt. GFP expression was increased in all three chronic conditions 
compared to memory ANDxNur77 T cells (Figure 13B). Interestingly, high AND T cells with 
internalized TCRs and reduced LAT expression levels, reported TCR signal transduction by 
induced Nur77-GFP expression. These findings suggest that TCR signal transduction is 
induced by persisting antigen-presentation of all three levels.  
 
4.3.2 Calcium ion release and nuclear NFATc1 translocation by persisting antigen  
Upon TCR stimulation T cells release Ca2+ ions from intracellular stores and the cellular 
environment to initiate activation programs (Baine et al., 2009; Hogan et al., 2010; Zhang et al., 
2005). T cells chronically exposed to intermediate dose of antigen are able to flux Ca2+ (Han et 
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al., 2010), indicating that this pathway is not affected by intermediate levels of antigen. Whether 
high AND T cells are also able to induce Ca2+ flux is unclear. We thus asked whether Ca2+ flux-
dependent pathways are also still intact. Ca2+ flux potential of rested high AND T cells was 
measured in our laboratory by Shu-Hung Wang. He showed that rested high AND T cells were 
not able to flux Ca2+ in response to TCR engagement (achieved by α-CD3/CD4 cross-linking 
with streptavidin). Ca2+ fluxes were not detectable after an o/n rest in vitro, nor after two days of 
rest in vivo accomplished by a secondary transfer into antigen-free hosts. These results indicate 
that Ca2+ flux is a rather robust pathway but rendered dysfunctional by the high dose of 
persisting antigen. 
Upon Ca2+ influx, calcium ions bind to calmodulin and activate the protein phosphatase 
calcineurin (Klee et al., 1998). Activated calcineurin dephosphorylates the transcription factor 
NFATc1, a member of the NFAT family of Ca2+-dependent transcription factors, and thus 
enables NFAT translocation from the cytoplasm to the nucleus (Martinez et al., 2015). In the 
nucleus NFAT cooperates with AP-1 (a heterodimer of Fos and Jun) to induce the transcription 
of effector genes. Recently it has been reported that NFAT, in cooperation with AP-1, favors T 
cell differentiation towards a memory phenotype and in absence of AP-1 towards an exhaustion-
associated phenotype (Martinez et al., 2015).  Hence, we investigated whether nuclear NFATc1 
translocation was induced by chronic TCR stimulation. We first performed a pilot experiment to 
analyze NFATc1 translocation induced by PMA/IM stimulation in vitro using imaging flow 
cytometry (Figure 15A). AND T cells were transferred into wt mice to mimic later experimental 
conditions. Three days post transfer, splenocytes were either stimulated with PMA/IM in vitro or 
left untreated. NFATc1 was located in the cytoplasm of unstimulated CD4+ T cells (Figure 15B, 
left part) and showed nuclear translocation upon PMA/IM stimulation (Figure 15B, right part), 
visualized by NFATc1 staining (green) surrounding the nucleus stained with Draq5 (red) in 
unstimulated cells. Following T cell stimulation, both markers overlapped in the nucleus (see 
merge) and demonstrated the nuclear translocation of NFATc1. 
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Figure 15: NFATc1 in PMA/IM stimulated CD4+ T cells localizes to the nucleus. (A) Schematic outline of the 
experimental set-up. As a pilot experiment to visualize nuclear NFATc1 translocation in response to PMA/IM 
stimulation in vitro, 1x 106 AND T cells were transferred into B10.BR wild type recipients to mimic the later 
experimental procedure. The spleen was harvested three days post transfer, splenocytes were isolated, and 
stimulated with (w/) PMA/IM for 4 h in vitro or left untreated (w/o). (B) Representative imaging-flow-cytometry images 
show examples of cytoplasmic NFATc1 (left) or nuclear NFATc1 (right). T cells shown were gated on singlets, live, 
CD4+CD45.1+, nuclear dye (Draq5) and NFATc1 double positive and autofluorescence negative cells. BF = bright 
field image, NFATc1 staining (green), nuclear dye Draq5 (red), merged overlap (yellow), scale bar: 7 µm. 
 
 
We then compared memory, low, intermediate, and high CD4+ T cells with regard to nuclear 
NFATc1 translocation caused by chronic antigen stimulations in vivo. AND T cells were 
generated as described in Figure 10A, splenocytes were isolated on day 10 post transfer and 
fixed immediately ex vivo to prevent NFATc1 cytoplasmic relocation (Figure 16A). Comparisons 
of cellular NFATc1 expression levels indicated no difference in NFATc1 abundance under all 
four conditions (Figure 16B). NFATc1 expression is induced by T cell activation and apparently 
not affected by antigen persistence. However, looking at NFATc1 location within the cell 
compartments we found a significant increase of NFATc1 in the nucleus correlating with antigen 
dose. Interestingly, high ANDs showed the highest nuclear NFATc1 abundance (Figure 16C, 
D). These data imply that persisting TCR stimulation induces tonic TCR signal transduction that 
leads to nuclear NFATc1 translocation in a dose-dependent fashion. It is currently unclear 
whether TCR molecules send signals from the surface or endocytic compartments in the iMCC 
recipients (Saveanu et al., 2019). 
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Figure 16: Chronic TCR stimulation causes dose-dependent nuclear NFATc1 translocation. (A) Schematic 
outline of the experimental set up. (B – D) Quantification of 1 x 106 adoptively transferred AND T cells using imaging 
flow cytometry. Memory, low, int, and high AND T cells were generated as described in Figure 10A. Spleens were 
harvested 10 days post transfer, splenocytes were fixed immediately ex vivo. T cells shown were gated on singlets, 
live, CD4+CD45.1+, nuclear dye (Draq5) and NFATc1 double positive and autofluorescence negative cells. (B) 
Representative histograms of total intracellular NFATc1 expression of the same experiments also analyzed in C and 
D. (C) Representative histograms on NFATc1 translocation. Co-localization of NFATc1 (green) and nuclear marker 
Draq5 (red) was calculated using the similarity feature implemented in the IDEAS analysis software to identify cells 
with NFATc1 located to the nucleus. A similarity score less than 1.5 represents cells with predominantly cytoplasmic 
NFATc1, while a score larger than 1.5 represents cells with predominantly nuclear NFATc1 location. On top of the 
histograms are two representative images of AND T cells with cytoplasmic NFATc1 (left) and nuclear NFATc1 
location (right). Vertical line indicates the similarity score of 1.5. (D) Statistical quantification of AND T cells with 
nuclear NFATc1 location indicated by the percentages of cells with a similarity score larger than 1.5. Data were 
pooled from five independent experiments; each data point represents one mouse. **p < 0.001, ***p < 0.0001, 
parametric unpaired two-tailed t-test. Memory (mem), low, intermediate (int), and high represents the dose of antigen 
AND T cells have seen beyond the priming phase as schemed in Figure 10A. 
 
 
Th1 effector cell differentiation is established during the initial T cell priming phase and is 
influenced by certain factors, such as antigen dose (signal 1), co-stimulatory signals transmitted 
by CD28 (signal 2), and cytokine environment (signal 3) (Constant and Bottomly, 1997). TCR 
stimulation activates the JNK/MAP kinase signaling pathway which controls the Th1 effector 
response (Ip and Davis, 1998; Whitmarsh and Davis, 1996; Yang et al., 1998) by inducing 
certain gene expression, such as the expression of Il2. Upon activation the JNK kinase 
phosphorylates its substrate c-Jun (Rincon and Flavell, 1994). Jun and Fos family members 
form heterodimers described as activator protein 1 (AP-1) and act as transcription factors 
(Foletta et al., 1998; Nakabeppu et al., 1988; Rincon and Flavell, 1994). Transcriptional activity 
of AP-1 depends on TCR stimulation and co-stimulation e.g. transmitted by CD28/B7.1 or B7.2 
interaction (Rincon and Flavell, 1994) and on its DNA binding partners, such as NFAT proteins 
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(Jain et al., 1995; Jain et al., 1993; Rooney et al., 1995). Cooperative NFAT:AP-1 complexes 
are associated with CD8+ T cell effector function and the induction of activation-induced genes 
(Martinez et al., 2015). In contrast, in absence of AP-1 NFAT homodimers drive exhaustion- 
and anergy-associated CD8+ phenotypes by inducing exhaustion-related gene expression 
patterns (Martinez et al., 2015). Hence, we investigated Jun phosphorylation induced by chronic 
TCR stimulations of different antigen doses compared to naïve and memory AND T cells. These 
experiments were performed in our laboratory by Benedikt Lober. He found that upon additional 
TCR stimulation in vivo by injecting cognate antigen pMCC88-103 for 1 h 10 dpt, high AND T cells 
were not able to phosphorylate and thus to activate c-Jun, whereas naïve, memory, and 
intermediate AND T cells did (data not shown). However, over time, chronic TCR stimulation of 
intermediate dose also impaired Jun phosphorylation, as 31 days post T cell transfer 
significantly reduced Jun phosphorylation in response to pMCC88-103 injection for 1 h was 
reported (Han et al., 2010). Together, these findings suggest that high AND T cells with 
significantly reduced TCR surface expression could not activate the JNK/MAPK pathway and 
therefore lack the AP-1 transcription factor in the nucleus. As a result, partner-less NFATc1 may 
induce an altered gene-expression pattern. 
 
4.4 Characterization of AND T cells exposed to antigen for 30 days 
4.4.1 Experimental set-up and survival of AND T cells  
To analyze the effects of antigen persistence on CD4+ T cells over a truly chronic period of time 
we followed AND T cells for 30 days. We analyzed naïve, memory, low, intermediate, and high 
AND T cells on day 30 pt and included an additional condition where intermediate AND T cells 
were released from antigen on day 10 pt by switching off dox treatment and thus shutting down 
antigen presentation (int off) (Figure 17A).  
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Figure 17: Long-term survival of AND T cells during chronic antigen stimulation and upon antigen removal 
in iMCC-transgenic recipients analyzed on day 30. (A) Schematic outline of the dox treatment to generate naïve, 
memory, low, intermediate (int), and intermediate off (int off) AND T cells analyzed 30 days post transfer (dpt). 
Recipient mice were treated with high-dose dox (100 µg/mL) in the drinking water and injected with 20 µg α-CD40 
antibody one day before adoptive T cell transfer. Three dpt, dox treatment was either switched off to generate 
memory AND T cells, changed to low dose (10 µg/mL) to generate low AND T cells, or maintained on high dose (100 
µg/mL) for int and int off ANDs. Int ANDs were continuously feed with high-dose dox. To generate int off AND T cells, 
mice were taken off dox treatment 10 dpt. Dox-water was changed regularly each three to five days. (B, C) 
Quantification of adoptively transferred AND T cells isolated from recipient spleens using flow cytometry. AND T cells 
shown were identified using the gating strategy described in Figure 8A. Recipient mice were treated as indicated in 
(A). Representative data of at least five independent experiments. (B) Identification of transferred AND T cells on day 
30. (C) Graphs show percentage and absolute numbers of AND T cells 30 dpt.  
 
 
 
All mice were injected with α-CD40 i.p. and fed with dox water (100 µg/mL) the day before 
adoptive T cell transfer (1 x 106 AND T cells). Dox treatments were continued as indicated in 
Figure 17A. Using the intermediate off condition we asked if the antigen-exhausted phenotype 
on day 10 can be reversed by antigen removal or whether it is rather irreversibly programmed. 
Analyses by cytometry on day 30 pt revealed that high AND T cells were hardly detectable as 
they appeared below the detection rate (less than 0.01%) (Figure 17C) leading to the suspicion 
that cell death is induced by high-level antigen stimulation. Hence, we excluded the high AND 
T cells from further day 30 experiments. Memory, low, intermediate, and intermediate off AND 
T cells were detectable 30 days post transfer (Figure 17B, C). 
 
4.4.2 CD4+ Tex cells recover upon antigen removal 
When we analyzed the expression pattern of surface markers on day 30 by flow cytometry, we 
found CD44 expression still high upon antigen encounter, proving the recognition and activation 
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by cognate antigen. The homing receptor CD62L (Smalley and Ley, 2005) was expressed on 
naïve and memory CD4+ T cells but downregulated on antigen-exhausted T cells. Memory 
markers CD127 (IL-7 receptor alpha chain) (Huster et al., 2004; Wherry et al., 2003b)  and Ly6C 
(Hale et al., 2013; Hanninen et al., 2011; Tokoyoda et al., 2009) were expressed on memory 
CD4+ T cells but were reduced by low and intermediate dosages of antigen persisting (Figure 
18A). The expression of antigen sensitive markers, such as CD62L, CD127, and Ly6C tend to 
be reversible upon antigen-removal. 
 
 
        
 
Figure 18: Characterization of chronically exhausted AND T cells upon persisting exposure to low and 
intermediate antigen doses in iMCC-transgenic recipients analyzed on day 30. (A, B) Quantification of 1 x 106 
adoptively transferred AND T cells using flow cytometry. Spleens and LNs were harvested 30 days post transfer. 
Cells were generated as describes in Figure 16A. Naïve, memory (mem), low, intermediate (int), and intermediate 
off (int off) represents the time and dose of antigen AND T cells have seen beyond the priming phase. (A) Histograms 
showing surface marker expression of LN AND T cells. T cells shown were identified following the gating strategy 
described in Figure 8A. (B) Histograms showing intracellular cytokine expression of splenic AND T cells. Spleens 
were harvested 30 days post transfer, splenocytes were re-stimulated with PMA/IM for 4 h, Brefeldin A was added 
during the last 2 h of stimulation.  T cells shown were identified using the gating strategy described in Figure 8B. 
Data are shown from one experiment. 
 
 
 
To analyze the functionality of day 30 antigen-exhausted and rescued AND T cells we measured 
cytokine expression in response to in vitro re-stimulation with PMA/IM. Low dose of antigen 
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persistence resulted in a memory-like phenotype also shown by a cytokine-production profile 
similar to that of memory AND T cells. However, the intermediate dose of antigen impaired 
cytokine production (Figure 18B). Antigen removal on day 10 partially rescued this dysfunctional 
state, demonstrated by a cytokine-production profile comparable to the one of memory AND T 
cells (Figure 18B). These results suggest that the intermediate antigen-exhausted dysfunctional 
phenotype of CD4+ T cells is reversible in terms of cytokine production. These data have 
recently been reproduced by Pallavi Kadam in our laboratory. 
 
4.5 Transcriptome analysis of antigen-exhausted CD4+ T cells 
4.5.1 Sample preparation procedure to perform microarray analyses 
In order to analyze dose-dependent gene-expression changes induced during early (day 10) 
and late (day 30) phase of antigen persistence we performed microarray analyses on the 
different conditions and time points. To this end, we generated five biological replicas of each 
condition (day 10 and day 30 samples), as described in Figure 10A and Figure 17A, 
respectively. 
 
 
 
Figure 19: Characteristic Ly6C expression pattern validates the phenotypes of antigen-exhausted 
AND+RAG0/0 T cells at early (day 10) and late (days 30) time points for sorting. (A – D) Quantification of 1 x 106 
adoptively transferred AND+RAG0/0 T cells using flow cytometry. Naïve, memory (mem), low, intermediate (int), 
intermediate off (int off), and high AND+RAG0/0 T cells were generated as described in Figure 10A and 17A 
respectively. Spleens and LNs were harvested, slenocytes and LN cells were pooled, Ly6C staining was performed 
for phenotype validation prior sorting these cells. AND+RAG0/0 T cells shown were identified following the gating 
strategy described in Figure 8A. (A) Representative histograms indicating Ly6C expression pattern of day 10 
samples. (B) Statistical quantification of Ly6C expression on day 10 AND+RAG0/0 T cells. (C) Representative 
histograms indicating Ly6C expression pattern of day 30 samples. (D) Statistical quantification of Ly6C expression 
on day 30 AND+RAG0/0 T cells. Delta geometrical means were calculated by gMFIsample - gMFIisotype control. Data were 
pooled from five independent experiments; each data point represents one mouse. ns = not significant, **p < 0.001, 
***p < 0.0001, parametric unpaired two-tailed t-test. 
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Microarray analysis is a method to determine relative gene-expression changes. Using this 
technique, quantitative differences in RNA expression can be measured and compared between 
samples. Isolated RNA is converted to fluorescently labeled cDNA, which in turn is probed on 
the DNA-chip. The scanned fluorescence intensity of each gene is proportional to the gene-
expression levels. Thus, the ratio between several fluorescent intensities can be used to 
measure relative gene-expression levels. 
Phenotypes of AND+RAG0/0 T cells were confirmed by flow cytometry using Ly6C surface 
expression (Figure 19) before being used for microarray analyses. As expected, Ly6C was 
highly expressed by memory T cells on both, day 10 and day 30 samples and significantly 
reduced on the surface of chronically exposed T cells in a dose-dependent fashion. Rescued 
intermediate AND+RAG0/0 T cells (int off) showed significant increase in Ly6C surface 
expression compared to day 30 intermediate AND+RAG0/0 T cells. (Figure 19A – D). These 
results confirmed the expected phenotypes of the AND+RAG0/0 T cells to include these samples 
for microarray analyses accordingly. 
CD4+ T cells from all samples were negatively enriched and AND+RAG0/0 T cells were sorted 
twice to high purity and lysed in Trizol. Negative enrichment of CD4+ T cells was performed by 
magnetic-activated cell sorting (MACS) as described in section 4.3.2.2. To do so, lymphocytes 
were pooled from spleen and LNs and were stained for “non-CD4+-T-cell” markers using 
biotinylated mAbs. In a second step cells were bound via biotin to magnetic beads and small 
aliquots pre and post MACS were stained by streptavidin-PE (SA) to label cells to be depleted. 
Purity of MACS-enriched CD4+ T cells was determined using the flow cytometric gating shown 
in Figure 20A. SA-labeled cells were successfully depleted as they were reduced from about 
72% in pre-MACS samples to less than 2% in post MACS samples (Figure 20A). 
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Figure 20: Representative sorting strategies and purity control of microarray samples. (A) Representative flow 
cytometric gating strategy of adoptively transferred AND+RAG0/0 T cells pre and post magnetic-activated cell sorting 
(MACS). Lymphocytes to be depleted were labeled by linage-specific biotinylated mAbs and identified by 
streptavidin-PE (SA). After cell sorting the SA positive cell population was depleted thus, CD4+ T cells were negatively 
enriched. (B) Representative gating strategy how AND+RAG0/0 T cells were flow cytometrically sorted from MACS 
purified CD4+ T cells and purity control of sorted AND+RAG0/0 T cells. Each sample was sorted twice (first and second 
row) to ensure the highest possible purity of sorted AND+RAG0/0 T cells. After the second sort cells were sorted into 
500 µL Trizol for later analysis and a small aliquot of each sample was sorted into FACS buffer to check the purity of 
each sample (last row). AND+RAG0/0 T cells were identified and sorted as DapinegSAnegCD4+CD45.1+CD90.2+Vβ3+. 
All day 10 and day 30 samples for microarray analysis were sorted according to this strategy.  
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Subsequently, AND+RAG0/0 T cells were flow cytometrically sorted according to section 4.3.3.5 
in cooperation with Mathias Schiemann and Lynette Henckel, TU München. For cell sorting 
AND+RAG0/0 T cells were labeled with CD45.1 and the TCR β-chain Vβ3, lineage markers CD4 
and CD90.2, and SA to exclude other cells. Representative sorting data are shown in Figure 
19B. Each sample was sorted twice to ensure maximal purity of sorted cells (Figure 19B, first 
and second row). Small aliquots of the second sort were taken for purity control performed by 
flow cytometry (Figure 20B, last row) before the rest of the samples were directly sorted into 
Trizol for RNA isolation. Cell numbers were collected during the sorting procedures of day 10 
(Table 1) and day 30 (Table 2) samples. Between 1 x 104 and 6 x 105 AND+RAG0/0 T cells were 
sorted per sample with purities between 99 and 100% as revealed by purity control analysis 
(Table 1 and 2). 
 
 
Day 10 MACS purification FACS/Casy counter Sort #1 Sort #2   
# cell type 
total cell #     
pre MACS 
(x107) 
total cell # 
post 
MACS 
(x106) 
AND 
% 
total AND  
(x106) 
total cell #    
pre Sort #1  
(x106) 
total cell # 
post Sort 
#1 (x104) 
total cell #    
pre Sort #2  
(x104) 
total cell # 
post Sort 
#2 (x104) 
RIN 
1 naive  32,4 12,4 0,5 1,5 9,9 9,2 7,5 6,0 9,3 
2 naive  31,5 25,2 0,6 1,9 18,0 25,0 20,0 17,0 9,3 
3 naive  27,9 17,6 0,5 1,5 12,0 8,8 6,2 5,0 9 
4 naive  34,2 19,2 0,6 1,9 11,0 6,8 4,7 3,7 8,9 
5 naive  26,3 10,8 0,5 1,2 9,3 7,7 5,8 4,9 8,8 
6 memory 16,8 12,5 1,8 3,1 8,6 35,0 25,0 19,0 9,5 
7 memory 13,4 24,4 0,1 0,2 39,0 13,0 12,0 8,1 9,5 
8 memory 54,0 112,0 0,7 4,0 13,0 73,0 63,0 52,0 9,3 
9 memory 21,4 29,2 3,7 7,9 15,0 63,0 56,0 44,0 9,4 
10 memory 19,8 30,4 3,3 6,5 15,0 51,0 44,0 37,0 9,5 
11 low 16,8 9,6 1,9 3,1 4,5 17,0 14,0 13,0 9,6 
12 low 66,0 6,0 2,8 1,8 3,3 21,0 18,0 17,0 9,7 
13 low 11,1 12,4 2,3 2,5 5,6 27,0 22,0 21,0 9,7 
14 low 82,8 12,8 1,5 1,2 5,8 19,0 16,0 14,0 9,7 
15 low 63,6 8,8 1,7 1,5 4,7 18,0 14,0 13,0 9,4 
16 int 5,4 3,0 0,8 0,4 1,6 2,8 2,0 1,7 9,5 
17 int 8,8 6,7 1,0 0,9 4,1 7,8 6,0 4,9 9,4 
18 int 8,6 3,7 0,6 0,5 1,9 3,2 2,1 1,7 9,5 
19 int 14,9 9,2 0,6 0,9 3,2 6,4 4,7 4,1 9,2 
20 int 14,1 8,3 0,8 1,1 3,8 9,2 6,9 6,1 Nd 
21 high 24,0 15,2 3,3 7,8 10,0 100,0 85,0 59,0 9,4 
22 high 9,2 10,4 3,3 3,0 7,6 700,0 140,0 93,0 9,7 
23 high 9,3 12,0 4,5 4,2 5,6 49,0 41,0 25,0 9,8 
24 high 6,9 12,3 3,5 2,4 5,9 45,0 39,0 25,0 9,8 
25 high 14,4 22,8 4,0 5,7 9,3 31,0 25,0 18,0 9,5 
 
Table 5: Cell numbers of day 10 sorted naïve, memory, low, int, and high AND+RAG0/0 T cells. 
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Day 30 MACS purification FACS/Casy counter Sort #1 Sort #2   
# cell type 
total cell #     
pre MACS  
(x107) 
total cell # 
post 
MACS  
(x106) 
AND 
% 
total AND # 
(x105) 
total cell #    
pre Sort #1  
(x106) 
total cell # 
post Sort 
#1  (x104) 
total cell #    
pre Sort #2  
(x104) 
total cell # 
post Sort 
#2  (x104) 
RIN 
1 memory 5,6 8,2 0,3 1,8 3,2 3,6 2,6 2,4 9,5 
2 memory 4,3 7,7 0,8 3,4 4,4 1,1 5,5 4,9 9,2 
3 memory 5,4 7,8 0,2 0,8 4,2 2,3 1,4 1,2 9 
4 memory 8,8 9,6 0,3 2,2 5,7 4,8 2,5 2,3 9,7 
5 memory 1,0 12,8 0,1 1,4 6,1 2,4 1,8 1,7 8,3 
6 low 15,5 9,3 0,3 4,9 6,4 4,3 3,8 3,4 8,2 
7 low 15,8 9,4 0,4 6,3 5,9 5,1 4,0 3,7 9,6 
8 low 10,2 6,5 0,2 2,0 4,1 2,0 1,6 1,5 9 
9 low 21,6 6,8 0,1 1,7 4,2 3,3 2,7 2,4 9 
10 low 14,2 16,5 0,3 4,7 6,3 4,5 3,3 2,7 8,8 
11 int 4,9 7,4 0,3 1,5 4,7 4,1 2,4 1,6 9,2 
12 int 10,3 6,1 0,8 7,9 4,3 3,2 2,6 2,4 9,5 
13 int 4,2 4,2 0,3 1,4 2,5 4,0 2,8 2,6 8,8 
14 int 7,1 4,5 1,0 7,2 3,1 2,8 2,0 1,8 8,5 
15 int 6,9 8,4 1,0 6,6 5,5 4,2 3,1 2,9 9,4 
16 int off 11,5 23,6 0,2 2,0 12,0 5,7 3,2 2,7 9,2 
17 int off 9,5 12,3 0,4 3,3 7,4 6,2 3,3 2,8 9,6 
18 int off 11,2 13,2 0,2 2,2 8,5 4,5 2,3 2,1 9 
19 int off 6,2 12,6 0,4 2,3 6,3 4,9 2,6 2,4 8,8 
20 int off 12,0 19,2 0,2 2,6 9,3 3,7 2,1 1,9 9,2  
 
Table 6: Cell numbers of day 30 sorted naïve, memory, low, int, and high AND+RAG0/0 T cells. 
 
 
Total RNA was isolated as described in section 3.3.4. RNA quality indicated by the RNA integrity 
number (RIN, 0 – 10, with 10 representing the highest purity) and total RNA concentrations 
(Table 5 and 6) were measured as described in section 3.3.1.5 using a Bioanalyzer. Samples 
with high RIN values (> 8) were converted to cDNA and used for gene expression analysis (see 
3.3.6). Microarray technique was performed by Martin Irmler, Helmholtz Zentrum München. All 
RIN values are listed in Table 5 and Table 6. 
 
4.5.2 Chronic TCR stimulation causes unique gene expression pattern  
Principle component analysis (PCA) is a popular statistical method to visualize genetic distance 
and relation between distinct cell populations. In cooperation with Tobias Straub at the 
Bioinformatics Core Facility at the BMC, München we performed PCA on gene-expression 
patterns measured at early (Figure 21A) and late (Figure 21B) time points to determine and 
quantify the distance between both, the samples within a unique group and between the 
different groups. Unique samples that failed the quality control by PCA were excluded from 
further analyses. PCA analysis was done separately for day 10 and day 30 samples to avoid 
batch effects. 
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Figure 21: Gene expression pattern of antigen-exhausted CD4+ T cells clearly distinguish from memory CD4+ 
T cells. Principle component analysis (PCA) of day 10 and day 30 generated AND+RAG0/0 T cells exposed to varying 
antigen levels. (A) PCA of naïve, memory, low, int, and high AND+RAG0/0 T cells. Cells were generated as indicated 
and analyzed on day 10. Samples were phenotype-checked according to Figure 18 and sorted as described in Figure 
19. (B) PCA of naïve, memory, low, int, and int off AND+RAG0/0 T cells. Cells were generated as indicated and 
analyzed on day 30. Naïve AND+RAG0/0 T cells were generated once, together with day 10 samples and were re-
used for day 30 analysis. Samples were phenotype-checked according to Figure 18 and sorted as described in Figure 
19. Statistical analyses were performed by Dr. Tobias Straub, LMU. Naïve, memory (mem), low, intermediate (int), 
intermediate off (int off), and high represents the time and dose of antigen AND+RAG0/0 T cells have seen beyond 
the priming phase.  
 
 
PCA illustrated that the samples clustered according to their conditions of treatment. The more 
antigen persisted beyond the priming phase, the further separated from each other clustered 
the unique groups. The same pattern holds true over time. Low ANDs clustered very close to 
memory ANDs on day 10 and separated further away on day 30, indicating a closer relatedness 
in gene expression during the early phase than compared to the later time point (Figure 21A, B, 
light blue and green). Thus, low level of TCR stimulation induces a memory-like gene-
expression pattern that change slowly over time. Looking at the day 30 induced gene-
expression pattern of intermediate off ANDs with terminated antigen presentation on day 10 we 
found that this population spread among intermediate and low AND groups towards the memory 
population (Figure 21B, turquoise), indicating that some gene-expression changes are 
reversible. Together, these data indicate that the longer and the more antigen CD4+ T cells see 
beyond the priming phase, the more gene-expression changes and divergence occur, which 
are, at least partially, reversible by antigen removal.  
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To gain a deeper insight into gene-expression patterns and changes induced by chronic antigen 
presentations of different doses we analyzed, in cooperation with Tobias Straub at the BMC, 
the induced gene-expression profiles of all 15 possible gene-expression patterns as 15 clusters. 
To do so, we set the criteria to FC ³ 1.5 and FDR £ 0.05 and defined the 15 clusters of 
upregulated gene-expression patterns containing genes that were either uniquely expressed or 
shared between the different conditions for both, day 10 (Figure 22A) and day 30 (Figure 22B). 
We identified memory-associated clusters, such as cluster 1 and cluster 5, containing genes 
significantly induced in memory or in both, memory and low AND T cells, respectively. In these 
clusters, we found memory-associated genes, such as Jun, Fos, and Il7r on day 10 and on day 
30. 
 
 
Figure 22: Persisting antigen upregulates dose-dependently unique gene expression patter in specific CD4+ 
T cells. Cluster analyses of microarray data comparing gene expression pattern of naïve, memory, low, int, int off, 
and high, AND+RAG0/0 T cells early on day 10 or late on day 30. Samples were generated as describes in Figure 22. 
cDNA was probed with Mogene 2.0 microarrays. 15 clusters were identified for each analysis. All genes depicted 
fulfill the criteria FC³1.5 and FRD£0.05. (A) Gene-expression upregulated (red) early on day 10 compared to naïve 
T cells. (B) Gene-expression upregulated (red) late on day 30 compared to naïve T cells. Genes uniquely expressed 
in one condition are depicted in the left column and genes expressed in two or more conditions in the right column. 
Naïve, memory (mem), low, intermediate (int), intermediate off (int off), and high represents the time and dose of 
antigen AND+RAG0/0 T cells have seen beyond the priming phase. Red numbers on the left side of the columns 
indicate the cluster number followed by the number of regulated genes within the according cluster (black number). 
Representative genes of the corresponding cluster are listed next to its cluster, underlined genes were further 
analyzed in this thesis. FC: fold change, FDR: false discovery rate. 
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Genes that were re-induced by antigen termination on day 10, such as Il2, Tnf, Icos, and Nfatc3, 
were found in cluster 7, and genes that were antigen-dependently induced were found in cluster 
8 (Figure 22B). Within the chronic-associated clusters (4, 10, 14, and 15) we found genes 
encoding exhaustion-associates markers, such as PD-1, Lag-3, TIGIT, CD200/Ox2, Ox40, 
TOX, Maf, NFAT, Batf, as well as genes, encoding the Tfh-associated markers ICOS, CXCR5, 
IL-21, and the anergy-associated marker CD73 (Nt5e, cluster 15) (Figure 22A). These analyses 
suggest that chronic antigen presentation beyond the priming phase induces CD4+ T cell 
plasticity in a dose- and time-dependent manner. 
 
 
 
Figure 23: Persisting antigen dose-dependently downregulates certain gene expression in specific CD4+ T 
cells. Cluster analyses of microarray data comparing gene expression pattern of naïve, memory, low, int, int off, and 
high, AND+RAG0/0 T cells early on day 10 or late on day 30. Samples were generated as describes in Figure 22. 
cDNA was probed with Mogene 2.0 microarrays. 15 clusters were identified for each analysis. All genes depicted 
fulfill the criteria FC³1.5 and FRD£0.05. (A) Gene-expression downregulated (blue) early on day 10 compared to 
naïve T cells. (B) Gene-expression downregulated (blue) late on day 30 compared to naïve T cells. Genes uniquely 
expressed in one condition are depicted in the left column and genes expressed in two or more conditions in the right 
column. Naïve, memory (mem), low, intermediate (int), intermediate off (int off), and high represents the time and 
dose of antigen AND+RAG0/0 T cells have seen beyond the priming phase. Red numbers on the left side of the 
columns indicate the cluster number followed by the number of regulated genes within the according cluster (black 
number). Representative genes of the corresponding cluster are listed next to its cluster, underlined genes were 
further analyzed in this thesis. FC: fold change, FDR: false discovery rate. 
 
 
We also defined the 15 possible patterns of gene-expression as 15 clusters with downregulated 
genes compared to naïve T cells among the different groups on day 10 (Figure 23A) and on 
day 30 (Figure 23B). Interestingly, we found Lat in cluster 4, a cluster representing genes that 
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were exclusively downregulated by chronic high TCR stimulation. This finding is in agreement 
with our finding that LAT protein is significantly decreased in high AND T cells (Figure 14A).   
Gene Ontology (GO) enrichment analysis is used to perform statistically analyses on gene sets 
to identify significant similarities or differences between genomic samples and to gain insights 
into the functions and dynamics of gene sets. To identify molecular mechanisms induced or 
repressed by dose-dependent chronic antigen presentation we performed GO enrichment 
analysis of day 10 clusters upregulated in chronic condition (3, 4, 10, 11, 12, 14, and 15). We 
identified several statistically significant GO terms, including the ones listed in Figure 24. The 
diameter of the circles indicates the number of regulated genes associated with the 
corresponding terms and the color indicates the p-Values as indicated.  
 
 
          
 
Figure 24: Gene Ontology (GO) enrichment analysis of upregulated gene-expression clusters on day 10 
revealed gene-expression pattern associated with negative regulation of the MAPK cascade. GO terms 
enriched in gene sets upregulated within gene-expression clusters identified on day 10 (cluster 3, 4, 10, 11, 12, 14, 
and 15) described in Figure 22A. Each column represents a cluster; each row represents a GO pathway or process. 
The significances (p-values of student's t-test) are color coded and the number of genes per GO term is indicated by 
the diameters of the circles. Analyses were performed by Tobias Straub, BMC, LMU. 
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We found the highest number of significantly regulated GO terms associated to clusters with 
induced gene expression, either by intermediate antigen-dose only (cluster 3), shared by 
intermediate and high dose (cluster 10), or shared by all activating conditions (cluster 15). The 
gene-expression profile of cluster 10 indicates that signaling is affected and that gene-
expression modulates MAPK signaling, which is in agreement with our finding that c-Jun and 
S6 phosphorylation was significantly reduced under chronic conditions (describes above, data 
not shown) (Han et al., 2010). Cytokine production was positively regulated by all stimulating 
conditions (cluster 15) suggesting a post-transcriptional regulation, as cytokine production was 
antigen-dose-dependently impaired (Figure 13).  
In contrast, analyzing GO terms of downregulated genes, we found not many genes 
downregulated by chronic intermediate or high TCR stimulation (cluster 10). NF-κB signaling is 
significantly downregulated by high TCR stimulation (cluster 4) (Figure 25). 
 
 
           
 
 
Figure 25: Gene Ontology (GO) enrichment analysis of gene-expression clusters of downregulated genes on 
day 10. GO terms significantly associated with gene sets downregulated within gene-expression clusters identified 
on day 10 (cluster 3, 4, 10, 11, 12, 14, and 15) described in Figure 22A. Each column represents a cluster; each row 
represents a GO pathway or process. The significances (p-values of student's t-test) are color coded and the number 
of genes per GO term is indicated by the diameters of the circles. Analyses were performed by Tobias Straub, BMC. 
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 4.5.3 Gene-expression differences on day 10 are predictive for later gene expression 
patterns 
To examine if induced gene-expression patterns on day 10 correlate with the gene-expression 
profile of day 30 we compared upregulated day 10 gene-expression clusters shown in Figure 
22A (Figure 26A, red dots) with day 30 identified gene-expression profile of intermediate vs. 
memory AND T cells (Figure 26A, black dots). Genes identified in the day 10 memory-
associated cluster 1 were equally distributed among day 30 memory and intermediate AND T 
cells (Figure 26A). Gene Set Enrichment Analysis (GSEA) also revealed no significant 
correlation, indicated by the high false discovery rate (FDR) of 0.14 (Figure 26B). In contrast, 
gene clusters associated with chronic stimulation (cluster 3, 4, 10, 14, and 15) are significantly 
(indicated by very low FDR, Figure 26B) enriched in the int/mem comparison on day 30 (Figure 
26). This comparison indicates that gene-expression changes induced by persisting antigen by 
day 10 are predictive for later gene expression on day 30. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Figure 26: Early induced gene expression pattern (on day 10) are predictive for later gene-expression pattern 
(on day 30). (A) Gene expression pattern of day 30 memory (mem) and intermediate (int) AND+RAG0/0 T cells 
identified in Figure 22B are visualized in volcano plots (black dots). Genes expressed in AND+RAG0/0 T cells on day 
10 according to the conditions defined for unique clusters 3 and 4, or shared clusters 10, 14, and 15 were projected 
in red onto day 30 induced gene-expression pattern of int vs. mem AND+RAG0/0 T cells. Numbers on top of the 
volcano plots indicate the cluster number, the two red numbers within the panels indicate the cluster genes with an 
FDR < 1 and >1, respectively. (B) Gene set enrichment analysis (GSEA) showing the FDR of the corresponding 
comparisons. FDR: false discovery rate, FC: fold change, NES: Normalized enrichment score, t: t-value of Student´s 
test.  
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4.5.4 Exhaustion-associated surface markers and transcription factors are induced by 
persisting antigen in a dose-dependent fashion 
Chronic infections and cancer cause a dysfunctional state of T cells termed exhaustion and is 
associated with the loss of effector function, impaired proliferative capacity, upregulation of 
multiple inhibitory receptors, and altered expression of key transcription factors (Crawford et al., 
2014; McLane et al., 2019; Schietinger et al., 2016; Wherry and Kurachi, 2015; Yi et al., 2010). 
What role chronic antigen presentation itself plays in such a scenario and what influence the 
dose of presented antigen has on CD4+ T cells is not clear. We found increased RNA expression 
levels of several exhaustion-associated inhibitory receptors (Figure 22). To validate surface 
expression of the respective proteins, flow cytometric analyses were performed (Figure 27A, 
B). We found LAG-3, TIGIT, and Ox2 (CD200) being highly sensitive to persisting antigen levels 
as they showed a dose-dependent surface expression. Other markers responded exclusively 
to high dose antigen. Among them we found the expression of PD-1, Ox40, and IL18R 
significantly induced and the expression of CD137L significantly repressed on high AND T cells. 
These data show that the amount of antigen presentation beyond the priming phase matters for 
the upregulation of inhibitory receptors.  
Flow cytometric analysis of the induced transcription factors TCF-1, cMaf, and TOX (Figure 22) 
demonstrated different responses to chronic antigen presentations (Figure 27). TCF-1, which is 
associated with CD8+ T memory generation (Lin et al., 2016; Utzschneider et al., 2016b; Zhou 
et al., 2010) is not induced on protein-level but significantly reduced in high ANDs. The 
transcription factor cMaf was shown to be involved in Tr1 differentiation and in CD8+ T cell 
exhaustion (Chien et al., 2017; Gagliani et al., 2013; Giordano et al., 2015; Pot et al., 2009; 
Roncarolo et al., 2018). We found that cMaf expression was induced by high-dose antigen and 
the transcription factor TOX, which is associated with CD8+ T cell exhaustion (Alfei et al., 2019; 
Khan et al., 2019; Scott et al., 2019) to be dose-dependently induced, suggesting a more 
sensitive regulator (Figure 27). These data indicate that AND CD4+ T cells sense and respond 
to different antigen doses after the initial priming phase with the induction of transcription factors 
involved in CD8+ Tmem and Tex cell differentiation in viral and cancer models.  
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Figure 27: Exhaustion-associated markers and transcription factors respond dose-dependently to persisting 
antigen. Quantification of 1 x 106 adoptively transferred AND T cells using flow cytometry. Naïve, memory (mem), 
low, intermediate (int), and high AND CD4+ T cells were generated as described in Figure 10A. Spleens were 
harvested 10 days post transfer. AND T cells shown were identified using the gating strategy described in Figure 8A. 
(A) Representative histograms showing surface expression of inhibitory receptors identified by microarray analyses. 
(B) Statistical quantification. (C) Representative histograms of intracellular transcription factor expression identified 
by microarray analysis. (D) Statistical quantification. Delta geometrical means were calculated by gMFISample - 
gMFIisotype control. Data were pooled from at least two independently performed experiments, each data point 
represents one mouse. *p < 0.05, **p < 0.001, ***p < 0.0001, parametric unpaired two-tailed t-test. 
 
 
Analyzing the transcription factor expression pattern on day 30 we found IRF4 and cMaf 
responding to chronic intermediate amount of antigen presentations (Figure 28). TOX 
expression was repressed on day 30, indicating a rather early role in T cell dysfunctionality of 
the transcription factor, in contrast to IRF4 and cMaf, which are expressed in intermediate AND 
T cells also at later stages of stimulation.  
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Figure 28: Characterization of transcription factors in AND T cells chronically exposed to low and 
intermediate Ag doses in iMCC-transgenic recipients analyzed on day 30. Quantification of 1 x 106 adoptively 
transferred AND T cells using flow cytometry. Cells were generated as describes in Figure 10A. Spleens were 
harvested 30 dpt, T cells shown were identified by CD4 and CD45.1 expression using the gating strategy described 
in Figure 8B. Histograms showing intracellular transcription factor expression of splenic AND T cells. Data shown 
from one experiment. Memory (mem), low, intermediate (int), and high represents the dose of antigen AND T cells 
have seen beyond the priming phase as schemed in Figure 10A. IC = isotype control. 
 
4.5.5 Antigen-exhausted CD4+ T cells share gene-expression pattern with LCMV cl13-
exhausted CD4+ T cells 
Chronic Lymphocytic Choriomeningitis Virus (LCMV) infection is one of the best-studied 
systems of chronic infections in mice. During chronic LCMV cl13 infections T cells become 
exhausted. Thus, we compared mRNAs induced in antigen-exhausted CD4+ T cells with the 
ones induced in LCMV cl13-exhausted CD4+ T cells, published by Crawford et al., 2014. We 
identified shared induced genes (Figure 29, red dots) with LCMV cl13-exhausted CD4+ T cells 
analyzed 15 days (Figure 29A black dots, B) and 30 days post infection (Figure 29C black dots, 
D). Genes grouped in memory-associated cluster 5 (day 10) correlate with LCMV Armstrong 
(Arm) challenged CD4+ T cells (day 15), when memory CD4+ T cells are generated. This 
indicates that gene-expression pattern induced by transient antigen-presentation is similar to 
the one induced by LCMV Arm-specific memory CD4+ T cells. Exhaustion-associated clusters 
(cluster 10, and 14) correlate with LCMV cl13-exhausted phenotype analyzed on da 15 (Figure 
29A, B) as well as on day 30 (Figure 29C, D) indicating shared exhaustion-induced gene-
expression patterns. The observed differences in gene-expression patterns between LCMV- 
and antigen-exhausted T cells might be induced in an inflammation-driven manner. 
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Figure 29: Antigen-exhausted AND T cells share gene-expression pattern with LCMV cl13-exhausted CD4+ T 
cells. Gene expression pattern of antigen specific CD4+ T cells isolated upon 15 or 30 days of LCMV Armstrong 
(Arm) or clone13 (cl13) infections respectively, are visualized in volcano plots (black dots). Gene expression 
upregulated in acute LCMV arm infection fall to the left and genes upregulated in chronic cl13 infection fall to the 
right. Genes expressed in AND+RAG0/0 T cells on day 10 according to the conditions defined for the memory-
associated cluster 5 and exhaustion-associated clusters 4, 10 and 14 were projected in red onto (A) day 15 analyzed 
LCMV induced gene-expression pattern of Arm vs. cl13 CD4+ T cells and (C) day 30 LCMV induced gene-expression 
pattern of Arm vs. cl13 CD4+ T cells. Numbers on top of the volcano plots indicate the cluster number, the two red 
numbers within the panels indicate the cluster genes with an FDR < 1 and >1, respectively. (B and D) Gene set 
enrichment analysis (GSEA) showing the FDR of the corresponding comparisons. FDR: false discovery rate, FC: 
fold change, NES: Normalized enrichment score, t: t-value of Student´s test.   
  
4.5.6 Anergy-associated surface marker-expression is antigen dose-dependent and 
reversible 
The markers FR4 and CD73 are associated with T cell anergy (Kalekar et al., 2016; Martinez 
et al., 2012). We found Nt5e, the gene encoding for CD73, highly induced on gene-expression 
level in all antigen-experienced AND T cells (Figure 22, cluster 15). Thus, we assessed surface 
expression of CD73 with the surface expression of FR4 (which is not probed by the microarray 
used) on day 10 by flow cytometry. Naïve and memory AND CD4+ T cells barely expressed 
these markers, only approximately two and three percent, respectively. FR4 and CD73 surface 
expression was induced by antigen persistence beyond the priming phase in correlation with 
antigen-dose. The more antigen AND T cells have seen, the stronger FR4 and CD73 surface 
expression was upregulated (Figure 30A, B).  
Looking at the abundance of endogenous anergic CD4+ T cells of the recipient mice there was 
no significant difference detectable in percentage and absolute numbers, indicating there is no 
competition (Figure 30A, B). These data indicated that persisting antigen-stimulation induce the 
expression of anergy-associated markers in a dose-dependent fashion. 
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Figure 30: Anergy-associated markers respond to antigen dose (day 10). Quantification of 1 x 106 adoptively 
transferred AND T cells using flow cytometry. Naïve, memory (mem), low, intermediate (int), and high AND CD4+ T 
cells were generated as described in Figure 10A. Spleens were harvested 10 days post transfer. AND T cells shown 
were identified following the gating strategy described in Figure 8A. (A) Representative results showing increasing 
surface expression of the anergy-associated markers FR4 and CD73 on the surface of ANDs (color coded, right 
column) chronically exposed to increasing antigen dose and on endogenous anergic CD4+ T cells (in grey, left 
column). (B) Graphs show percentage and absolute numbers of AND T cells and endogenous anergic CD4+ T cells 
expressing the anergy-associated markers FR4 and CD73. Data are shown of eight independent experiments; each 
data point represents one mouse. *p < 0.05, **p < 0.001, ***p < 0.0001, parametric unpaired two-tailed t-test. Naïve, 
memory (mem), low, intermediate (int), and high represents the dose of antigen AND T cells have seen beyond the 
priming phase as schemed in Figure 10A. 
 
 
Next, we asked if the expression of the anergy-associated markers FR4 and CD73 depends on 
persisting antigen or is rather fixed. To this end we rescued intermediate and high AND T cells 
on day 10 by terminating dox treatment of intermediate mice (int off) and performed secondary 
transfer from high ANDs into antigen-free wt mice (high off). As controls we included memory 
and intermediate (int on) AND T cells as well as high ANDs secondarily transferred back into 
cMCC recipients presenting MCC at a high dose (high on) (Figure 31A). Splenocytes were 
analyzed on day 21 post primary transfer. The expression patterns of FR4 and CD73 on day 21 
pt represent the expression patterns shown on day 10 post transfer (Figure 30). Upon antigen 
withdrawal by either terminating dox treatment or secondary transfer surface expression of FR4 
and CD73 was significantly reduced (Figure 31B, C) indicating that the expression of these 
anergy markers depend on persisting antigen presentation. Thus, the anergic phenotype might 
be reversible upon antigen removal. This conclusion is in agreement with Kalekar et al., 2016 
showing that most anergic T cells downregulated their surface expression of FR4 and CD73 
when transferred into lymphopenic recipients.  
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Figure 31: The expression of the CD73 and FR4 markers associated with anergy is reversible upon 
discontinuation of antigen stimulation. Quantification of 1 x 106 adoptively transferred AND T cells using flow 
cytometry. (A) Schematic outline describing the treatment strategy to generate memory (mem), intermediate (int), 
intermediate off (int off), high and high off AND CD4+ T cells. Mem, int, and int off cells were generated as described 
in (Figure 10A) and analyzed 21 days post transfer (dpt). “High on” and “high off” AND T cells were generated by 
secondary transfer 10 days post primary transfer. High CD4+ T cells were MACS purified and 3x106 CD4+ T cells 
secondarily transferred into either high-dose antigen presenting cMCC or antigen-free wildtype mice. Spleens were 
analyzed on 21 dpt. T cells shown were identified according to the gating strategy described in Figure 8A. (B) 
Representative results showing reversible surface expression of the anergy-associated markers FR4 and CD73 on 
AND T cells rescued in vivo by terminating antigen presentation (color coded, right column) and on endogenous 
anergic CD4+ T cells (in grey, left column). (C) Graphs show percentage and absolute numbers of AND T cells 
expressing the anergy-associated markers FR4 and CD73 analyzed on day 21 post transfer. Data are shown of three 
independent experiments; each data point represents one mouse. *p < 0.05 parametric unpaired two-tailed t-test. 
 
 
4.5.7 Gene expression profile of antigen-exhausted CD4+ T cells strongly correlate 
with the one of anergic CD4+ T cells 
The finding that the expression of anergy markers FR4 and CD73 was induced dose-
dependently (Figure 30) suggested comparisons of the gene-expression profiles described with 
those of endogenous anergic CD4+ T cells. To this end, we sorted endogenous anergic CD4+ T 
cells based on CD4+CD44+FR4+CD73+ and non-anergic control CD4+ T cells based on 
CD4+CD44+FR4–CD73– surface expression (according to Figure 32 and Table 7). Total RNA 
was isolated and microarray analysis was performed as described in section 3.3.1.6). 
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Figure 32: Sorting strategies for endogenous anergic and control CD4+ T cells used for microarray analysis. 
Representative gating strategy for sorting endogenous anergic and naïve non-anergic cells. Samples were sorted 
directly into Trizol for later analysis. Anergic cells were sorted based on DapinegCD4+CD44+FR4+CD73+ and non-
anergic control cells based on DapinegCD4+CD44+FR4-CD73-.  
 
 
 
Anergy MACS purification Sort #1   
# cell type 
total cell #     
pre MACS  
(x107) 
total cell # 
post MACS  
(x106) 
total cell # 
post Sort #1   
(x105) 
RIN 
1 FR4+CD73+ 2,0 16,4 2,0 9,9 
2 FR4+CD73+ 10,4 9,7 2,0 9,8 
3 FR4+CD73+ 8,8 7,9 2,0 9,8 
4 FR4+CD73+ 9,2 10,6 2,0 9,4 
5 FR4+CD73+ 7,9 8,6 2,0 9,7 
6 FR4-CD73- 2,0 16,4 2,9 9,4 
7 FR4-CD73- 10,4 9,7 4,9 9,2 
8 FR4-CD73- 8,8 7,9 3,4 9,2 
9 FR4-CD73- 9,2 10,6 4,2 7,7 
10 FR4-CD73- 7,9 8,6 3,8 9,3  
  
Table 7: Cell numbers of sorted endogenous anergic (FR4+CD73+) and non-anergic control (FR4–CD73–) cells. 
 
 
The gene-expression pattern of endogenous anergic cells were plotted against expression 
pattern of non-anergic control cells (Figure 33A, black dots). We highlighted the genes of the 
memory-associated day 10 cluster 1 and the exhaustion-associated clusters (3, 4, 10, 14, and 
15) on to anergic vs. control gene-expression volcano plots (Figure 33A, red dots). Genes of 
the memory-associated cluster 1 were preferentially expressed in non-anergic cells, though the 
false discovery rate FDR = 0,15 indicated no statistical significance (Figure 33B). Comparing 
exhaustion-associated clusters of interest with anergy-induced gene-expression pattern, genes 
strongly correlate with the anergic phenotype (Figure 33A, right) with low FDRs (FDR = 
0.000125) calculated by GSEA. Thus, these results show a significant correlation of genes 
preferentially expressed by anergic and antigen-exhausted cells.  
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Figure 33: Early antigen-exhausted AND+RAG0/0 T cells share gene-expression patterns with 
endogenous anergic CD4+ T cells. Gene expression pattern of polyclonal anergic CD4+ T cells and polyclonal 
naïve, non-anergic CD4+ T cells, both from untreated wildtype B10.BR mice were analyzed with microarrays 
and visualized in volcano plots (black dots). Gene expression specific to non-anergic control cells fall to the left 
and genes identified for polyclonal anergic cells fall to the right. Genes expressed in AND+RAG0/0 T cells on day 
10 according to the conditions defined for the memory-associated cluster 1 and exhaustion-associated clusters 
3, 4, 10, 14, and 15 were projected in red onto anergic vs. non-anergic gene-expression pattern. (B) Gene set 
enrichment analysis (GSEA) showing the FDR of the corresponding comparisons. FDR: false discovery rate, 
FC: fold change, NES: Normalized enrichment score, t: t-value of Student´s test.  
  
4.5.8 Chronic TCR stimulation is not sufficient to induce precursor cells of regulatory 
FoxP3+CD4+ T cells  
Anergic CD4+ T cells have been suggested to include precursor cells of regulatory FoxP3+CD4+ 
T cells (Treg) (Kalekar et al., 2016). It also has been shown that low level antigen can induce 
peripheral Treg cell differentiation in vivo (Kretschmer et al., 2005; Verginis et al., 2008). 
Therefore, we measured intracellular FoxP3 expression by flow cytometry to ask if Treg cells 
were generated in our experimental system. Naïve, memory, low, intermediate, and high AND 
T cells were generated (Figure 10A) and splenocytes were analyzed 10 dpt. FoxP3 expression 
was induced in none of our conditions (Figure 34), indicating that persistent antigen presentation 
itself is not sufficient to induce Treg precuror cells in this model. Our finding is in agreement with 
Szymczak-Workman et al., showing that TCR stimulation is not absolutely required for Treg 
activation (Szymczak-Workman et al., 2009).  
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Fig 34: Treg differentiation is not induced by persisting antigen presentation in the periphery. Quantification 
of 1 x 106 adoptively transferred AND T cells using flow cytometry. Naïve, memory (mem), low, intermediate (int), 
and high AND CD4+ T cells were generated as described in Figure 10A. Spleens were harvested 10 days post 
transfer. AND T cells shown were identified using the gating strategy described in Figure 8B. (A) Representative 
histograms showing intracellular expression levels of the Treg-specific transcription factor FoxP3 in endogenous 
(CD4+CD45.1–) and transferred AND T cells (CD4+CD45.1+). (B) Statistical quantification. Data were pooled from 
three independently performed experiments, each triangle represents one mouse.  
 
4.5.9 CD4+ T cells chronically exposed to antigen fail to transmit B cell help 
During acute infections, Tfh cells promote B-cell-mediated immunity (Crotty, 2015; Hale et al., 
2013). Whether CD4+ T cells differentiate towards Tfh(-like) cells during chronic conditions 
(Brooks et al., 2006a; Elsaesser et al., 2009; Fahey et al., 2011) or become exhausted (Vella 
et al., 2017) is unclear. To address this question, we analyzed Tfh-associated markers and B 
cell proliferation transmitted by antigen-exhausted AND T cells. Gene-expression analyses 
showed significantly increased RNA levels encoding Tfh-associated markers such as PD-1, 
CXCR5, and ICOS, the key transcription factor Bcl-6, and interleukin IL-21. Dose-dependent 
induction of PD-1 expression was validated in Figure 27A. Here, we tested for surface 
expression of CXCR5 and ICOS on naïve, memory, low, intermediate, and high AND T cells 
using flow cytometry.  Cells were generated according to Figure 10A, splenocytes were isolated 
and analyzed. In all three antigen-persisting conditions CXCR5 and ICOS expression was 
significantly induced. Intermediate AND T cells showed the highest expression of CXCR5. ICOS 
expression was induced with increasing antigen dose (Figure 35A, B). 
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Figure 35: CD4+ T cells chronically exposed to antigen failed to transmit help to B cells. (A and B) 
Quantification of 1 x 106 adoptively transferred AND T cells using flow cytometry. Naïve, memory, low, int, and high 
AND CD4+ T cells were generated as described in Figure 10A. Spleens were harvested 10 days post transfer (dpt). 
AND T cells shown were identified using the gating strategy described in Figure 8A. Memory (mem), low, intermediate 
(int), and high represents the dose of antigen AND T cells have seen beyond the priming phase as schemed in Figure 
10A. (A) Representative histograms showing surface expression of Tfh-associated markers CXCR3 and ICOS 
analyzed on day 10 pt. (B) Statistical quantification of the markers described in (A). Delta geometrical means were 
calculated by gMFISample - gMFIisotype control. (C, D) Pilot experiment to analyze B and T cell proliferation in response to 
antigen presentation. (C)  Schematic outline of the experimental set up. (D) CTV dilution of AND T cells and different 
B cells; B10.BR (wt) B cells as non-antigen presenting B cells, iMCC B cells without dox treatment also serve as non-
antigen presenting B cells, and cMCC B cells presenting cognate antigen to AND T cells constitutively. (E – G) B cell 
help transmitted by antigen-exhausted AND T cells. (E) Experimental set up and treatment strategy to analyze T and 
B cell interaction upon chronically T cells stimulation. Memory, int (day 10), and int (day 30) were generated as 
indicated. Dox treatment of memory mice was switched on again on day 9 pt. Control mice were all set the same day 
as indicated, AND T cells were transferred into wt hosts. 10 dpt 5x106 CTV labeled cMCC B cells were transferred 
into the mice hosting AND T cells. One day after B cell transfer 1 ng hen egg lysozyme (HEL) was injected ip. Five 
days post B cell transfer Spleens were harvested and analyzed using flow cytometry. (F) Representative results 
showing CTV dilution of B cells. (G) Graph shows the percentage of B cells that have proliferated at least once. Data 
were pooled from at least three (B), one (D), and 15 (G) independently performed experiments, each data point 
represents one mouse. *p < 0.05, **p < 0.001, ***p < 0.0001, parametric unpaired two-tailed t-test.  
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These data suggest that chronic antigen stimulation induces a Tfh-like phenotype. Therefore, 
we examined if antigen-exhausted AND T cells were able to transmit help to B cells. As a 
readout we used B cell proliferation induced by intermediate day 10 and day 30 AND T cells. 
To establish T and B cell interaction we ran a pilot experiment which showed that B cell 
proliferation was induced only in antigen-expressing B cells. CTV-labeled AND T cells were 
transferred into iMCC recipient mice and CTV-labeled, congenically marked B cells were 
transferred one day later (Figure 35C). Recipient #1 received B10.BR wt B cells, #2 iMCC B 
cells, both are not antigen-specific and do not express MCC on Ek, and #3 received cMCC B 
cells expression MCC on Ek. Splenocytes were analysed five days post B cell transfer. AND T 
cells proliferated in all recipients in response to MCC expressed by host DCs (Figure 35D, left) 
but only antigen-presenting B cells (#3) proliferated (Figure 35D, right). These results 
demonstrate that AND T cells mediate proliferation of antigen-presenting B cells. Thus, 
indicating that effector AND T cells are able to transmit help to B cells inducing proliferation.  
We then asked if antigen-exhausted AND T cells are also able to provide help to B cells. We 
analyzed B cell proliferation induced by day 10 and day 30 antigen-exhausted AND T cells, 
compared to day 10 memory AND T cells. T cell phenotypes were established before B cells 
were transferred (Figure 35E) to read out the effect of antigen-persistence at an intermediate 
dose on T cell functionality. A set of negative controls were included to establish that B cell 
proliferation was induced by functional T cell help only. 3x106 CTV-labeled cMCCxSW B cells, 
expressing MCC on Ek (MHC II) and a hen egg lysozyme (HEL)-specific transgenic BCR (Brink 
et al., 2015), were used. Very low dose of HEL (1 ng) was injected as indicated. HEL was not 
sufficient to induce B cell proliferation itself, as there was no B cell proliferation detectable in 
control #3 (Figure 35F). All spleens were harvested and analyzed on the same day, 5 days post 
B cell transfer. Memory AND T cells were able to induce B cell proliferation (Figure 35F, G). 
However, the B cell proliferation rate was significantly reduced by antigen-persistence in a time-
dependent manner. B cells interacting with day 10 antigen-exhausted AND T cells showed 
significantly reduced proliferation, which was completely lost when AND T cells were exposed 
to antigen for 30 days (Figure 35F, G). These results indicate that even though AND T cells up-
regulate Tfh-associated surface markers, such as CXCR5, ICOS, and PD-1, they fail to transmit 
help to B cells. 
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5. Discussion 
 
Protective immunity against chronic infections or tumor cells significantly relies on intact CD4+ 
T cell functionality. An important question concerning protective immunity is whether and how 
CD4+ T cells become exhausted by chronic antigen presentation. In contrast to CD8+ T cell 
exhaustion, the cause of CD4+ T cell dysfunctionality and its plasticity are rarely investigated.  
Both, CD4+ T cell exhaustion as well as Tfh cell differentiation caused by chronic TCR 
stimulation have been reported. Here, we have analyzed the effects of mere antigen persistence 
beyond the priming phase, with the focus on antigen dose and timing, on phenotype, 
functionality, signaling, and transcription of antigen-specific CD4+ T cells. We have shown that 
chronically stimulated CD4+ T cells have impaired cytokine production and exhibit a dose-
dependent upregulation of exhaustion-, anergy-, and Tfh-associated genes. Our data further 
demonstrated that chronic CD4+ T cells are able to continuously sense persistent antigen, even 
at the highest dose where TCR/CD3 complexes and downstream signaling molecules and 
pathways were chronically downregulated. Furthermore, qualitative and quantitative changes in 
the cells' transcriptional profiles highlighted a common signature describing antigen-induced T 
cell anergy and exhaustion. We have also shown that antigen-exhausted CD4+ T cells lose their 
ability to provide help to B cells over time. Together, our results underline the importance of 
antigen disappearance after priming to generate functional Tmem cells. Persistent antigen, 
dependent on dose and timing, contribute to the plasticity of CD4+ T cells and determine their 
range of dysfunctionality or anergy. 
5.1 CD4+ T cells are sensitive to initial antigen quality  
Different amounts of cognate antigen during the priming phase of CD4+ T cells induced dose-
dependent T cell activation and proliferation. Intermediate- and high-doses of antigen activated 
antigen specific CD4+ T cells already 16 hours post transfer in vivo and induced rapid phenotypic 
changes. In contrast, low-level antigen failed to do so, evidenced by baseline expression of the 
early activation marker CD69 and Nur77-GFP, a reporter for TCR signal strength (Moran et al., 
2011). Thus, this indicates that CD4+ T cells require a certain degree of stimulation to become 
activated. If the stimulating dose of antigen was low, T cell activation was delayed, and 
phenotypic changes established only slowly. Further, the proliferative capacity of specific CD4+ 
T cells reflected a dose-dependent response. The more antigen T cells encountered, the more 
homogenous were the proliferation profiles. This indicates that CD4+ T cells accumulate weak 
TCR stimulations over time to overcome a certain threshold of activation. Thus, we conclude 
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that CD4+ T cells are able to sense and discriminate antigen quality and respond antigen-dose-
dependently. This conclusion is in agreement with the finding that CTLs, stimulated by 
increasing amount of cognate antigen presented by APCs in a coculture system in vitro, 
revealed a dose-dependent cytotoxic activity, which exhibited hyporesponiveness in response 
to high-dose pMHC (Wolchinsky et al., 2014).  
5.2 Persisting antigen impairs CD4+ T cell memory differentiation  
In the mouse model used here, antigen removal by day five allows for the differentiation of a T 
cell memory phenotype, as shown by efficient production of IL-2, TNF-α, and IFN-γ (Han et al., 
2010; Obst et al., 2007). In contrast, persistent antigen presentation beyond the priming phase 
impaired memory cell formation. The dose of persistent antigen determined the level of reduced 
IL-2, TNF-α, and IFN-γ production in response to PMA/IM re-stimulation on day 10. Loss of 
effector function appeared in a dose-dependent and progressive fashion with IL-2 being most 
sensitive to antigen dose, while TNF-α and IFN-γ production was reduced more gradually in 
correlation with antigen quality. Our data confirm the findings of Brooks et al., 2006a and 
Crawford et al., 2014, showing that IL-2, TNF-α, and IFN-γ production are impaired in LCMV 
cl13-exhausted CD4+ T cells. Several studies on CD8+ T cell exhaustion caused by chronic 
LCMV cl13 infections reported that cytokine production is being lost progressively. IL-2 
production is lost first, followed by TNF-α and subsequently, by IFN-γ (Agnellini et al., 2007; 
Fuller et al., 2004; Mackerness et al., 2010; Shin et al., 2009; Wherry et al., 2003a) thus, 
supporting our findings. Additionally, surface-expression levels of the memory-associated 
markers CD127 (Boettler et al., 2006; Huster et al., 2004; Kaech et al., 2003), CD62L (Smalley 
and Ley, 2005), and Ly6C (Hale et al., 2013; Hanninen et al., 2011; Tokoyoda et al., 2009) were 
reduced, suggesting phenotypic changes induced by persistent antigen. Taken together, our 
data demonstrate that CD4+ T cell memory differentiation is affected early if chronic TCR 
stimulation exceeds a certain threshold. Mere chronic antigen presentation caused the loss of 
the regular Th1-associated effector functions and impaired memory generation. Thus, we 
postulate that CD4+ T cells are sensitive to persistent TCR stimulation and adjust their functional 
unresponsiveness to the dose of persisting antigen. 
5.3 Features of antigen-exhausted/anergic CD4+ T cells 
After CD4+ T cell depletion, LCMV-cl13-infected mice establish a lifelong unresolving viremia 
(Matloubian et al., 1994). There is evidence suggesting that CD4+ T cells are not entirely 
dysfunctional during chronic viral infections but rather differentiate away from a regular Th1-
associated phenotype towards a Tfh-associated one (Elsaesser et al., 2009; Fröhlich et al., 
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2009). As we and others showed that chronic CD4+ T cells lose their regular effector 
mechanisms (Crawford et al., 2014; Han et al., 2010) and enter a hyporesponsive state, 
considered to be an important tolerance mechanism (Schwartz, 2003; Wells, 2009; Wolchinsky 
et al., 2014), it is important to investigate the changes antigen-specific CD4+ T cells undergo 
during chronic conditions. 
5.3.1 Persisting antigen alters effector function and phenotype 
In addition to the progressive loss of the regular Th1 memory-associated cytokine profile, 
several research groups published that CD4+ Tex cells skew their cytokine production towards 
Tfh-associated cytokines, such as IL-21 (Brooks et al., 2006b; Crawford et al., 2014; Elsaesser 
et al., 2009; Fahey et al., 2011; Fröhlich et al., 2009). Our transcriptome analyses support these 
findings. Il-21 mRNA expression was significantly increased in CD4+ T cells chronically 
stimulated by persistent antigen (day 10, up cluster 10 and cluster 14 respectively). In 
agreement with the hypothesis of Tfh-like differentiation induced by chronic TCR stimulation 
(Fahey et al., 2011), the Tfh-associated markers ICOS, CXCR5, and PD-1 were significantly 
upregulated on mRNA and protein levels. ICOS and PD-1 expression positively correlated with 
antigen dose, while CXCR5 expression was highest at intermediate strength. Our findings agree 
with data on LCMV cl13-exhausted CD4+ T cells demonstrating high-level surface expression 
of CXCR5, ICOS and PD-1 (Crawford et al., 2014). Further, expression of the key Tfh-specific 
master transcription factor B cell lymphoma 6 (BCL-6) is induced in LCMV cl13-exhausted CD4+ 
T cells (Crawford et al., 2014). In our experiments, bcl-6 mRNA expression was also elevated 
by persistent TCR stimulations of intermediate and high amount compared to the conditions 
leading to memory differentiation (day 10, down cluster 5). A key feature of Tfh cells is to ensure 
B cell-mediated immunity by driving GC development, promoting antibody affinity maturation, 
and supporting long-lived plasma cell differentiation (Crotty, 2015). We have shown that 
chronically stimulated CD4+ T cells downregulate CD154 (CD40L) expression in an antigen 
dose-dependent fashion. CD40L is a specific ligand for CD40 expressed on professional APCs, 
such as B cells. CD40L/CD40 ligation triggers bi-directional signals between antigen-specific T 
and antigen-specific B cells and is necessary for proliferation of both (Evans et al., 2000), 
provides costimulatory signals by inducing or sustaining co-stimulatory receptor (CR) 
expression such as CD80 (B7-1) and CD86 (B7-2) (Grewal and Flavell, 1998; Kennedy et al., 
1994; Ranheim and Kipps, 1993) and mediates contact-dependent T cell help for B cell 
differentiation and proliferation (Evans et al., 2000). Humans and mice deficient in either CD40 
or CD40L expression lack T cell-mediated antibody responses and GCs (Foy et al., 1996; 
Kawabe et al., 1994). Our experiments found a reduced CD40L expression and the limited 
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capacity of chronically stimulated CD4+ T cells to induce B cell proliferation. Nevertheless, there 
is evidence that chronic TCR stimulation induces Tfh differentiation (Elsaesser et al., 2009; 
Fahey et al., 2011; Fröhlich et al., 2009). Tfh-associated markers are induced and significant 
amounts of virus-specific T-cell-dependent antibodies are generated during chronic LCMV cl13 
infections in mice and during HCV infections in man (Bartosch et al., 2003; Buchmeier et al., 
1980; Vella et al., 2017). Additionally, broadly neutralizing antibodies are generated in HIV 
patients several years after infection, even if they appear only very rarely (Caskey et al., 2019; 
West et al., 2013). Tfh-like T cells have also been described in cancer patients  (Crotty, 2019) 
and autoimmune disease (Crotty, 2019) such as rheumatic disease (Deng et al., 2019). Thus, 
it is tempting to speculate that at least some features of T cell help to B cells remain intact. 
5.3.2 Persisting antigen causes surface expression of multiple IRs 
Another key feature of CD8+ Tex cells is an increased and sustained surface expression of 
multiple IRs (Bengsch et al., 2010; Blackburn et al., 2009; Day et al., 2006; Kaufmann et al., 
2007; Petrovas et al., 2006; Radziewicz et al., 2007; Trautmann et al., 2006; Urbani et al., 2006; 
Wherry et al., 2007). IRs negatively influence T cell activation and function. Transient 
expression is important to restrain immune responses and attenuating T cell activation when 
the infection is cleared to prevent dangerous auto-pathology. Prolonged IRs surface expression, 
however, was described to induce dysfunctional states of CD8+ Tex cells (Bengsch et al., 2010; 
Blackburn et al., 2009; Day et al., 2006; Kaufmann et al., 2007; Petrovas et al., 2006; 
Radziewicz et al., 2007; Trautmann et al., 2006; Urbani et al., 2006; Wherry et al., 2007). 
Previously, IR surface expression was also reported on LCMV cl13-exhausted CD4+ T cells 
(Crawford et al., 2014). In line with this, we show in this study a dose-dependent increase in 
expression levels of PD-1, LAG-3, TIGIT, and CD200/Ox2 on chronically stimulated CD4+ T 
cells. Since antigen dose and surface-expression levels of IRs positively correlated we suggest 
that the dose of persistent antigen beyond the priming phase determines the degree of CD4+ T 
cell dysfunctionality and can be used to characterize the different states of unresponsiveness/ 
anergy.  
5.3.3 Chronic high-dose TCR stimulation results in loss of CD4+ T cells 
Recently, several authors described the heterogeneity of the CD8+ Tex pool, consisting of stem-
like progenitor Tex cells with the potential of self-renewal and more terminally differentiated 
exhausted T cells (Paley et al., 2012). Bengsch et al. identified nine different subsets of CD8+ 
Tex cells based on their specific surface marker expression characteristics (Bengsch et al., 
2018). The majority of Tex cells represent terminal CD8+ Tex cells, which have lost the ability 
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to proliferate and finally enter activation-induced cell death when high-dose antigen stimulation 
continues to persist (Paley et al., 2012).  
Accordingly, even though chronic antigen stimulations allowed CD4+ T cell accumulation on day 
10 post transfer to a similar extent when compared to memory CD4+ T cells, we failed to detect 
chronically high-dose stimulated CD4+ T cells 30 days post transfer. In contrast, low- and 
intermediate-dose TCR stimulation induced a long-lived phenotype (> 30 days). Since 
exclusively T cells stimulated with a high-dose failed to survive, we hypothesize that high-dose 
antigen stimulation possibly drives activation-induced cell death as a physiological negative 
feedback mechanism, preventing overstimulation/overactivation-mediated auto-pathology 
within a chronic stimulatory microenvironment.  
5.4 Development of antigen-exhausted CD4+ T cells 
CD8+ Tex cells isolated within the first two weeks from chronically LCMV cl13 infected animals 
and transferred back into acutely infected wild type mice are able to reverse their exhausted 
phenotype and recover towards functional memory T cells (Angelosanto et al., 2012; Brooks et 
al., 2006a). In contrast, extended priming by persistent antigen stimulation induces irreversible 
CD8+ T cell dysfunction and an exhausted immunophenotype (Angelosanto et al., 2012; Brooks 
et al., 2006a; Utzschneider et al., 2016b). This is evidence to conclude that CD8+ T cell 
exhaustion develops in a progressive way and that its severity depends on the duration of 
antigen persistence. For CD4+ T cells such experiments have not been done. Here, we 
addressed the role of chronic TCR stimulation during CD4+ Tex differentiation. 
5.4.1 Role of chronic TCR signaling during CD4+ Tex cell differentiation 
The severity of CD8+ T cell exhaustion correlates with the dose of antigen and its exposure time, 
as shown during LCMV cl13 infections in mice and during HBV, HCV, and HIV infections in man 
(Boni et al., 2007; Goepfert et al., 2000; Reignat et al., 2002; Shankar et al., 2000; Wherry and 
Kurachi, 2015; Wherry et al., 2003b; Zajac et al., 1998). One observation of this study was that 
TCR/CD3-complex surface expression is exclusively downregulated by high-dose TCR 
stimulation. This phenomenon is associated with T cell activation (Cai et al., 1997; Valitutti et 
al., 1995b; Viola and Lanzavecchia, 1996), and is induced especially by high affinity TCR/pMHC 
engagement (Cai et al., 1997; Rothenberg, 1996; Valitutti et al., 1995a; Valitutti et al., 1996; 
Zanders et al., 1983). It has been suggested that TCR/CD3 downmodulation is a mechanism to 
protect against autoimmunity caused by extensive TCR signaling (Alcover et al., 2018; 
Rothenberg, 1996). In the experimental system used here, TCR downregulation was induced 
early, already by day three, and persisted. TCR/CD3-complex degradation has been described 
  Discussion 
 
 89 
as a modulatory mechanism to reduce TCR surface expression and facilitating or promoting 
intracellular signal transduction (Alcover et al., 2018; Rothenberg, 1996). We found that 
TCR/CD3 complexes are intracellularly maintained upon downmodulation and rapidly recycle 
back to the cell surface in absence of antigenic stimulations. These re-expressed surface 
TCR/CD3 complexes are not able to transmit TCR signals when stimulated directly via TCR, 
even though the cells still remained their capacity to produce IFN-γ when stimulated indirect via 
PMA/IM bypassing TCR/CD3 complexes. This suggests a problem in signal transduction 
proximal to the TCR/CD3 complex.  
With the help of network analysis, we identified lat mRNA expression, encoding for the linker of 
activated T cells (LAT), being significantly reduced exclusively upon high-dose TCR 
stimulations. We validated this finding also on the protein level. Usually, after productive TCR 
stimulation LAT is phosphorylated by zeta-chain-associated protein kinase 70 (ZAP-70) (Au-
Yeung et al., 2018; Paz et al., 2001). Once phosphorylated, LAT serves as a central adaptor 
protein recruiting several signaling molecules and thus mediates TCR-mediated signals leading 
to T cell activation, proliferation, differentiation, and cytokine production. Besides reduced lat 
mRNA expression in high CD4+ T cells LAT protein is also degraded, while TCR/CD3 complexes 
were maintained intracellular. There is evidence that internalized TCR complexes are still able 
to transmit TCR signals (Rothenberg, 1996; Saveanu et al., 2019). With the help of the Nur77-
GFP reporter for TCR signaling (Moran et al., 2011) we were able to measure TCR signal 
transduction induced by all three persistently stimulating conditions, even at the highest dose, 
at which TCR/CD3 complexes were internalized. Thus, it is tempting to speculate that LAT 
downregulation serves as a negative regulatory mechanism to prevent stimulation-induced T 
cell overactivation. Reduced LAT protein level might explain why rescued TCR/CD3 complexes 
fail to transmit productive T cell activating signals and thus, failed to induce Ca2+ flux and 
cytokine production. Thus, LAT downregulation/degradation might play an important role during 
the progression of T cell exhaustion/dysfunctionality. Hence, it is of interest to investigate the 
dynamics of this adaptor molecule especially in regard to therapeutic approaches trying to 
reinvigorate/improve effector functions. In a next step, it would be interesting to analyze if lat 
mRNA expression will also recover after TCR re-appearance at the cell surface in absence of 
antigen and to see whether its protein expression will be re-induced. 
5.4.2 Transcriptional profile of antigen-induced CD4+ Tex cells 
Previous studies have demonstrated that CD8+ Tex cells represent a unique cell lineage, which 
is clearly distinct from Teff and Tmem cells regarding their phenotype and functionality (McLane 
et al., 2019). Network analyses revealed that gene expression profiles of CD8+ and CD4+ LCMV 
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cl13-exhausted T cells exhibit unique gene-expression patterns and simultaneously share a 
common gene-expression signature of exhaustion (Crawford et al., 2014). To gain further 
insights into the mechanisms and pathways involved in CD4+ T cell exhaustion we performed 
genome-wide transcriptional profiling of naïve, memory, antigen-exhausted, and endogenous 
anergic T cells. We aimed to identify impaired signal-transduction pathways and genes 
potentially involved in CD4+ T cell exhaustion. We have shown that antigen-exhausted CD4+ T 
cells have adjust their gene expression to persisting antigen quantity and quality. We could not 
identify an obvious skewing towards one specific T helper cell subset. Comparing exhaustion-
associated gene-expression clusters with the gene-expression profile of endogenous anergic 
CD4+ T cells revealed a strong correlation between the gene-expression of both differentiation 
states. Thus, there is evidence suggesting that persistent antigen presentation induces multiple 
states of anergy. Interestingly, comparing exhaustion-associated gene-expression clusters 
identified at an early exhaustion phase (10 days post T cell transfer) with a later chronic phase 
(30 days post transfer) we found a substantial overlap of induced genes (FDR = 0.00011), 
indicating that gene-expression patters induced on day 10 are predictive for later induced gene-
expression profiles. Hence, genetic changes driving CD4+ T cell dysfunction/anergy induction 
are probably induced early and are maintained over time.  
5.4.3 Transcriptional driver of T cell exhaustion/anergy  
Transcriptome analyses revealed an antigen-dependent increase in RNA expression of several 
transcription factors. As expected, Fos and Jun expression levels were significantly induced in 
early memory T cells (Foletta et al., 1998). Cluster analyses identified Fos and Jun message 
within the day 10 memory-associated cluster 1. Monomers of Fos and Jun form heterodimers 
called AP-1, a transcription factor family associated with T cell memory generation (Nakabeppu 
et al., 1988). NFATc1 expression was found (together with Tigit and Il-21) in cluster 14, a cluster 
representing genes that were antigen-dose-dependently expressed. Interestingly, NFATc1 was 
equally expressed on protein levels in mem, low, intermediate, and high CD4+ T cells. The 
transcription factors Tbx21, Runx2, and Maf were found in cluster 15 (together with CD44 and 
CXCR3), a cluster representing genes that were induced upon antigen encounter, irrespective 
of the TCR stimulation intensity beyond the priming phase.  
We found cMaf protein expression exclusively upregulated by high-dose TCR stimulation. Thus, 
post-transcriptional regulation of the transcription factors NFATc1 and cMaf is likely. In cluster 
4, which contains genes significantly induced exclusively upon high TCR stimulation, we 
identified the transcription factors Tox and Id2. Surprisingly, we found TOX protein expression 
dose-dependently and uniquely induced by persistent TCR stimulations. The more antigen T 
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cells encountered beyond the priming phase, the more TOX was expressed. Therefore, we 
conclude that Tox induction is dependent on the stimulants´ nature, e.g. antigen quantity and 
quality. So far, TOX has been described to be important during thymic CD4+ T cell development 
(Wilkinson et al., 2002) and there was no correlation to chronic infections or cancer. However, 
very recently TOX was identified as a key transcription factor driving CD8+ T cell exhaustion 
(Alfei et al., 2019; Khan et al., 2019; Scott et al., 2019). Kahn, Scott, and Alfei described 
simultaneously the central role of this transcription factor for CD8+ Tex differentiation. The 
authors showed that Tox expression is induced in CD8+ T cells by chronic high-dose antigen 
stimulations (Alfei et al., 2019; Khan et al., 2019; Scott et al., 2019). Elevated Tox expression-
levels were found upon chronic LCMV cl13 infections in mice and HCV infections in human, as 
well in human CD8+ TILs and peripheral blood mononuclear cells (PBMCs) isolated from 
melanoma, breast, lung, and ovarian cancers. Further, robust Tox expression correlates with 
increased surface expression of multiple IRs, such as PD-1, Lag-3, 2B4, and Tim-3 (Alfei et al., 
2019; Khan et al., 2019; Scott et al., 2019) and translates chronic TCR stimulations into a certain 
CD8+ Tex gene-expression profile fostering CD8+ Tex commitment (Khan et al., 2019). Tox-
depleted CD8+ T cells normally differentiate into Teff and Tmen cells upon acute LCMV 
Armstrong infections demonstrating a redundant role of TOX for Teff and Tmem differentiation 
(Scott et al., 2019). Tox-depleted tumor-specific T cells fail to survive within the chronic tumor 
microenvironment. Together, there is evidence to suggest that the TOX-driven Tex program is 
induced by persistent TCR stimulations during chronic viral infections and within the TME and 
prevents overstimulation/activation-induced cell death (Scott et al., 2019). This finding coincides 
with the strong contraction observed for CD8+ Tex cells expressing a TOX variant, with a 
mutated DNA-binding domain that can no longer function as a transcription factor (Alfei et al., 
2019). This mutant, however, shows reduced PD-1 expression and increased cytokine-
production leading to a polyfunctional phenotype (Alfei et al., 2019). These findings agree with 
Scott et al., showing that Tox depleted CD8+ T cells failed to induce an exhaustion-associated 
program, as mRNAs encoding for IRs (Pdcd1, Entpd1, Havcr2, Cd244, Tigit) were not induced 
by persisting antigen even though their chromatin accessibility was still intact (Scott et al., 2019). 
The non-exhausted immunophenotype of Tox-depleted or -mutated “Tex cells” and the fact that 
ectopic TOX expression induces a Tex-associated gene-expression profile (Scott et al., 2019) 
provides evidence for TOX being a key transcription factor driving CD8+ T cell exhaustion and 
dysfunction (Alfei et al., 2019; Khan et al., 2019; Scott et al., 2019). Taking these data on CD8+ 
Tex cells and our own data demonstrating an antigen-dose-dependent expression of TOX into 
consideration, it is likely that TOX plays also a central role in controlling CD4+ T cell hypo-
responsiveness. To address this hypothesis directly, a Toxfl/fl locus has to be deleted in the 
exhaustion phase and the effects monitored. 
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Scott et al. compared Chip-seq data previously published by Martinez et al. (Martinez et al., 
2015) with their own ATAC-seq data (Philip et al., 2017; Scott et al., 2019) and found that NFAT 
binds to regions within the Tox locus of CD8+ TILs exhibiting increased chromatin accessibility 
(Khan et al., 2019; Scott et al., 2019). This suggests a hierarchical role of NFAT in regulating 
TOX expression. NFAT is a Ca2+-dependent transcription factor that has to be 
dephosphorylated by activated calcineurin in order to translocate from the cytoplasm into the 
nucleus to function as a transcriptional regulator (Jain et al., 1993). Inhibition of calcineurin-
mediated dephosphorylation of NFAT (using the inhibitor FK506 (Flanagan et al., 1991; Jain et 
al., 1993; Philip et al., 2017)) prevents nuclear NFAT translocation and causes reduced TOX 
and PD-1 expression-levels (Scott et al., 2019). These findings are consistent with results 
reporting that TOX expression requires Ca2+ signaling and NFATc1 transcriptional activity (Khan 
et al., 2019). Here, we demonstrate that nuclear NFATc1 correlates with the dose of persistent 
antigen. The higher the antigen stimulus of CD4+ T cells was beyond the priming phase, the 
more NFATc1 translocated into the nucleus. Interestingly, CD4+ T cells stimulated with the 
strongest stimulus exhibited the highest amount of nuclear NFATc1, even though these cells 
downregulated TCR/CD3 surface complexes, had reduced LAT protein levels, and did not show 
detectable Ca2+ release. Yet, it is unclear if high-dose TCR stimulations caused undetectable 
tonic Ca2+ release close to base-line levels and thus provoked NFATc1 translocation or whether 
NFATc1 relocation mechanisms were inhibited by high-dose antigen causing NFATc1 to be 
trapped inside the nucleus upon its translocation in response to very early, strong TCR 
stimulation. Nevertheless, once in the nucleus NFAT regulates gene-expression pattern 
depending on its binding partner. For instance, cooperative NFAT:AP-1 complexes act to favor 
T cell differentiation towards a memory phenotype, are associated with CD8+ T cell effector 
functions and trigger activation-induced genes (Martinez et al., 2015). In contrast, NFAT 
homodimers, so-called partnerless NFAT that are generated in the absence of AP-1, drive an 
exhaustion-associated immunophenotype (Martinez et al., 2015). AP-1 itself is a heterodimer 
of Jun and Fos family members (Foletta et al., 1998; Nakabeppu et al., 1988; Rincon and Flavell, 
1994), which drives Th1 effector responses (Ip and Davis, 1998; Whitmarsh and Davis, 1996; 
Yang et al., 1998). AP-1 generation depends on TCR-mediated activation of the JNK/MAP 
kinase signaling pathways (Ip and Davis, 1998; Whitmarsh and Davis, 1996; Yang et al., 1998). 
Activated JNK kinase phosphorylates its substrate c-Jun (Rincon and Flavell, 1994), which is 
subsequently able to generate heterodimers with Fos. We found that CD4+ T cells stimulated 
with intermediate- or high-doses of antigen were impaired or not able to phosphorylate c-Jun, 
hence no heterodimers with Fos were formed and no AP-1 transcription factors generated. 
Consequently, high-quality TCR stimulations that downregulated TCR/CD3 surface complexes 
and intracellular LAT abundance, failed to activate the JNK/MAPK pathway and therefore lack 
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AP-1 transcription factors in the nucleus generating partnerless NFATc1 to induce an altered, 
exhaustion-associated transcriptional profile. Taken together, partnerless NFATc1 and IR 
expression, such as PD-1, Lag-3, and Ox2, correlate with the strength of TCR stimulation. 
These findings, together with the observations described for chronic CD8+ T cells, strengthen 
the hypothesis that “asymmetrical” signaling via partnerless NFATc1 drives Tox expression 
within chronically stimulated CD4+ T cells in an antigen-dose-dependent manner. This may 
mean that TOX is a key transcription factor driving CD4+ T cell exhaustion/dysfunction/anergy 
and requires experimental investigations.  
5.5 Dysfunctional CD4+ T cells maintain plasticity  
Anergy has been described as an acquired state of immune cells hallmarked by 
unresponsiveness and describes an antigen-specific state of dysfunctionality. It is been seen 
as a mechanism to protect from autoimmune disorders (Chappert and Schwartz, 2010; Kalekar 
et al., 2016; Schwartz, 1990; Wells, 2009) and immunopathology (Knoechel et al., 2005; 
Martinez et al., 2012). Mueller and colleagues, have described two surface markers that 
characterize anergic T cells: CD73 (Nt5e) and FR4 (Izumolr) (Kalekar et al., 2016; Martinez et 
al., 2012). Interestingly, both markers positively correlate with the amount of antigen presented 
beyond the priming phase to CD4+ T cells. So far, anergic T cells have been described in cancer 
patients where positive signal 2/co-stimulation is missing or is being overwritten by a negative 
signal 2 mediated by IRs (Blank et al., 2004; Curiel et al., 2003; Zou and Chen, 2008). Since 
anergic T cells are additionally characterized by reduced IL-2 production, increased IR surface 
expression (PD-1, CTLA-4, and Lag-3), and impaired mTOR and MAPK signaling (Zheng et al., 
2012), we performed transcriptome analyses of endogenous anergic CD4+ T cells to compare 
their specific gene signature with the signature of antigen-exhausted CD4+ T cells. We found 
that the transcriptional profiles of antigen-exhausted and endogenous anergic CD4+ T cells 
strongly overlapped. A central role in anergy induction was ascribed to the homodimers of the 
transcription factors early growth response gene 2 (Egr2) and NFAT (Anandasabapathy et al., 
2003; Soto-Nieves et al., 2009; Zheng et al., 2012). The mRNA levels of both transcription 
factors were significantly induced by persisting TCR stimulation. Nfatc1 was induced upon TCR 
stimulation independent of antigen dose, while Egr2, according to transcriptome analysis, was 
uniquely induced by an intermediate dose of persistent TCR stimulation. As discussed above, 
while nuclear NFATc1 correlated with the strength of stimulation, MAPK pathway activity 
showed an inverse correlation. As a consequence of an interrupted MAPK pathway by high-
dose TCR stimulations, Jun phosphorylation was inhibited, AP-1 generation disrupted and thus, 
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NFAT homodimer generation induced. NFAT homodimers were linked previously to the 
generation of CD8+ T cell exhaustion (Martinez et al., 2015). 
Further, anergic T cells have been proposed to be precursor cells for peripheral FoxP3-
expressing Treg cells (Kalekar et al., 2016). We analyzed FoxP3 expression levels of antigen-
exhausted AND T cells and found no FoxP3 induction detectable, neither on mRNA nor on 
protein levels. Therefore, we conclude that mere antigen persistence is not sufficient to induce 
Treg differentiation of AND T cells, a clone generally unlikely to commit to the Treg fate 
(Szymczak-Workman et al., 2009).  
We found that surface expression of anergy-associated markers FR4 and CD73 remained 
reversible upon antigen removal on day 10. Thus, our data confirm the observation that T cell 
anergy is reversible when anergic CD4+CD44+FR4+CD73+ T cells were transferred into 
lymphopenic mice (Kalekar et al., 2016). Under a lymphopenic condition, anergic T cells 
downregulated their FR4 and CD73 surface expression and regained their proliferative capacity 
(Kalekar et al., 2016). We further found that the expression of the memory-associated markers 
CD127 and Ly6C, for CD154/CD40L also remained reversible. The same was true for surface 
expression of IRs such as PD-1 and even for the production of regular Th1-associated effector 
cytokines, such as IL-2, TNF-α, and IFN-γ. Our results are in agreement with the finding that 
progenitor CD8+ Tex cells are able to re-establish effector functions when isolated early, within 
the first two weeks of chronic LCMV cl13 infections, while terminal Tex cells fail to do so 
(McLane et al., 2019). Thus, there is evidence to suggest that CD4+ T cell dysfunction remain 
reversible upon antigen removal. All together, we conclude that mere antigen presentation 
beyond the priming phase drives CD4+ T cell differentiation towards multiple states of anergy 
depending on antigen-dose and -timing, thus on quality and quantity of chronic antigen 
presentation and that the dysfunctional state of CD4+ T cells can be reversed.  
CD4+ T cells chronically exposed to different levels of antigen beyond the priming phase deviate 
towards multiple states of anergy. Our data demonstrate that functional 
unresponsiveness/anergy is caused in the periphery by mere chronic antigen presentation as a 
gradual and reversible process. Anergy induction is important to protect from dangerous 
autoimmune disorders and immunopathology, but it comes with the cost of an impaired/lost 
defense against chronic viral infections and cancer. 
5.6 Therapeutic implications 
Our findings may be exploited for the generation of novel immunotherapeutic strategies. Only 
about 20 – 30% of cancer patients treated with immune checkpoint blocking antibodies benefit 
from therapy (Fesnak et al., 2016). In these patients Tex cells, the key cells responding to 
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checkpoint blockades (Huang et al., 2017; Kamphorst et al., 2017; Twyman-Saint Victor et al., 
2015) fail to proliferate, lack cytotoxic activity, and reveal reduced effector cytokine production 
ex vivo. This indicates that T cell exhaustion can hamper immunotherapies. Thus, our results 
provide important clues on how to optimize dose and timing of therapeutic antibodies or adapter 
molecules (specific antibody conjugates) that recruit endogenous and/or CAR T cells to the 
tumor, in order to minimize the induction of T cell exhaustion or anergy. As T cell dysfunctionality 
is caused by persisting TCR stimulation and is still reversible during early stages, therapeutic 
antibody derivates should be administered discontinuously. This way T cells will not be 
persistently stimulated and consequently, hopefully do not enter anergic states. It is tempting to 
speculate that a defined pause of treatment could prevent T cell exhaustion. This, however, has 
to be further investigated. Moreover, since we show that the dose of TCR stimulus plays a 
decisive role in the loss of effector function, the amount of administered therapeutic antibodies 
could be given a careful consideration. 
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5.7 Graphical summary  
 
 
 
 
 
Figure 36: Gradually induced functional unresponsiveness of antigen-exhausted CD4+ T cells. Transient 
antigen presentation drives functional CD4+ Tmem generation (green cell). Low level of persistent cognate antigen 
generated an anergic state, which progressed slowly over time and was characterized by a memory-like phenotype 
and transcriptional profile but also by impaired IL-2 production, reduced memory marker expression (CD127 and 
CD62L), and low but significant upregulation of anergy-associated markers (FR4 and CD73) (light-blue cell). 
Intermediate antigen-level generated an anergic state, characterized by unique gene expression patterns, impaired 
effector functions (IL-2, TNF-α, and IFN-γ production), reduced memory- (CD127, Ly6C, and CD62L), and increased 
anergy-marker expression (FR4 and CD73). An exhaustion-associated transcription factor profile (partnerless 
nuclear NFATc1 and intermediate dose of TOX) and impaired transmission of B cell help were further characteristics 
(middle-blue cell). And high-level of chronic antigen presentation caused an anergic state, characterized by unique 
gene expression patterns, impaired effector functions (IL-2, TNF-α, and IFN-γ production), reduced memory- 
(CD127, Ly6C, and CD62L), and increased anergy-associated marker expression (FR4 and CD73), as well as 
upregulated multiple IRs (PD-1, LAG-3, TIGIT, Ox2/CD200). An exhaustion-associated transcription factor profile 
(partnerless nuclear NFATc1, high dose of TOX and cMaf), and modified TCR signal pathway (MAPK) including 
significantly reduced surface TCR complexes and LAT expression levels and finally activation induced cell death 
defined this anergic state (dark-blue cell). However, anergic CD4+ T cells revealed their plasticity upon the termination 
of chronic TCR stimulation (FR4 and CD73, as well as IRs expression, and cytokine production was reversible upon 
antigen termination). Nevertheless, they might not be able to skew (back) towards a common memory path of 
differentiation (Crawford et al., 2014) but rather represent a unique redirected program (Hale et al., 2013). Hence, 
implying that the dose and time of antigen presented beyond the priming phase has the power to fundamentally 
change the transcriptional and translational regulation and thus, the phenotype and functionality of CD4+ T cells. 
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